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The studies in this dissertation were designed to investigate the immunomodulatory changes 
that occur in the cytotoxic lymphocyte populations of the horse at the systemic and regional 
levels during early pregnancy.  
Pregnant mares demonstrate a reduction in cytotoxic T lymphocyte (CTL) reactivity 
against target cells from the breeding stallion. I investigated whether this effect is limited to 
activity against paternal Major Histocompatibility Complex (MHC) antigens, and whether it 
occurs during MHC compatible pregnancy. Mares carrying MHC incompatible pregnancies 
demonstrated reduced CTL activity against lymphocytes from horses with unrelated MHC 
haplotypes in addition to those from the breeding stallion. This effect was also observed in mares 
carrying MHC compatible pregnancies, suggesting that an antigen-independent mechanism may 
be responsible for the decrease in CTL reactivity.
 I then examined whether natural killer (NK) cells may be present in the uterus among the 
dense lymphocytic infiltrate that surrounds the placental trophoblasts of the endometrial cups.  
Using quantitative molecular techniques, I identified the equine homologs of the NK cell marker 
genes NKP46, CD16, CD56, and CD94 and found that gene expression of all four markers was 
significantly higher in lymphocytes isolated from the endometrial cups compared to peripheral 
blood lymphocytes (PBL) isolated from the same animal on the same day. This provides the 
first evidence for the existence of NK cells in the equine endometrium during pregnancy.  After 
developing panels of monoclonal antibodies that specifically recognize the equine homologs of 
NKp46 and CD16, I performed experiments to characterize equine NK cells.  The two markers 
labeled a small percentage of PBL, and were also expressed on a subpopulation of CD3+ cells 
in most horses, suggesting that NK cells in the horse may have a CD3+ NK cell phenotype 
that differs from other species, or that the primary cell type recognized by these markers is 
the Natural Killer T cell. Immunohistochemical labelling of endometrial cup tissue sections 
showed that endometrial cup lymphocytes (ECL) consisted of predominantly CD16+ cells, 
which overlapped with a previously observed CD3+ population. This novel finding suggests 
that the CD3+ ECL population is also CD16+, and represents a dramatic increase over the small 
peripheral CD16+ population. 
Overall, this study advances knowledge of changes in maternal immunity during pregnancy 
in the mare and provides a more complete characterization of uterine leukocytes in the horse.  
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1CHAPTER 1
INTRODUCTION1
1Noronha, L.E., and Antczak, D.F. (2010). Maternal immune responses to trophoblast: the con-
tribution of the horse to pregnancy immunology. Am J Reprod Immunol 64, 231-244. Reprinted 
with permission from John Wiley & Sons.
2Abstract
The horse has proven to be a distinctively informative species in the study of pregnancy immu-
nology for several reasons.  First, unique aspects of the anatomy and physiology of the equine 
conceptus facilitate approaches that are not possible in other model organisms, such as non-
surgical recovery of early stage embryos and conceptuses, and isolation of pure trophoblast cell 
populations.  Second, pregnant mares make strong cytotoxic antibody responses to paternal Ma-
jor Histocompatibility Complex (MHC) class I antigens expressed by the chorionic girdle cells, 
permitting detailed evaluation of the antigenicity of these invasive trophoblasts and how they 
affect the maternal immune system.  Third, there is abundant evidence for local maternal cellular 
immune responses to the invading trophoblasts in the pregnant mare.  The survival of the equine 
fetus in the face of strong maternal immune responses highlights the complex immunoregula-
tory mechanisms that result in materno-fetal tolerance.  Finally, the parallels between human and 
horse trophoblast cell types, their gene expression, and function make the study of equine preg-
nancy highly relevant to human health.  Here, we review the most pertinent aspects of equine 
reproductive immunology, and how studies of the pregnant mare have contributed to our under-
standing of maternal acceptance of the allogeneic fetus.
Introduction 
In the nearly 60 years since Sir Peter Medawar first compared the fetus to a successful tissue 
transplant (Medawar, 1953), rigorous study of pregnancy immunology has yielded many insights 
into the mechanisms of materno-fetal tolerance.  The inability to formulate a unifying hypothesis 
is likely due to the fact that the processes behind maternal acceptance of the fetus are complex, 
multifactorial, and often compensatory (Aluvihare et al., 2005; Billington, 2003; Croy and Mur-
phy, 2008; Guleria and Sayegh, 2007; Koch and Platt, 2007; Moffett and Loke, 2006; Seavey and 
Mosmann, 2008; Trowsdale and Betz, 2006; Zenclussen et al., 2007).  One approach to move the 
field forward is to incorporate insights gained from comparative studies of multiple mammalian 
species (Carter and Enders, 2004; Carter et al., 2006; Enders and Carter, 2004).
3For centuries, scientific study of the horse (Equus caballus) has contributed to the medical com-
munity’s understanding of anatomy and physiology (North and National Library of Medicine, 
2006).  In recent years, studies of equine pregnancy have likewise advanced the fields of repro-
duction and immunology.  As we discuss below, the horse is a natural model for immune recog-
nition of the fetus.  The pregnant mare demonstrates a clear immune response to placental allo-
antigens, thus addressing the central question of whether the mother is immunologically ignorant 
of, or tolerant to, her gestating fetus.  
This review discusses the ways in which the horse has contributed to our understanding of preg-
nancy immunology and how equine research can advance the field.  Here, we focus on the events 
of early pregnancy, as that is the period when there is abundant evidence for engagement and 
alteration of the maternal immune response.  We first discuss the pertinent anatomic and physi-
ological aspects of early horse pregnancy. We then discuss the concept of materno-fetal tolerance 
as it pertains to the horse. Finally, we describe resources that make the horse a valuable species 
for the study of reproductive immunology and address pressing unanswered questions in our 
understanding of equine pregnancy.
Equine placentation and the endometrial cups
The equine placenta is characterized as diffuse and epitheliochorial, with six intact tissue layers 
between the maternal and fetal blood supplies (Amoroso, 1952).  The majority of the interface 
between the uterus and placenta is formed by the tight apposition of the endometrial epithelium 
with the non-invasive trophoblasts of the allantochorion (Samuel et al., 1975).  This attachment 
occurs by the interdigitation of highly branched allantochorion villi with the facing endometrium 
to form microcotyledons. The microcotyledons, located near capillaries in the maternal and pla-
cental tissues, act as the primary units for nutrient exchange between mother and fetus (Samuel 
et al., 1976).  In this regard, the horse is similar to other species with epitheliochorial placenta-
tion, such as the pig. However, the equine placenta is distinguished by the specialized, highly 
invasive trophoblasts of the chorionic girdle. 
4The chorionic girdle, first described in 1897 (Ewart, 1897), is so named because it forms a 
circumferential band around the developing conceptus (Figure 1.1a, b). It is first visible at ap-
proximately 25 days of gestation, following the fusion of the allantois and chorion which form 
the allantochorion membrane.  At the junction of the allantochorion and the regressing yolk sac, 
the cells of the chorionic girdle proliferate rapidly, forming a discrete region of pseudo-columnar 
epithelium with alternating ridges and pits (Figure 1.1c) (Enders and Liu, 1991).  By day 36, the 
chorionic girdle trophoblasts develop an invasive phenotype and are able to penetrate the uterine 
epithelium and invade the maternal endometrium well into the stromal layer (Allen et al., 1973).  
Prior to this event, the conceptus is held in place at the base of one uterine horn largely by uterine 
tension without firm attachment to the endometrium.  This very late attachment of the conceptus 
allows equine embryos and conceptuses from days 7 to 36 to be collected through non-surgical 
uterine lavage (Adams and Antczak, 2001); a great advantage for the study of the early phases of 
development of the fetus and placenta.
The cells of the chorionic girdle invade the endometrium like an advancing phalanx, with the 
leading cells followed closely by subsequent layers of cells (Figure 1.4A).  By day 38, girdle 
invasion is usually complete, and the binucleate girdle cells quickly transform into terminally 
differentiated, sessile trophoblasts (Figure 1.1e, f) (Wooding et al., 2001).   These tightly packed 
trophoblast cells are grossly visible as discrete plaques of tissue in the superficial endometrium 
known as endometrial cups (Fig.1d) (Schauder, 1912).  The endometrial cup trophoblasts are the 
sole source of the high concentrations of equine chorionic gonadotropin (eCG) detectable in the 
blood of pregnant mares between days 40 and 120 of pregnancy (Allen and Moor, 1972; Cole 
and Saunders, 1935).
eCG has both LH and FSH-like activities and shares functional parallels with human chorionic 
gonadotropin (hCG) (Stewart, 1976).  The primary function of eCG is considered to be its role 
in the luteinization of secondary ovarian follicles (Allen and Stewart, 2001; Squires and Ginther, 
1975).  These in turn secrete progesterone which maintains the pregnancy until approximately 
5Figure 1.1 Overview of the equine chorionic girdle and endometrial cups.  Diagram (a) and 
gross specimen (b) of a day 34 conceptus obtained by uterine lavage.  The size of the concep-
tus is approximately 4 cm in diameter.  Note the pale band of chorionic girdle trophoblasts. The 
white box in panel b represents the region visualized in the scanning electron micrograph (c) 
of the junction of the allantochorion (bottom) and the chorionic girdle (top; x 200).  (d) Gross 
specimen of endometrial cups shown in situ on the lumenal surface of the endometrium at day 44 
of pregnancy. (e) Immunohistochemical labeling of an endometrial cup section from day 44 of 
pregnancy using a monoclonal antibody to eCG (mAb 67.1) and (f) horse trophoblast (mAb 71.8; 
6
7day 100 of the 340-day gestation of the mare, when sufficient progesterone is produced by the 
placenta proper.  
The uterine epithelium re-grows over the cups, severing the connection between the trophoblasts 
and the conceptus.  At the same time, maternal mononuclear leukocytes are recruited into the 
endometrial stroma around the cups, forming a striking infiltrate at the cup periphery (Figure 
1.2a,b) (Allen, 1975).   No such accumulation is evident along the interface between the maternal 
endometrium and the non-invasive allantochorion (Figure 1.2c) (Samuel et al., 1974).  Despite 
the seemingly hostile environment in which the cups exists, they persist in situ until their even-
tual death and desquamation which occurs around days 100 to 120 of pregnancy (Allen, 1979).  
At this time, eCG production, which peaks at around day 70, precipitously declines (Figure 1.3b) 
(Allen, 1975; Amoroso, 1952).
Mechanisms of maternal tolerance to the developing fetus
Studies of maternal immunological tolerance to the developing fetus in several species, including 
the horse, have identified overlapping and complex mechanisms that have both antigen specific 
and non-specific effects.  These mechanisms can be grouped into three categories: 1) the repres-
sion of expression of paternally inherited alloantigens, particularly MHC antigens, by the pla-
centa, 2) systemic alterations in the maternal immune response during pregnancy, and 3) local 
immune modulation at the placental interface in the uterus.  
Regulation of MHC expression on trophoblast cells
The primary foreign antigens expressed by placental tissues are the products of the paternal Ma-
jor Histocompatibility Complex (MHC) genes.  MHC class I and II genes encode the molecules 
that stimulate rapid and potent cell-mediated and humoral immune responses during convention-
al allograft rejection.  In the various eutherian species that have been studied, expression of MHC 
molecules by most trophoblast cells is repressed, presumably as strategy to avoid recognition and 
8Figure 1.2  The local maternal cellular response to the equine endometrial cups.  (a-c) 
H&E stained, formalin fixed tissue sections from day 60 of pregnancy. (a) Low power im-
age of an endometrial cup showing the dramatic accumulation of maternal lymphocytes at the 
periphery. The white box indicates the trophoblast-lymphocyte interface magnified in (b). (c) 
Interface between the endometrium and the non-invasive allantochorion in areas away from 
the endometrial cups, showing interdigitation of microvilli.  Note the paucity of leukocytes 
in the endometrial stroma. (d-e) Immunohistochemical labeling of frozen serial sections of an 
endometrial cup from day 44 of pregnancy using monoclonal antibodies against equine CD8 
and CD4 (HT14A, HB61A, respectively) demonstrating that the maternal leukocytic infiltrate 
surrounding the trophoblasts is comprised primarily of CD8+ (d) and CD4+ (e) lymphocytes.
9
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destruction by the maternal immune system. However, in several species, minor subpopulations 
of trophoblasts paradoxically express some MHC class I molecules.
The trophoblast cells of the horse are unique in the combination of both spatial and temporal 
regulation of MHC expression they exhibit during placentation. The allantochorion trophoblasts, 
which comprise the majority of the fetal-maternal interface, do not express MHC class I proteins, 
although some mRNA can be detected in these cells (Bacon et al., 2002). During a short win-
dow in early pregnancy, the trophoblasts of the chorionic girdle and endometrial cups transiently 
express very high levels of polymorphic MHC class I antigens (Figure 1.3a) of both maternal and 
paternal origin (Donaldson et al., 1994).  Starting at day 30, the chorionic girdle expresses MHC 
class I genes at levels approximately 10-fold higher than somatic cells, comparable to levels 
seen in lymphoid tissues (Figure 1.3b) (Bacon et al., 2002).   The expression of these allogeneic 
molecules is maintained during chorionic girdle invasion into the maternal tissues.  It remains 
high until shortly after the cells differentiate into endometrial cup trophoblasts, then drops off to 
nearly undetectable levels by day 45 (Crump et al., 1987; Donaldson et al., 1992; Donaldson et 
al., 1990; Kydd et al., 1991; Maher et al., 1996).  
The MHC class I antigens of the chorionic girdle induce strong cytotoxic antibody responses 
in nearly 100% of mares carrying histoincompatible pregnancies (Figure 1.3b) (Antczak et al., 
1982; Antczak et al., 1984; Kydd et al., 1982).  Antibodies to paternal MHC class I antigens are 
usually detectable by day 60 in primiparous mares, at levels similar to those induced by alloge-
neic skin grafts (Adams et al., 2007).  Multiparous mares demonstrate evidence of anamnestic 
responses, with antibodies detectable by day 41, indicating full engagement of the adaptive im-
mune system, including T-lymphocyte help for the strong secondary antibody responses (Ad-
ams et al., 2007; Antczak et al., 1984).  By comparison, only about 30% of multiparous women 
develop antibodies to paternal MHC class I antigens (Densmore et al., 1999), and in primiparous 
women the antibodies are rarely detected before week 28 (Regan et al., 1991).  Isolated chorionic 
girdle trophoblasts are capable of inducing antibody on their own, as has been demonstrated by 
11
Figure 1.3 Temporal and spatial expression patterns of MHC class I molecules on equine 
trophoblast. (a) Immunohistochemical labeling of trophoblast dissected from a day 34 concep-
tus and stained with a monoclonal antibody specific for MHC class I (H58A).  Note the negative 
chorion (Chr) and basement membrane adjacent to and below the strongly positive chorionic 
girdle (CG) trophoblasts. (b) Schematic illustration of the pattern of cytotoxic antibody against 
paternal MHC class I antigens generated in early equine pregnancy.  Antibody appears shortly 
after eCG is first detectable in maternal serum.  Gray column indicates period in which the 
chorionic girdle and early endometrial cups express MHC class I antigens (day 30 – 45 of gesta-
tion); red column indicates period of trophoblast invasion (days 36-38).
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transplantation experiments (Adams and Antczak, 2001; Donaldson et al., 1994).  The horse, 
therefore, more than any other species yet identified, provides incontrovertible evidence for the 
antigenic capacity of trophoblast cells.  
MHC class I antigens are expressed on trophoblast subpopulations in several other species. The 
invasive extravillous trophoblast cells of the human placenta express MHC molecules from 
several loci: HLA-C, -E, and –G (Apps et al., 2009).  Mouse labyrinthine trophoblasts express 
paternal MHC class I (Raghupathy et al., 1981).  The interplacentomal trophoblasts of the cow 
express both classical and non-classical MHC class I genes late in pregnancy (Davies et al., 
2006).  As in other species, MHC class II molecules are not expressed by any equine trophoblast 
populations (Donaldson et al., 1990; Holtz et al., 2003).
Systemic alterations in maternal immune responses
While the pregnant mare is capable of mounting a robust and reproducible humoral immune re-
sponse against paternal MHC class I antigens, this is not the case with the cell-mediated immune 
response.  Equine pregnancy appears to induce a state of “split-tolerance” to trophoblast— a 
situation where one compartment of the immune system responds to an antigen, while another is 
tolerant (de Mestre et al., 2010; Hunziker et al., 1997; Sprent et al., 1995).  In the pregnant mare, 
this presents as a dramatic allospecific anti-paternal humoral immune response with a simultane-
ous dampening of certain T cell-mediated responses.
Peripheral blood lymphocytes isolated from pregnant mares demonstrate a reduced capacity to 
develop into effective cytotoxic T-lymphocytes (CTL) capable of lysing target cells from the 
breeding stallion (Baker et al., 1999).  This reduction in T cell-mediated alloreactivity reverts 
after parturition or pregnancy termination, and it is not observed in males or non-pregnant fe-
males.  This phenomenon seems logical, as the formation of anti-paternal cytotoxic cells during 
pregnancy could be disastrous for the semi-allogeneic fetus.  However, a generalized reduction in 
cell-mediated immunity would make the mother susceptible to certain types of infections.  It has 
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not yet been determined whether the alteration in the CTL activity of pregnant mares is limited 
to responses against paternal alloantigens.  Studies using transgenic mice have demonstrated that 
peripheral maternal lymphocytes specific for paternal antigens may be inactivated or deleted dur-
ing pregnancy (Ait-Azzouzene et al., 1998; Jiang and Vacchio, 1998; Tafuri et al., 1995).  Studies 
of infectious diseases in conventional pregnant mice suggest broader antigen-independent mech-
anisms (Krishnan et al., 1996; Pejcic-Karapetrovic et al., 2007).  Likewise, pregnant women 
appear to experience an increased susceptibility to infections such as Listeria and Toxoplasma 
(Avelino et al., 2003; Smith, 1999).  While mares are vulnerable to a number of pregnancy-asso-
ciated abortogenic infections (Ellis et al., 1983; Givens and Marley, 2008; Lunn et al., 2009), it 
is not clear whether this is due to a general systemic immune tolerance or pregnancy-associated 
tissue tropism.   
The peripheral lymphocyte populations of pregnant mares have demonstrated few significant 
detectable alterations in phenotype.  A modest increase in the number of circulating lymphocytes 
that express the TH2 cytokine IL-4 has been demonstrated during pregnancy (de Mestre et al., 
2010).  This finding is consistent with the high levels of paternal alloantibodies observed during 
pregnancy, as the presence of IL-4 favors a humoral immune response.
Locally acting mechanisms of immune tolerance
The maternal leukocytes that accumulate around the equine endometrial cups represent one of 
the most dramatic examples of a local cellular immune response to the conceptus.  Immunohis-
tochemical labeling of endometrial cup tissues has identified these leukocytes as primarily CD4+ 
and CD8+ T cells (Figure 1.2d,e) (Grunig et al., 1995).  Mechanisms that operate where these 
maternal immune cells directly encounter placental antigens may dampen their effector activities 
by creating a local immunosuppressive environment. This strategy seems advantageous in that 
the systemic maternal responses can remain largely intact to defend against pathogens. Work by 
multiple groups has demonstrated trophoblast-produced soluble factors that may create such an 
environment by modulating the proliferation and blastogenesis of maternal lymphocytes.  Ex-
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tracts from day 80 placenta have been shown to inhibit the proliferation of maternal lymphocytes 
(Lea and Bolton, 1991), and co-culture of chorionic girdle trophoblasts with maternal lympho-
cytes caused a decrease in proliferation and a reduction in cytokine production (Flaminio and 
Antczak, 2005; Flaminio et al., 2004).  Also, a >100,000 kDa molecule isolated from culture 
supernatants of day 20 conceptuses, termed horse conceptus-derived immunosuppressive factor, 
was found to inhibit lymphocyte proliferation by inhibiting IL-2R expression (Roth et al., 1992).  
Further investigation of trophoblast-produced immunomodulatory factors is warranted, based 
upon the important role they play in other species.  In humans and mice, trophoblast molecules 
such as Fas ligand and indoleamine 2,3 dioxygenase (IDO) have been identified as providing 
protection from T-cell cytotoxicity (Hunt et al., 1997; Mellor and Munn, 2000); and the mol-
ecules Crry (mouse) and decay accelerating factor (human) confer protection from the comple-
ment cascade (Cunningham and Tichenor, 1995; Xu et al., 2000).   hCG has been implicated 
as immunoregulatory molecule in human pregnancy (Tsampalas et al., 2009); however a study 
measuring in vitro inhibition of equine lymphocyte proliferation did not support such a role for 
eCG (Lea and Bolton, 1991). 
Evidence also exists that the endometrium of the pregnant mare may be a primary source of local 
immunosuppressive factors.  Prostaglandins in culture supernatant from endometrium of preg-
nant mares were shown to reduce lymphocyte blastogenesis (Watson, 1990; Watson and Zane-
cosky, 1991).  Recently, local populations of regulatory T cells (Tregs) have been identified at the 
equine materno-fetal interface.  The Treg marker FOXP3 has been demonstrated at both the gene 
and protein levels in the CD4+ cells that surround the endometrial cups (de Mestre et al., 2010).  
Endometrial cup lymphocytes isolated from day 43-46 of pregnancy showed a 3-fold increase in 
the number of CD4+FOXP3+ cells compared to peripheral lymphocytes. This is consistent with 
an increase in Tregs observed during pregnancy in multiple other species (Aluvihare et al., 2004; 
Oliveira and Hansen, 2008; Sasaki et al., 2007; Tilburgs et al., 2008; Zenclussen et al., 2006).  
Local regulatory activity by Tregs at the placental interface may be a mechanism by which the 
early MHC class I+ trophoblast populations are able to resist destruction by the large accumula-
15
tion of maternal lymphocytes with which they are in contact.  
In the same day 43-46 endometrial cup lymphocyte samples, an increase in the number of in-
terferon gamma (IFNG)+ lymphocytes was also observed.  This observation initially appears to 
be in conflict with the traditional dogma of a TH2 bias during successful pregnancy.  However, 
recent studies have implicated IFNG at the materno-fetal interface as having a critical role in hu-
man, murine, and porcine pregnancy (Murphy et al., 2009).
Value of the horse in the study of pregnancy immunology
Several aspects of equine pregnancy make its study useful in understanding eutherian materno-
fetal interactions. In addition to the aforementioned maternal immune responses that distinguish 
the horse, its specialized trophoblast populations, combined with advances in assisted reproduc-
tive technologies, immunological reagents, and genomic resources, make the horse a uniquely 
valuable species in the advancement of pregnancy immunology.
The trophoblast populations of human and horse placentas share significant phenotypic similari-
ties.  For each of the three principal types of equine trophoblast, there is a human counterpart 
(Figure 1.4). The basic cell types and essential properties are conserved between these parallel 
groups, however some functions have been distributed differently. The equine allantochorion 
trophoblasts correspond to the human villous cytotrophoblasts (Figure 1.4, orange).  Both are 
mononuclear cells with stem cell-like properties that enable them to differentiate into other 
trophoblast types. They both express low levels of MHC class I mRNA, but not protein (Bacon 
et al., 2002; Hunt et al., 1990).  The allantochorion trophoblasts are the primary mediators of 
nutrient exchange in the horse, whereas the syncytiotrophoblast layer provides this function in 
the human placenta. The chorionic girdle trophoblasts are similar to human extravillous tropho-
blasts (Figure 1.4, red).  Both cell types are invasive and migrate into the endometrial stroma.  
They both express MHC class I antigens from more than one locus, although the genes are not 
homologous (Donaldson et al., 1994; Hunt et al., 1990; Kovats et al., 1990; Moffett-King, 2002).  
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Figure 1.4  Comparison of horse and human trophoblast populations. This diagram sum-
marizes the similarities in cell type, gene expression, and function between the three principal 
horse (A) and human (B) trophoblast types during early pregnancy.  Analogous trophoblast 
populations of the two species are color matched. See text for a detailed comparison.  The top of 
the horse diagram (A) depicts the period surrounding the invasion of the chorionic girdle tro-
phoblasts into the endometrium; the bottom shows after the endometrial cups have been estab-
lished.  The diagram of the human placental villus (B) represents a time during the first trimester 
when extravillous cytotrophoblasts migrate into the endometrium.
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Lastly, the equine endometrial cup trophoblasts correspond to the human syncytiotrophoblasts 
(Figure 1.4, blue).  Both cells types are multi-nucleate, sessile, and terminally differentiated. 
They suppress MHC class I gene expression at the transcriptional level (Hunt et al., 1990; Maher 
et al., 1996) and secrete chorionic gonadotropins. Only primate and equid species are known to 
produce placental gonadotropins (Fiddes and Talmadge, 1984; Pierce and Parsons, 1981).  Ad-
ditionally, recent molecular studies have identified transcription factors involved in trophoblast 
differentiation that are conserved between horse and human placentas (de Mestre et al., 2009).
Another relevant similarity between human and horse pregnancy is the extended gestation length. 
The mare’s 340 day gestation allows adequate time for full engagement and commitment of the 
adaptive immune system.   The resulting anti-paternal humoral immune response observed in 
nearly all mares carrying histoincompatible pregnancies is easily monitored through measure-
ment of serum antibody levels (Antczak et al., 1982; Antczak et al., 1984).  
Up to day 36, the equine conceptus can be recovered non-surgically from the mare’s uterus, 
enabling the collection of pure trophoblasts which can be further investigated in vitro (Antczak et 
al., 1987). The purified trophoblasts can be maintained in culture and driven to differentiate, al-
lowing the opportunity for in vitro manipulation of specific populations (de Mestre et al., 2008).  
Isolated chorionic girdle trophoblast can also be transplanted into non-pregnant recipient mares 
using a novel in vivo system (Adams and Antczak, 2001; de Mestre et al., 2008).  The transplant-
ed trophoblasts undergo autonomous terminal differentiation in ectopic sites independent of the 
physiological state of pregnancy.  They stimulate maternal antibody responses and attract T cells 
to the sites of transplantation, and yet evade immediate destruction by the immune system of the 
recipients.  The trophoblasts also maintain their endocrine capacity and produce eCG (de Mestre 
et al., 2008).  
In addition to the characteristics that make the horse unique as a species in the study of preg-
nancy immunology, many advantages offered by commonly used animal models apply.  The 
MHC of the horse has been well-characterized using functional and genetic studies (Carpenter 
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et al., 2001; Ellis et al., 1995; Gustafson et al., 2003; Lazary et al., 1988; Tallmadge et al., 2010; 
Tallmadge et al., 2005).  Horses have been selectively bred for homozygosity at the MHC region, 
enabling the establishment of MHC-compatible and -incompatible pregnancies to investigate 
the role of paternal antigens in maternal immune recognition (Adams and Antczak, 2001).  Ad-
vanced assisted reproductive techniques, such as artificial insemination and embryo transfer, are 
routinely used in horse breeding.  Notably, embryo transfer is performed in thousands of horses 
every year worldwide with high success rates (Carney et al., 1991), suggesting that the insemi-
nation-induced tolerance that plays a role in pregnancy in some species (Robertson and Sharkey, 
2001) may be less important in others.  Other more advanced techniques such as oocyte transfer, 
intracytoplasmic sperm injection, and nuclear transfer (cloning), are also successfully used in 
horse reproduction (Coutinho da Silva, 2008).  These techniques are primarily used to generate 
genetically desirable offspring, but they can also be useful tools in understanding early reproduc-
tive events such as fertilization and conception.  
Recent advances in equine genomics and immunology have expanded opportunities for the study 
of pregnancy immunology at the mechanistic level.  A 6.8X sequence of the equine genome has 
been determined and extensively annotated (Wade et al., 2009).  Multiple horse-specific expres-
sion microarrays have been developed and validated, allowing researchers to investigate the 
expression of thousands of genes simultaneously (Glaser et al., 2009; Gu and Bertone, 2004; 
Mienaltowski et al., 2009; Ramery et al., 2009).  Molecular advances have also facilitated the 
development of new horse-specific monoclonal antibodies (Wagner et al., 2006; Wagner et al., 
2008a; Wagner et al., 2008b; Wagner et al., 2005) and immune assay technologies (Wagner and 
Freer, 2009). 
Discussion
Our understanding of the mare’s immune responses during pregnancy has progressed substan-
tially, but several critical questions still remain. Firstly, why do the chorionic girdle trophoblasts 
20
express such high levels of paternal MHC class I while invading the maternal endometrium?  
The horse is not unique in this respect— MHC class I expression can be observed in trophoblast 
populations of other species at various stages of placentation.  However, the horse demonstrates 
the clearest evidence for maternal immune recognition of paternal alloantigens expressed by 
trophoblast.  A proposed role for the expression of HLA molecules by human invasive extravil-
lous trophoblasts is to confer protection from cytotoxic NK cells (Rouas-Freiss et al., 1997).  NK 
cells have been putatively identified in the periphery of the horse (Lunn et al., 1995; Viveiros 
and Antczak, 1999),  but not yet in the uterus.  In vitro, peripheral equine NK-like lymphokine 
activate killing (LAK) cells have shown the capacity to lyse differentiated MHC class I negative 
binucleate chorionic girdle cells (Vagnoni et al., 1996).  However, their role in vivo has not been 
determined.  Studies of porcine pregnancy have demonstrated that NK cells can be recruited to 
the uterus of a species with epitheliochorial placentation (Croy et al., 1988).  The advent of new 
reagents to detect equine NK cells should help address this question.
A second pressing question is why and how the endometrial cups are ultimately destroyed after 
two months of successful evasion of maternal immune effectors.  Clusters of CD4+ and CD8+ 
lymphocytes and inflammatory leukocytes are seen within sections of dying cups (Grunig et 
al., 1995).  Here, in the absence of MHC class I antigen expression it is possible that NK cells 
could be acting as cytotoxic cells.  However it is not clear whether infiltrating immune cells are 
a primary cause of destruction of the cups or if they simply undergo apoptosis at the end of their 
natural lifespan. 
Evidence for an immunological basis for endometrial cup destruction has been demonstrated by 
experimental interspecies matings.  In a standard MHC incompatible horse mating, there is no 
change in the lifespan of the cups with multiple pregnancies (Adams et al., 2007).  However, 
when mares are mated to male donkeys to produce mule pregnancies, the cups are destroyed ear-
lier in subsequent pregnancies, suggestive of an anamnestic response (Antczak and Allen, 1984). 
Lymphocytes from mares carrying mule pregnancies do not demonstrate reduced CTL activity in 
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vitro against cells from the donkey sire (Baker et al., 1999), indicating a failure in the systemic 
dampening of cell mediated immunity in these interspecies matings. 
A more dramatic version of an apparent immune-based destruction of the endometrial cups is 
seen in the donkey-in-horse pregnancy model.  While most females of the genus Equus can 
successfully carry a pregnancy from any of the other species following embryo transfer, only 
rarely can a horse maintain a transferred donkey embryo (Allen, 1982; Allen et al., 1987).  In this 
situation, the chorionic girdle fails to invade the endometrium of the surrogate mare.  No endo-
metrial cups form and there is no detectable eCG in the serum.  Large numbers of endometrial 
leukocytes are seen at the border of the non-invasive allantochorion, which abnormally expresses 
MHC class I antigens and fails to interdigitate with the maternal endometrium (Antczak and 
Allen, 1988; Enders et al., 1996; Kydd et al., 1991).  Furthermore, these mares carrying embryo 
transfer donkey conceptuses also appear to demonstrate an anamnestic response; mares that abort 
one donkey pregnancy abort subsequent pregnancies of this type earlier in gestation (Enders et 
al., 1996).
The breeding of in utero immunotolerized chimeric twins has also lent insights into the role of 
immune mechanisms in endometrial cup destruction.  In an experiment where female horses 
were bred to their male co-twins, peripheral eCG was detectable through day 220-260, roughly 
double the normal time-frame (Bouters et al., 1978; Spincemaille et al., 1975).  This significantly 
extended lifespan of the endometrial cups suggests that foreign paternal antigens may play a role 
in their destruction. With the increased success of equine cloning (Hinrichs, 2006), this question 
may be further addressed.
Endometrial cup destruction is sometimes delayed, leading to a clinical condition termed “per-
sistent endometrial cups” (Allen et al., 2007; Willis and Riddle, 2005).  It can occur in mares 
that abort after the endometrial cups have formed, and in normal post-partum mares. It has some 
similarities to post-partum microchimerism seen in women (Gammill and Nelson, 2010). The 
persistent cups remain active and eCG can be detectable in the sera beyond the usual time-frame.  
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Consequently, return to estrous cyclicity is delayed (Willis and Riddle, 2005).  The persistent 
cups eventually die, but it is not know why they survive beyond the standard time frame as mul-
tiple allografts within a non-pregnant animal.  Further study of this phenomenon would be useful 
in understanding the signals that initiate and terminate maternal tolerance.
In conclusion, the pregnant mare’s immune responses to the trophoblast of her developing pla-
centa are fascinating in their complexity. By providing a window into the nature of materno-fetal 
interactions, the horse has illuminated immunological events not easily detectable in other spe-
cies. Future studies in equine pregnancy hold great promise in the revelation of more secrets of 
the materno-fetal immunological relationship.
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CHAPTER 2
SPLIT IMMUNOLOGICAL TOLERANCE TO TROPHOBLAST1,2
1 de Mestre, A., Noronha, L., Wagner, B., and Antczak, D.F. (2010). Split immunological toler-
ance to trophoblast. International Journal of Developmental Biology 54, 445-455. Reprinted 
with permission from UBC press.
2LEN contribution: peripheral cells studies; FOXP3 cloning and qPCR
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Abstract 
Split immunological tolerance refers to states in which an individual is capable of mounting 
certain types of immune responses to a particular antigenic challenge, but is tolerant of the same 
antigen in other compartments of the immune system.  This concept is applicable to the immuno-
logical relationship between mother and fetus, and particularly relevant in equine pregnancy.  In 
pregnant mares, antibody responses to paternal foreign Major Histocompatibility Complex class 
I antigens are robust, while anti-paternal cytotoxic T cell responses are diminished compared to 
those mounted by non-pregnant mares.  Here we compared the distribution of the major lympho-
cyte subsets, the percentage of lymphocytes expressing Interferon Gamma (IFNG) and Inter-
leukin 4 (IL4) and the level of expression of the immunoregulatory transcription factor FOXP3 
between pregnant and non-pregnant mares, and between peripheral blood and the endometrium 
during pregnancy.  In a cohort of mares in which peripheral blood lymphocytes were tested 
during early pregnancy and in the non-pregnant state, there were only slight changes observed 
during pregnancy.  In contrast, comparison of peripheral blood lymphocytes with lymphocytes 
isolated from the endometrial cups of pregnant mares revealed striking differences in lympho-
cyte sub-populations.  The endometrial cups contained higher numbers of IFNG+ lymphocytes, 
and lower numbers of lymphocytes expressing IL4.  The endometrial cup lymphocytes also had 
higher numbers of FOXP3+ cells compared to peripheral blood lymphocytes.  Taken together, 
these results strengthen the evidence for a state of split tolerance to trophoblast, and furthermore 
define sharp differences in immune reactivity during equine pregnancy between peripheral blood 
lymphocytes and lymphocytes at the maternal-fetal interface. 
Introduction
The paradox of the successful fetus-as-allograft paradigm was first proposed by Peter Medawar 
in 1953, and hypotheses put forth in that classic paper have generated numerous clinical and 
experimental studies in the field of pregnancy immunology.  Now 55 years later, many strategies 
and mechanisms have been identified that may explain how the fetus escapes recognition 
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and destruction by the maternal immune system.  These include repression of expression of 
alloantigens and tissue specific antigens in the placenta, systemic alterations in the character of 
maternal immune responses during pregnancy, and locally operating mechanisms of trophoblast 
cells that protect the fetal tissues against destruction by maternal immune effector cells and 
molecules.  Progress in these areas has been evaluated in a number of comprehensive reviews 
(Billington 2003; Caucheteux et al., 2003; Koch and Platt, 2003; Hunt, 2005; Moffett and Loke, 
2006; Trowsdale and Betz, 2006; Zenclussen et al., 2007; Seavey and Mossman, 2008).  
In descriptions of the fetal-maternal immunological relationship, the concept of maternal toler-
ance to the fetus is often used (Mellor and Munn, 2000; Robertson and Sharkey, 2001; Kannel-
lopoulos-Langevin et al., 2003; Aluvihare et al., 2004; Blois et al., 2007).  Although immuno-
logical tolerance is well understood operationally, tolerance can be achieved by many distinct 
mechanisms, and not all of them have yet been elucidated.  A number of experimental approach-
es have identified both antigen-specific and non-specific tolerogenic mechanisms operating 
during pregnancy.  In T cell transgenic mice there is evidence for either deletion or inactivation 
of T cells (Tafuri et al., 1995; Jiang & Vacchio, 1998) or B cells (Ait-Azzouzene et al., 1998, 
2001) reactive with paternal Major Histocompatibility Complex (MHC) class I antigens or the 
H-Y minor histocompatibility antigen.  The antigen-specific effects have largely been detected 
using transgenic mice expressing only a single specificity of T cell receptor, whereas non-specific 
mechanisms have been detected in normal mice (Krishnan et al., 1996a, b; Aluvihare et al., 2004; 
Pejcic-Karapetrovic et al., 2007).  
It is not clear if and how these two principal types of feto-maternal tolerance are related.  Antigen 
specific mechanisms have the great advantage of leaving the remainder of the mother’s immune 
system intact, allowing her to defend herself against infection during pregnancy.  However, they 
also require that the conceptus express the antigens to which tolerance is induced.  The antigen 
non-specific mechanisms of tolerance do not require information about the specific histocompat-
ibility challenge of the fetus.  Their disadvantage, however, is that they might alter the mother’s 
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immune system in ways that would make her more susceptible to certain types of infection 
during pregnancy.  The increased susceptibility of pregnant women to Toxoplasma and Listeria 
infection may reflect such an untoward effect (Smith, 1999; Avelino et al., 2003). 
The mechanisms by which maternal tolerance to the fetus is induced are not yet fully understood, 
but critical components may include local signals from sperm, seminal fluid, and the developing 
conceptus, the hormonal state of pregnancy, and in the case of antigen-specific tolerance, 
expression of MHC molecules by the conceptus in a context that favors tolerance over immunity 
(Robertson et al., 1997; Robertson & Sharkey, 2001).  The detection of expanded numbers 
of circulating or locally accumulated regulatory T cells (Tregs) in normal mouse (Aluvihare 
et al., 2004; Zenclussen et al., 2006) and human (Tilburgs et al., 2008) pregnancy provides a 
framework focused on a CD4+CD25+ FOXP3+ T cell (Ramsdell, 2003; Wood & Sakaguchi, 
2003; Nagler-Anderson et al., 2004).  
The term ‘split tolerance’ has two meanings in immunology.  In the context of tissue and organ 
transplantation, it refers to the observation that grafts of some tissues, classically liver, may be 
accepted by a recipient while grafts of other tissues from the same donor, for example, skin, are 
rejected (Qian et al., 1997; Chan et al., 2008; Chung et al. 2005; Luo et al., 2007; Matthes et al., 
2003).  The second and more relevant use of the term for this study has broader implications in 
immunological tolerance.  It refers to states in which an individual is capable of making some 
types immunological responses to a particular antigenic challenge, but is apparently tolerant 
to the same antigen from the perspective of other immune system compartments (Sprent et 
al., 1995; Hunziger et al., 1997; Baker et al., 2001).  Although the mechanisms leading to split 
tolerance are not well understood, we propose that the operational definition as presented may be 
useful in shaping a new framework for the complex immunological relationship between mother 
and fetus.  
The equine placenta is of the non-invasive epitheliochorial type, with six intact cell layers 
separating maternal and fetal blood supplies.  The principal interface between uterus and 
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placenta is an interdigitation of  endometrial epithelium with allantochorion trophoblast that 
forms characteristic microvilli (Allen 1975).  The trophoblast cells at this interface do not 
express either MHC class I or MHC class II antigens (Donaldson et al., 1990, 1992; Maher et 
al., 1996), and thus do not pose an immunological challenge to the mother.  However, equids 
also have a minor subpopulation of invasive trophoblasts that do express MHC molecules as 
they migrate into the endometrium to form the endometrial cups (Fig. 1).  The invasive equine 
chorionic girdle trophoblasts and the early endometrial cup trophoblast cells express very high 
levels of polymorphic, paternal and maternal MHC class I antigens during a short window in 
early pregnancy between days 30 and 45 of gestation (Donaldson et al., 1992, 1994).  The level 
of expression of these MHC class I antigens is similar to that found on lymphocytes and other 
antigen presenting cells of the immune system, and about 10 fold higher than the level found on 
other somatic tissues (Bacon et al., 2002).  
Virtually 100% of mares carrying MHC incompatible pregnancies mount strong primary or 
secondary antibody responses to the foreign paternally inherited MHC class I antigens of their 
fetuses, and the timing of this response is consistent with induction by the MHC class I positive 
chorionic girdle and early endometrial cup cells (Antczak et al., 1982, 1984).  Transplantation of 
allogeneic trophoblast has demonstrated that the chorionic girdle cells are capable of producing 
this immunological sensitization on their own (Adams & Antczak, 2001; de Mestre et al., 2008).  
These observations demonstrate conclusively that the B cell compartment of the pregnant mare’s 
immune system is not tolerized, and suggests that T cells required to ‘help’ B cells produce 
antibody may also be activated during pregnancy.  
At the level of the fetal-maternal interface, the invading MHC class I positive trophoblasts 
of the early endometrial cups attract a striking accumulation of maternal CD4+ and CD8+ 
T lymphocytes around them, but this apparent cellular immune response does not result 
in immediate destruction of the endometrial cups (Fig. 2) (Grunig et al., 1995).  Once the 
endometrial cups are fully formed, the binucleate, equine chorionic gonadotrophin (eCG) 
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Figure 2.1 Gross specimens of day 34 equine conceptus and endometrial cups from day 45 
of gestation.  A. Day 34 conceptus showing the horizontal band of invasive trophoblast of the 
chorionic girdle, demarcated by the vertical bracket and arrows.  At day 36-38 of gestation the 
chorionic girdle cells migrate into the endometrium to form the mature, eCG secreting endome-
trial cups.  Specimen obtained by non-surgical uterine lavage.  B. Mature endometrial cups at 
day 45 of gestation shown in the endometrium.  Arrow points to a strip of cups, which average 
1 cm in diameter.  Specimen obtained at necropsy.
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Figure 2.2  Histological images of endometrial cups and endometrium from early equine 
pregnancy. H&E stained fixed sections: A. Low power image of endometrial cup showing 
accumulations of maternal lymphocytes concentrated along the periphery of the cup.  B. High 
power image from A., showing aggregations of maternal lymphocytes, endometrial glands, and 
large binucleate pale staining endometrial cup trophoblast cells. C. Endometrium – allantocho-
rion border.  Note the lack of lymphocyte accumulations at the placental-uterine interface.  D-F 
Immunohistochemical labeling of frozen sections of endometrial cups.  D. Monoclonal antibody 
102.1 (anti-horse trophoblast), showing distinct margin of the endometrial cup.  Anti-horse CD4 
antibody (E.) and anti-horse CD8 antibody (F.) labeling the respective T cell subsets surround-
ing endometrial cup trophoblasts (T).  Size bar indicates 100μm in all panels except A (400μm).  
All specimens are from day 43-46 of gestation.
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secreting trophoblast cells of the cups down regulate expression of their MHC genes (Donaldson 
et al., 1992; Maher et al., 1996).  Paradoxically, the local lymphocyte-dominated response 
appears to eventually result in the destruction of the endometrial cups, which is usually complete 
between days 80 and 120 of the mare’s  335 day gestation (Allen 1979). 
Earlier work from our group identified a decrease in the capacity of peripheral blood lympho-
cytes from pregnant mares and jenny donkeys to develop into alloreactive cytotoxic lymphocytes 
after in vitro culture with irradiated lymphocytes from MHC incompatible mating stallions or 
jack donkeys (Baker et al., 1999).  Thus, the peripheral cytotoxic T cell (CTL) response to pater-
nal alloantigens seems to be impaired during normal equine pregnancy, while the B cell response 
remains intact.  We hypothesized that other systemic differences might exist between peripheral 
lymphocytes of pregnant and non-pregnant mares, and we therefore examined several variables 
for this study.  We also tested a second hypothesis, that immune reactivity would differ between 
peripheral and local immune compartments, and here we compared tissue lymphocytes from the 
endometrium and endometrial cups with peripheral blood lymphocytes obtained on the same day 
of gestation from pregnant mares.  
Materials and Methods
Animals
Adult horses of mixed breeds and ages were used in this research (Tables 1 and 2).  Horses 
were maintained at the Baker Institute for Animal Health, Cornell University.  Animal care was 
performed in accordance with the guidelines set forth by the Institutional Animal Care and Use 
Committee of Cornell University.  Pregnancies were established as previously described (Adams 
and Antczak, 2001).  Major Histocompatibility Complex haplotypes were assigned to the horses 
based on results of tissue typing using a panel of well-characterized alloantisera that had been 
validated in international workshops (Lazary et al., 1988).  
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Table 2.1  Mares used for comparison of immune status in  
peripheral blood in the pregnant and non-pregnant states. 
Mare ID
Mare MHC
haplotype#
Mating stallion
MHC haplotype#
Gestational day of 
PBMC isolation
3845 A5 / W16 A2 / A2 31
3837 ? / ? A2 / A2 29
3157 A3 / A3 A2 / A2 30
3638 A7 / ? A3 / A3 30
2885 A3 / A3 A2 / A2 31
3419 A2 / A5 A3 / A3 32
3099 A2 / A2 A3 / A3 29
3725 A2 / ? A3 / A3 31
3641 A3 / A19 A2 / A2 31
3820 A19 / W16 A2 / A2 32
3354 A3 / A3 A2 / A2 29
3640 A3 / ? A2 / A2 30
3493 A2 / ? A3 / A3 31
2998 ? / ? A3 / A3 30
3821 A6 / W16 A3 / A3 30
# MHC types of the horses were determined by a standard lymphocyte 
microcytotoxicity assay using alloantisera to Equine Leukocyte Antigen (ELA) 
markers that had been validated in international workshops, as described in the 
Materials and Methods.  Equine MHC haplotypes are designated by the letter 
A followed by a number.  The two mating stallions were purpose-bred MHC 
homozygotes from the Cornell experimental herd.  Mares known to be MHC 
homozygotes are indicated with the same nomenclature used for the stallions.  
Mares with one or two “?” designations are either homozygotes for the single 
defined haplotype they carry, or heterozygotes carrying a haplotype (or two) for 
which no identifying antisera are available.  The undetermined MHC haplotypes 
were not ELA-A2 or ELA-A3. 
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Table 2.2  Mares used for endometrial cup lymphocyte isolation and characterization 
Mare 
ID
Mare MHC 
haplotype#
Mating stallion 
MHC haplotype#
Gestational day 
of PBMC and 
ECL* isolation
Number of cells iso-
lated from endometrial 
cups
3382 A10 / ? A3 / A3 46 60.5 x 106
3549 A19 / ? A3 / A3 43 26.0 x 106
3842 A5  / ? A2 / A2 45 16.7 x 106
3845 A5  / ? A3 / A3 44 6.2 x 106
3837 A8  / ? A3 / A3 44 26.5 x 106
3901 A2 / A19 A2 / A2 45 25.5 x 106
# For a description of the MHC typing methods and assignments,  
see footnote to Table 1. 
* ECL: Endometrial Cup Lymphocytes
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Tissue and cell preparation
Heparinized samples of venous jugular blood were collected from mares during diestrus, at 
day 31+2 of pregnancy, or immediately prior to euthanasia, as indicated.  Peripheral blood 
mononuclear cells (PBMC) and peripheral blood lymphocytes (PBL) were isolated using 
methods described previously (Antczak et al, 1982; Wagner et al., 2008).  Endometrial cup 
lymphocytes (ECL) and endometrial lymphocytes (ENDO L) were isolated using an adaptation 
of a previously described method for human endometrial lymphocytes (Flynn et al., 1999).  
Equine uteri were obtained surgically immediately following euthanasia of six mares confirmed 
by transrectal ultrasonography to be day 43 to day 46 pregnant.  One mare was pregnant with 
twins. The tissue was placed immediately into Hanks Balanced salt solution (Gibco Invitrogen 
Corp, Carlsbad, CA) supplemented with 5% fetal calf serum (FCS, Hyclone, Logan, Utah).  The 
endometrial cups and approximately 2-3 mm of adjacent endometrium were dissected free of 
the remaining uterine tissues.  The average weight of the endometrial cup tissue was nine grams. 
Endometrial tissue was collected from a site distal to the endometrial cups.  Tissue was minced 
using scissors, then placed into a enzyme solution containing RPMI medium with 25 mM Hepes 
(Gibco Invitrogen Corp), 1% FCS, 1% (w/v) bovine serum albumin (Sigma, St Louis, MO), and 
35 U/ml DNase (Sigma) and incubated at 37 degrees.  After 10 minutes, collagenase (Sigma) 
was added to the enzyme solution at a concentration of 200 U/ml and the tissue incubated at 37 
degrees for an additional 20 minutes.  Tissue was then passed through 100 µm and 40 µm cell 
strainers (BD Biosciences, San Jose, CA).  The cell suspension was then washed in phosphate 
buffered saline (PBS) /0.5% FCS. Cell suspensions were subjected to fractionation using Ficoll-
Paque Plus (GE Healthcare, Piscataway, NJ).  Lymphocyte enriched cell suspensions were 
then washed twice in PBS /0.5% FCS.  Viability of isolated cells was confirmed using trypan 
blue exclusion, and found to be greater than 80-90% for all samples.  The total number of cells 
isolated from endometrial cups ranged from 1.1-3.6 x 106 cells/g of tissue (Table 2).  
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Cell Culture and Fluorescent labeling of cells and flow cytometry
ECL, ENDO L and PBMC were either fixed in 2% paraformaldehyde (Sigma) or stimulated with 
25 ng/ml phorbol 12-myristate 13-acetate (PMA) and 1 µM ionomycin (IO) in the presence of 
10 µg/ml brefeldin A as previously described (Wagner et al., 2008).  After 4 hours in culture, the 
stimulated cells were washed in PBS and fixed.  Cells were labeled with monoclonal antibodies 
to equine cell surface markers CD4 (HB61A, VMRD, Pullman, WA), CD8 (CVS8, Lunn et al, 
1998) and CD19 (CZ2.1, Lunn et al, 1998).  Cytokine staining was performed using anti-bovine 
interferon gamma (IFNG) (MorphoSys, AbD Serotec, Oxford, UK) and anti-equine interleukin 4 
(IL4) as previously described (Wagner et al., 2005, 2006).  CD4, CD8, and IL4 antibodies were 
conjugated to Alexa dyes (A647 or A488) and anti-bovine IFNG was FITC conjugated by the 
supplier.  For detection of intracellular expression of forkhead box P3 (FOXP3), ECL or PBL 
were isolated as described above.  Freshly isolated cells were labeled with a directly conjugated 
antibody to equine CD4, followed by fixation, permeabilization, and labeling using a FOXP3 
staining kit (eBioscience, San Diego, CA) and a cross reactive PE conjugated antibody to human 
FOXP3 (clone PCH101, eBioscience) or an IgG2a isotype control antibody (eBioscience) as per 
the manufacturer’s instructions.  Immunofluorescence flow cytometry was performed using a BD 
FACSCalibur (BD, Franklin Lakes, NJ) and data analysis was performed using Flowjo software 
(Tree Star, Ashland, OR).  For statistical comparison of the ECL and PBMC/PBL samples, and 
pregnant and non-pregnant PBMC, paired two-tailed Student’s t tests or Wilcoxon rank sum tests 
were used with alpha error = 5% using GraphPad Prism software.  For statistical comparison of 
the ECL, PBMC, and ENDO L samples, Krustal-Wallis or Tukey’s one-way analysis of variance 
tests were used with an alpha error = 5% using GraphPad Prism software. 
RNA isolation, cDNA synthesis Real Time RT-PCR
ECL and PBMC were isolated as described above.  RNA was isolated from 5 x106 snap frozen 
cells, following homogenization by QIAshredder (Qiagen, Valencia, CA), using a RNeasy kit 
(Qiagen) as directed by the manufacturer.  Five hundred nanograms of RNA was treated with 
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DNase I (Invitrogen, Carlsbad, CA), then first strand cDNA synthesis was carried out using M-
MLV Reverse Transcriptase (USB, Cleveland, OH) as per the manufacturer’s guidelines.  SYBR 
Green (Applied Biosystems, Shelton, CO) real time RT-PCR reactions for amplification of 
equine FOXP3 or the housekeeper gene equine ubiquitin-conjugating enzyme E2D 2 (UBE2D2) 
(de Mestre et al., 2003) mRNA were performed using a ABI PRISM 7700 or 7500 Fast sequence 
detector (PerkinElmer Life Sciences) in a total volume of 20 µl.  Primers were designed over 
intron / exon boundaries to prevent amplification of genomic DNA.  A dissociation curve was 
performed after each experiment to confirm that a single product was amplified.  A standard 
curve was generated for FOXP3 and UBE2D2 genes using known copy numbers of a plasmid 
that contained the cDNA specific to the gene.  Each FOXP3 sample was first normalized to 7500 
copies of UBE2D2. The percentage of CD4+ lymphocytes in an aliquot of each sample was 
determined by flow cytometric analysis and FOXP3 mRNA expression was normalized to 50% 
CD4+ lymphocytes.  The sequences of the oligonucleotides are FOXP3RT1: TGGCAAATG-
GTGTCTGCAA; FOXP3RT2: GCGCTCTGCCCTTCTCATC; UBC1: TGAAGAGAATCCA-
CAAGGAATTGA; UBC2: CAACAGGACCTGCTGAACACTG.  Changes in expression were 
analyzed for statistical significance by using a paired two-tailed Student’s t test.
Tissue immunohistochemistry
Sections of endometrial cups and endometrium obtained at necropsy were fixed in buffered form-
aldehyde for conventional histology or transferred immediately to O.C.T. embedding compound 
(VWR Scientific Products, Willard, OH), snap frozen in an isopentane bath in liquid nitrogen, 
and then stored at -80 degrees C.  Immunohistochemical labeling of frozen sections was per-
formed as previously described (de Mestre et al., 2008). 
Results 
Prior work had established that lymphocytes from pregnant mares show a decrease in capacity to 
generate cytotoxic T cells towards the mating stallion compared to the non-pregnant state (Baker 
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et al. 1999).  In the first part of this study, selected additional aspects of the immune status of a 
cohort of 15 mares was compared during pregnancy and in the non-pregnant state.  Jugular blood 
samples were obtained prior to the establishment of pregnancy, and again at about 30 days of 
gestation, a stage in which the decrease in CTL reactivity had been readily detected.  The compo-
sition of the lymphocyte populations, cytokine profiles, and FOXP3 expression were determined 
in PBMC samples from the mares.  All of the mares were mated to produce MHC incompatible 
conceptuses, using one of two MHC homozygous stallions (Table 1).  
Peripheral CD4 and CD8 populations in early pregnancy in the mare
Flow cytometry with equine specific monoclonal antibodies was used to determine the 
percentage of peripheral blood lymphocytes expressing the T lymphocyte subset markers CD4 
or CD8 (Figure 3).  The average percentage of CD4+ lymphocytes was 56% in the non-pregnant 
state, and 54% in the pregnant state, and ranged between 40% and 70% of total lymphocytes.  
The average percentage of CD8+ lymphocytes was 16.5% in the non-pregnant state, and 17% 
in the pregnant state, and ranged between 9% and 23% of total lymphocytes.  There were no 
significant changes in the percentages of CD4+ lymphocytes or CD8+ lymphocytes between the 
pregnant and non-pregnant states.  However, there was a trend towards decreasing CD4+ lym-
phocytes and increasing CD8+ lymphocytes in the mares during pregnancy.  Thus, the ratio of 
CD4:CD8 was significantly reduced in pregnancy compared to the non-pregnant state. 
Changes in cytokine producing lymphocytes in early equine pregnancy
The percentages of peripheral blood lymphocytes expressing IFNG or IL4 were determined 
using newly characterized monoclonal antibodies reactive with these equine cytokines (Figure 
4).  In the population of mares under study, the percentage of IFNG+ lymphocytes varied con-
siderably in both the non-pregnant and pregnant groups.  In the mares sampled when pregnant, 
there was a trend towards increases in the percentages of IFNG+ cells in the overall lymphocyte 
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Figure 2.3 Cell surface marker expression by peripheral lymphocytes from mares during 
the pregnant and non-pregnant states.  Flow cytometric analysis of paired samples of PBMC 
isolated during early pregnancy (days 29-33) or the luteal phase of estrous (n=15).  Cells were 
labeled with monoclonal antibodies to cell surface markers as described in Materials and Meth-
ods.  A. Percentage of peripheral lymphocytes expressing CD4.  B. Percentage of peripheral 
lymphocytes expressing CD8.  C. The ratio of CD4+:CD8+ peripheral lymphocytes.
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Figure 2.4  Cytokine expression by peripheral lymphocytes from mares during the preg-
nant and non-pregnant states.  Flow cytometric analysis of IFNG and IL4 expression of paired 
samples of PBMC isolated during early pregnancy (days 29-33) or the luteal phase of estrous 
(n=15).  Cells were stimulated then stained for intracellular cytokines and cell surface markers as 
described in materials and methods.  A. Percentage of peripheral lymphocytes expressing IFNG.  
Β. Percentage of CD8+ peripheral lymphocytes expressing IFNG.   C. Percentage of peripheral 
lymphocytes expressing IL4.  D. The ratio of IFNG+:IL4+ peripheral lymphocytes. 
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population (Fig. 4A) and in the sub-population of CD8+ T cells (Fig. 4 B), although these chang-
es were not statistically significant.  However, there was a modest increase in the percentage of 
IL4+ cells (Fig. 4C) and a decrease in the IFNG:IL4 ratio (Fig. 4D) in the overall lymphocyte 
population in the mares during pregnancy.  
FOXP3 expressing lymphocytes were unchanged during early equine pregnancy
A quantitative RT-PCR assay was used to determine the number of transcripts of the immunoreg-
ulatory transcription factor FOXP3 in lymphocyte samples collected from mares in the pregnant 
and non-pregnant state (Fig. 5).  The values were normalized to the percentage of CD4+ lympho-
cytes detected in the PBMC samples.  There was a trend towards an increase in FOXP3 expres-
sion in the pregnant group, but the difference was not statistically significant. 
Figure 2.5  FOXP3 expression by peripheral lymphocytes from mares during pregnant 
and non-pregnant states.  Quantitative real-time PCR analysis of FOXP3 expression in paired 
samples of cDNA from PBMC isolated during early pregnancy (days 29-33) or the luteal phase 
of estrous (n=15).  Absolute numbers of FOXP3+ transcripts were determined and normalized to 
a housekeeper gene and the number of CD4+ lymphocytes as described in Materials and Meth-
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Phenotype of lymphocytes at the equine fetal-maternal interface
The second part of this study compared immune reactivity of equine peripheral blood 
lymphocytes with tissue lymphocyte populations from the endometrium in samples obtained at 
necropsy in a group of six pregnant mares between days 43 and 46 of gestation.  The endometrial 
cup reaction is characterized by focal accumulations of CD4+ and CD8+ lymphocytes which 
are located both within and immediately surrounding the eCG secreting terminally differentiated 
invasive trophoblast cells.  The endometrium located away from the endometrial cups contains 
only small numbers of leukocytes (Fig. 2C and Grunig et al., 1995).  For these investigations 
we isolated cells from both the endometrial cups and the endometrium.  The endometrial cups 
represent only a small portion of the total endometrial surface (Fig. 1B).  On average, 9 grams 
of endometrial cup tissue was recovered from each uterus.  The endometrial cups were dissected 
from the endometrium by trimming away all but 2-3 mm of adjacent endometrial tissue, and 
subjected to enzyme mediated digestion.  This yielded an average of 38 million cells for analysis. 
In contrast, about 30 grams of endometrium was typically used for cell isolation, resulting in 
recovery of only about 10 million total cells.  
In order to determine the phenotype of the cells isolated from endometrial tissues, we performed 
flow cytometric analysis with equine specific monoclonal antibodies.  Using gates set for lym-
phocytes, the percentages of cells expressing equine CD4, CD8, and CD19 were determined and 
compared to values obtained from peripheral blood samples taken from the mares on the day of 
necropsy.  The cells isolated from the endometrial cups were comprised of 35% CD4+ lympho-
cytes, 20% CD8+ lymphocytes, and only about 3% B cells.  In the endometrial cell population 
4.7% of the cells were CD4+, with 7.7% positive for CD8, and less than 1% B cells.  The cells 
isolated from endometrial cups and endometrium contained variable numbers of contaminating 
non-lymphoid cells.  The PBMC populations had an average of 53% CD4+ lymphocytes, 12% 
CD8+ lymphocytes, and 14% B cells.  Although the ratios of CD4+:CD8+ cells appeared dif-
ferent in the three groups, because of high variance in the PBMC group the differences were not 
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Figure 2.6  Cell surface marker expression of lymphocytes isolated from the equine ma-
ternal-fetal interface at day 43-46 of pregnancy. A. Flow cytometric analysis of lymphocytes 
isolated from endometrial cups (ECL): CD4 n=6, CD8 n=6, CD19 n=4; pregnant endometrium 
(ENDO. L): n=5; and PBMC: n=6. Cells were labeled for the cell surface markers CD4, CD8, 
and CD19 as described in Materials and Methods.  Upper left panel shows a representative 
image of forward scatter (FSC) and side scatter (SSC) of ECL and the gate set to analyze the 
lymphocyte population.  A similarly positioned gate was set to analyze ENDO. L and PBMC.  
B. The ratio of CD4+:CD8+ lymphocytes at the site of endometrial cups (ECL), in pregnant 
endometrium (ENDO. L.) and in the periphery (PBMC) (n=6).
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statistically significant (Fig. 6B). 
Cytokine expression by lymphocytes at the equine fetal-maternal interface
The percentages of lymphocytes expressing IFNG or IL4 in peripheral blood and in the endome-
trial cup lymphocyte population were determined in samples paired from the same donor mares 
(Fig. 7).  In every comparison between peripheral blood and endometrial cups, the percentage of 
IFNG+ lymphocytes was increased and the percentage of IL4+ lymphocytes was decreased in 
the local compartment in the uterus (Fig. 7 A and B).  There was a 36% increase in IFNG+ lym-
phocytes and a 65% decrease in IL4+ lymphocytes surrounding the endometrial cups (Fig. 7B).  
In the CD8+ subpopulation, this change was accentuated for IFNG, where there was an 84% 
increase in IFNG+ lymphocytes around the endometrial cups compared to PBMC (Fig. 7 C).  
Finally, these changes resulted in an approximately 3-fold increase in the ratio of IFNG to IL4 in 
the endometrial cups lymphocytes compared to lymphocytes from peripheral blood (Fig. 7 D). 
Evidence for regulatory T cells at the equine fetal-maternal interface
A combination of flow cytometry and quantitative RT-PCR assays were used to compare the 
expression of FOXP3 protein and messenger RNA in paired samples of CD4+ lymphocytes from 
the endometrial cups and peripheral blood of pregnant mares (Fig. 8).  In all cases the expression 
of FOXP3 was higher in the local lymphocyte population from the uterus compared to periph-
eral blood, and the levels in the grouped samples did not overlap.  There was a 3-fold increase in 
FOXP3 mRNA expression, which correlated well with the 3.2-fold increase in FOXP3+ cells in 
the same population.  It is likely that these CD4+, FOXP3+ lymphocytes represent equine regula-
tory T cells.  
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Figure 2.7  Cytokine expression by lymphocytes at the equine maternal-fetal interface.  
Flow cytometric analysis of IFNG and IL4 expression by paired samples of endometrial cup 
lymphocytes (ECL) and PBMC. Cells were stimulated ex vivo for 4 hours with PMA and IO 
in the presence of Brefeldin A.  A. Images of representative dot plots of ECL and PBMC cells 
isolated from one mare following labeling with IFNG (left panel), IL4 (middle panel) or an iso-
type control antibody (right panel).  Lymphocyte gates were set to analyze cytokine expression 
by the lymphocyte population.  B. Percentage of lymphocytes expressing IFNG (n=5 mares) or 
IL4 (n=4 mares).  C. Percentage of CD8+ lymphocytes surrounding the endometrial cups (ECL) 
or in the periphery (PBMC) producing IFNG (n=5) or IL4- (n=4).  Lymphocyte and CD8 gates 
were set to analyze the IFNG and IL4 populations.  D. The ratio of IFNG+:IL4+ lymphocytes at 
the site of endometrial cups (ECL) and in the periphery (PBMC) (n=4).
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Figure 2.8  Tregs are increased at the equine maternal-fetal interface.  A. Flow cytomet-
ric analysis of FOXP3 expression in paired samples of lymphocytes isolated from endome-
trial cups (ECL) and PBL (n=4 mares).  Lymphocyte and CD4 gates were set to analyze the 
FOXP3 population.  Representative dot plots of ECL used to calculate the FOXP3 population 
are shown.  B. FOXP3 mRNA expression in paired samples of lymphocytes isolated from 
endometrial cups (ECL) and PBMC (n=5 mares). 
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Discussion 
This study addressed aspects of two unresolved issues in reproductive immunology.  First is 
the question of systemic changes in maternal immune reactivity during pregnancy, and second 
is the relevance of those changes in the periphery to local immunological events at the fetal-
maternal interface.  The pregnant mare is a good subject in which to address these issues because 
the horse provides the opportunity for examination of peripheral immune responses before and 
during pregnancy in the same individual, and also for direct comparison of peripheral and local 
responses in the uterus.  In the mare there is an early, robust, and consistent antibody response 
to the fetus (Antczak et al., 1984), and evidence for diminished capacity to generate cytotoxic 
lymphocytes reactive against paternal MHC class I antigens during pregnancy (Baker et al., 
1999).  In a large, well-controlled cohort of mares sampled before and during pregnancy, we 
detected only slight changes in the character and composition of peripheral blood lymphocytes.  
In contrast, we measured significant differences in the same variables when comparing the 
periphery with the endometrium in pregnant mares.  
Many physiologic changes accompany the transition from the non-pregnant to the pregnant 
state, including alterations in cells and molecules of the immune system.  These changes 
may reflect specific maternal immunological recognition of the conceptus (Antczak, 1989), a 
generalized shift in the character of the maternal immune system that favors the development of 
the semi-allogeneic fetus (Baker et al., 1999; Krishnan et al., 1996a; Pejcic-Karapetrovic et al., 
2007), or specific tolerance to paternal and / or fetal alloantigens (Tafuri et al., 1995; Jiang & 
Vacchio, 1998; Ait-Azzouzene et al., 1998, 2001; Erlebacher et al., 2007).  It is in this context 
that the term ‘split tolerance to trophoblast’ offers a novel framework for defining the complex 
immunological relationship between mother and fetus.  
At the systemic level represented by the circulating cells of the immune system, there is evidence 
for changes during pregnancy in several species in the percentages of lymphocytes producing 
specific cytokines (Faas et al., 2005), in the ratios and numbers of lymphocytes and lymphocyte 
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subsets (Faas et al., 2005), and in the numbers of regulatory T cells (Aluvihare et al., 2004; 
Somerset et al. 2004; Saito et al. 2005; Oliviera & Hansen, 2008).  In humans, it has been 
reported that in peripheral blood the percentage of lymphocytes producing IFNG decreases, and 
the percentage of lymphocytes producing IL4 does not change.  In contrast, in rats the percentage 
of IFNG and IL4 producing lymphocytes during pregnancy did not change, although the total 
number of circulating lymphocytes was reduced (Faas et al., 2005).  In cattle, at day 33-34 
of pregnancy no changes in the numbers of CD4, CD8, or gamma-delta T cells were detected 
compared to the non-pregnant state, but the percentage of CD4+ T cells that also expressed 
CD25+ (presumed Tregs) was increased (Oliveira and Hansen, 2008).  The changes measured 
in one species are not always identified in studies in other species, but overall, the research cited 
supports the generality of peripheral immune system alterations during pregnancy.  One of the 
most consistent changes noted in these studies is the increase in regulatory T cells in peripheral 
blood during pregnancy.  
The immune status differences we measured in the periphery between the pregnant and 
non-pregnant state in mares were not dramatic.  Thus, the ratios of CD4+:CD8+ T cells, the 
percentages of T cells expressing either IFNG or IL4, and the number of FOXP3 transcripts in 
lymphocytes were not drastically altered during pregnancy.  Taken together, our results have 
not identified immunological pathways that might account for either the decreased capacity of 
mares to mount CTL responses against MHC class I antigens of the mating stallions (Baker et 
al., 1999), or the strong antipaternal alloantibody responses characteristic of MHC incompatible 
pregnancies in the mare (Antczak et al., 1984).  These results reinforce the idea that different 
components of the immune system are affected differentially during pregnancy. 
At the local level of the uterus, there is increasing evidence for the accumulation in the 
endometrium of lymphocytes with the CD4+CD25+FOXP3+ phenotype of Tregs in mice 
(Aluvihare et al., 2004; Zenclussen et al., 2006) and in humans (Tilburgs et al., 2006; Sasaki et 
al., 2007).  This is consistent with our findings in the mare reported here. We measured increased 
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numbers of FOXP3+ CD4+ T cells around the endometrial cups compared to peripheral blood 
(Fig. 8).  In the lymphocytes recovered from the endometrial cups, there was also a marked 
increase in IFNG+ cells in the total population and in the CD8+ subpopulation and a decrease 
in lymphocytes expressing IL4 (Fig. 7). Our results are in agreement with a recent study that 
reported high levels of expression of IFNG and undetectable levels of IL4 by human decidual 
CD8+ lymphocytes (Scaife et al., 2006). Interestingly, our findings, as well as those of Scaife 
and colleagues in human pregnancy, are in conflict to the traditional dogma that pregnancy is 
associated with a decrease in the ratio of Th1:Th2 cytokines. Again this highlights the important 
differences that exist between local and peripheral compartments of the immune system during 
pregnancy, and furthermore suggests that the cytokine milieu during pregnancy is more complex 
than previously reported. 
The increase in IFNG+ lymphocytes at the fetal-maternal interface may be related 
mechanistically to the increase in FOXP3.  It has been shown that IFNG conditions the 
development of Tregs that can mediate allograft acceptance in mice (Feng et al., 2008).  Five 
of the six pregnant mares we studied carried MHC incompatible conceptuses, and the sixth 
carried an MHC compatible conceptus.  Previous studies demonstrated that the lymphocyte 
accumulations around the endometrial cups are not diminished in MHC compatible pregnancies 
(Allen et al., 1984), and the results presented here suggest that the lymphocyte, cytokine, and 
FOXP3 profiles are also similar to those of MHC incompatible pregnancies.  To our knowledge, 
our results represent the first description of regulatory T cells in the horse.  
The immunological events in equine pregnancy are consistent with a state of split tolerance to 
trophoblast.  The early, robust alloantibody response in mares is induced locally in the uterus 
by the invasion of the chorionic girdle cells bearing high levels of polymorphic cell surface 
MHC class I antigens (Antczak et al., 1984; Donaldson et al, 1990, 1992).  Mares can generate 
very high secondary antibody responses in early pregnancy after prior priming in the periphery 
by skin grafting (Adams et al., 2007), and chorionic girdle cells transplanted to sites outside 
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the uterus in non-pregnant mares can stimulate alloantibody responses without any additional 
components of the conceptus (Adams and Antczak, 2001; de Mestre et al., 2008).  These results 
all point to the ability of the invasive trophoblast to induce a local B cell (antibody) response to 
the fetus in the endometrium.  
The involvement of the T cell arm of the immune system in the response to invading trophoblast 
seems much more complex.  The invasion of the endometrium by the chorionic girdle is 
accompanied by the accumulation of large numbers of CD4+ and CD8+ T lymphocytes 
around the base of the cups (Fig. 2 and Grunig et al., 1995).  An early interpretation of this 
endometrial cup reaction was that it represented T cell mediated recognition that would result in 
destruction of the endometrial cup trophoblast cells (Allen 1975, 1979).  The discovery that the 
chorionic girdle expresses high levels of polymorphic paternal MHC class I antigens, while the 
allantochorion trophoblast does not (Donaldson et al., 1990), suggested a reason why the uterine 
lymphocyte accumulations of early equine pregnancy were restricted to the area around the 
endometrial cups, and not the endometrium-allantochorion border.  
This solution, however, posed another question.  How do the endometrial cup trophoblasts avoid 
destruction by the surrounding T cells during their normal 50 – 70 day lifespan?  Although the 
invading chorionic girdle and early endometrial cups do express polymorphic MHC class I 
antigens, these molecules are lost from the cell surface as the cup trophoblast cells mature into 
their, binucleate, eCG secreting, terminally differentiated state (Donaldson et al., 1992, Maher 
et al., 1996).  This down regulation of MHC class I genes and molecules in the cup cells may 
extend their lifespan; classical alloreactive cytotoxic T lymphocytes should be unable to kill 
the mature, MHC class I negative endometrial cup trophoblasts.  This would enable to cups 
to safely secrete the eCG that is necessary to induce the secondary corpora lutea that provide 
the progesterone needed to maintain equine pregnancy until approximately day 100, when the 
placenta itself develops the capacity to produce progesterone.  The mechanisms that result 
in the death of the endometrial cup trophoblasts remain elusive: are they killed by an as yet 
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uncharacterized immune response, perhaps mediated by NK cells, or do they self-destruct, 
having outlived their usefulness? 
Equally intriguing are the mechanisms that prevent T cell mediated destruction of the day 38 - 45 
chorionic girdle and early endometrial cup trophoblasts that express MHC class I antigens.  In 
vitro studies demonstrated that equine MHC class I chorionic girdle trophoblasts are susceptible 
to killing by alloreactive cytotoxic lymphocytes, when the responding lymphocytes are obtained 
from non-pregnant horses (Baker et al., 2000).  Longitudinal studies of the leukocyte response 
to the endometrial cups revealed that the numbers of T lymphocytes around the cups diminish 
as the cups mature, and then increase again towards the end of the normal lifespan of the cups 
(Grunig et al., 1995).  This was interpreted as evidence for immunoregulatory events aimed at the 
T cells surrounding the cups.  The molecular and cellular phenotyping studies of endometrial cup 
lymphocytes reported here strengthen that hypothesis.  It may be that CD4+FOXP3+ regulatory 
T cells in the mare’s uterus are recruited to the site of chorionic girdle invasion, where they could 
act to prevent the pre-mature destruction of the endometrial cups before the cup trophoblasts 
down regulate their MHC class I antigens and thus become invisible to cytotoxic T cells.  
Co-cultures of invasive trophoblast cells and peripheral lymphocytes resulted in diminished 
lymphocyte proliferation to mitogenic stimuli (Flaminio and Antczak, 2005).  That model system 
may be an in vitro correlate of mechanisms operating in and around the endometrial cups.  
It is not known if the local regulatory T cells of the endometrial cups are related to the peripheral 
decrease in CTL capacity in the pregnant mare, but it seems unlikely, because the peripheral 
lymphocytes of pregnant mares had the same level of FOXP3 expression as lymphocytes from 
the mares when not pregnant.  The systemic, strong antibody responses of equine pregnancy 
highlight the robust, intact, B cell compartment of the mare during pregnancy and the ability 
of the mare’s immune system to generate serological responses to antigenic stimulation by 
the conceptus within the uterus.   In contrast, the evidence for different peripheral and local 
regulation of aspects of T cell immunity in the pregnant mare emphasizes the split nature of 
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tolerogenic mechanisms protecting the equine fetus from destruction by the maternal immune 
system. 
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CHAPTER 3
ANTIGEN-INDEPENDENT MODULATION OF  
T-CELL REACTIVITY DURING EQUINE PREGNANCY1
1Noronha, L.E. and Antczak, D.F., Antigen-Independent Modulation of  T-Cell Reactivity during 
Equine Pregnancy. To be submitted to the American Journal of Reproductive Immunology.
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Abstract 
Problem: Pregnant mares demonstrate a reduction in cytotoxic T lymphocyte (CTL) reactivity 
against cells from the breeding stallion. We investigated whether this effect is limited to activity 
against paternal MHC antigens, and whether it occurs during MHC compatible pregnancy.
Method of Study: Mares were mated to carry MHC compatible or incompatible pregnancies.  
CTL activity of these mares when pregnant and non-pregnant was measured against cells from 
horses with MHC haplotypes unrelated to the mare or breeding stallion.  
Results: While carrying MHC incompatible pregnancies, mares demonstrated reduced CTL 
activity against lymphocytes from third party horses in addition to those from the breeding 
stallion.  This effect was also observed in mares carrying MHC compatible pregnancies.  
Conclusions: The decrease in maternal T-cell reactivity characteristic of normal equine 
pregnancy is not restricted to paternal alloantigen, and occurs during MHC-matched matings. 
This suggests that antigen-independent mechanisms may be responsible for this reduction in cell-
mediated immune activity.
Introduction
The placenta expresses fetal molecules of paternal origin at the maternal-fetal interface and 
thus represents a source of foreign antigens within a pregnant mother.  However, unlike a 
conventional tissue graft, the semi-allogeneic fetus is not rejected during normal pregnancy. 
Although the maternal-fetal immunological relationship has been intensively researched, 
the complex mechanisms that lead to maternal tolerance remain unclear. Due to the obvious 
evolutionary advantage of reproductive success, it is likely that multiple overlapping processes 
exist at the placental, fetal, and systemic levels to ensure acceptance of the fetus.  The scope 
of this study focuses on pregnancy-protective changes that occur at the systemic level of the 
maternal immune response, specifically in the T-cell compartment.
In general terms, modulation of maternal responses to fetal antigens could be the result of a 
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failure to recognize the fetus (ignorance), or a failure to act upon that recognition (tolerance). 
There is evidence from multiple species that the maternal immune system is capable of 
recognizing paternal antigens such as Major Histocompatibility Complex (MHC) and minor 
histocompatibility (H) antigens. Humans, horses, mice, and rats can develop allospecific 
antibodies as a result of exposure to paternal MHC during pregnancy or birth (Van Rood, 
Eernisse et al. 1958; Antczak, Bright et al. 1982; Roe and Bell 1982; Antczak, Miller et al. 
1984; Smith, Amsden et al. 1986). Therefore maternal awareness of paternal antigens appears 
to be intact; in fact, evidence from several groups suggests that maternal recognition of paternal 
alloantigen is the stimulus for inducing maternal tolerance (Seavey and Mosmann 2006; 
Robertson, Guerin et al. 2009; Tilburgs, Scherjon et al. 2009; Zenclussen, Thuere et al. 2010). 
Systemic maternal tolerance to fetal antigens could be achieved by a generalized modulation 
in T-cell responses, or one limited to those that respond to paternal antigen.  While a reduction 
in reactivity to paternal alloantigens has obvious benefits to the maintenance of the fetus, a 
generalized immunosuppression could leave the pregnant mother susceptible to infectious 
disease. The existence of such an antigen-independent T-cell modulation is suggested by the 
observation that pregnant women (van der Klooster and Roelofs 1997; Smith 1999; Avelino, 
Campos et al. 2003) and mice (Luft and Remington 1982; Krishnan, Guilbert et al. 1996; 
Rowe, Ertelt et al. 2011) display increased susceptibility to intracellular infections such as 
toxoplasmosis, listeriosis, and salmonellosis. Also, women (Ostensen and Husby 1983) and mice 
(Waites and Whyte 1987) with cell-mediated auto-immune diseases, such as rheumatoid arthritis, 
may experience an amelioration of symptoms during pregnancy due to dampened T-cells 
responses.  
Evidence also exists for an antigen-specific modulation of maternal cell-mediated immune 
responses.  CD8+ and cytotoxic T lymphocytes (CTL), the primary effectors of cell-mediated 
immune responses, are responsible for allograft rejection and are therefore potentially deleterious 
to pregnancy. Indeed, increases in CD8+ and CTL have been associated with pregnancy loss in 
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women (Manyonda, Pereira et al. 1993; Yamada 1993; Kotlan, Fulop et al. 2001).  Decreases 
in anti-paternal CD8+ and CTL responses have been observed during pregnancy in several 
species (Clark and McDermott 1978; Parvin, Isobe et al. 1992; Tafuri, Alferink et al. 1995; Jiang 
and Vacchio 1998; Baker, Bamford et al. 1999; Erlebacher, Vencato et al. 2007; van Halteren, 
Jankowska-Gan et al. 2009).  In transgenic mouse models, some groups determined that the 
loss of function was antigen specific, and was the result of a specific clonal deletion (Tafuri, 
Alferink et al. 1995; Jiang and Vacchio 1998; Erlebacher, Vencato et al. 2007) and/or a functional 
unresponsiveness (Jiang and Vacchio 1998; Zhou and Mellor 1998; Erlebacher, Vencato et al. 
2007) of lymphocytes that recognize paternal antigen. 
However, others have observed a less restricted decrease in CTL function during pregnancy. In 
women, a reduction in CTL activity against viral infections such as Epstein-Barr virus has been 
observed (Nakamura, Miyazaki et al. 1993).  CTL isolated from pregnant mice have shown a 
reduced ability to lyse cells from a third party, i.e. with MHC antigens not of maternal or paternal 
origin (Hamilton and Hellstrom 1977; Clark, McDermott et al. 1980; Chaouat, Monnot et al. 
1982; Slapsys and Clark 1982; Thomas and Erickson 1986).  Some of these results were obtained 
during syngeneic (MHC compatible) matings, where no foreign paternal MHC antigens were 
present.  Therefore the antigen-specificity of maternal CTL modulation remains unclear.
Pregnancy in the horse has been uniquely informative in better understanding maternal tolerance 
to the fetus (Noronha and Antczak 2010).  Pregnant female horses (mares) demonstrate a 
clear immunological recognition of the fetus.   Nearly all mares carrying MHC incompatible 
pregnancies generate high cytotoxic alloantibody titers against the MHC antigens of the breeding 
stallion (Antczak, Bright et al. 1982; Antczak 1984) at levels similar to those resulting from 
conventional skin allografts (Adams, Oriol et al. 2007). However, pregnant mares demonstrate 
a reduced ability to generate effective CTL responses against stallion MHC antigens (Baker, 
Bamford et al. 1999). This effect is transient, and reverts after parturition; and it is not observed 
in males or non-pregnant females.  It is not known whether this effect is specific for, or 
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dependent upon paternal alloantigens.
The purpose of this study was to use better understand the specificity of this diminished cell-
mediated immune response in the pregnant mare. To this end, we utilized a herd of horses 
bred for homozygosity at the MHC region of the genome (Ellis, Bontrop et al. 2006) in order 
to generate MHC compatible and incompatible pregnancies.  Specifically, our aims were to 
determine: 1) if the decrease in maternal CTL activity is only observed against paternal MHC 
antigens, and 2) if it requires a MHC mismatch between the breeding mare and stallion.
Materials and Methods
Animals
Clinically healthy adult horses of mixed breeds and ages were used in these experiments (Table 
3.1).  Major Histocompatibility Complex haplotypes were assigned to the horses based on results 
of tissue typing using a panel of well-characterized alloantisera validated
in international workshops, complemented by genomic analysis (Lazary, Antczak et al. 1988; 
Tseng, Miller et al. 2010). Horses were maintained at the Equine Genetics Center, Baker Institute 
for Animal Health, Cornell University. Animal care was performed in accordance with the 
guidelines set forth by the Institutional Animal Care and Use Committee of Cornell University.  
Mares of various MHC haplotypes were artificially inseminated with fresh semen collected from 
either a stallion homozygous for the ELA-A2 or -A3 haplotype to generate MHC matched (n=4) 
or mismatched (n=6) pregnancies.  The day of ovulation was determined by daily transrectal 
ultrasound examination, from which gestational ages were deduced.  Fetal viability was 
confirmed by observing fetal heartbeat via transrectal ultrasonography prior to blood collection.
CTL Assays
Excepting animal #3164 (gestation day 320), matched heparinized venous blood samples were 
collected from each mare at 31-34 days of pregnancy and before and/or after pregnancy.  It 
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Table 3.1: Summary of mares used for CTL assays.
Mare
Accession#
Age 
(years)
Mare MHC 
type1
Breeding 
Stallion 
MHC type1
Histocompatibility 
of Pregnancy2
Day of 
gestation 
tested
3725 6 A2/? A3/A3 Incompatible 33
3558 15 A2/A2 A3/A3 Incompatible 31
3819 8 A6/? A2/A2 Incompatible 34
4066 6 A2/A19 A3/A3 Incompatible 31
4065 9 A19/? A3/A3 Incompatible 33
30993 17 A2/A2 A3/A3 Incompatible 32
30993 17 A2/A2 A2/A2 Compatible 33
3601 8 A3/A3 A3/A3 Compatible 34
3164 16 A3/A3 A3/A3 Compatible 320
3880 3 A3/A3 A3/A3 Compatible 32
1Equine MHC Haplotypes were assigned as described in Materials & Methods.  Haplotypes are 
designated as Equine Leukocyte Antigen (ELA)-AX where X is a number that refers to a haplotype 
defined by serological +/- molecular tissue typing.  Animals assigned “?”  carry a haplotype for which 
no identifying antisera are available, but which has been determined to be distinct from the breeding 
stallions and third party animals. 2Pregnancies generated from two animals of the same MHC type are 
designated as “histocompatible;” those from animals with different MHC types are “histoincompatible.” 
3Mare 3099 was mated to generate 2 different pregnancies, separated by 2 months.
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was previously determined that there is no difference in CTL activity as a result of previous 
matings (Baker, Bamford et al. 1999).  Peripheral blood mononuclear cells  (PBMC) were 
isolated using density gradient centrifugation as previously described (Wagner, Hillegas et al. 
2008).  CTL assays were performed as previously described (Baker, Bamford et al. 1999) with 
modifications as follows.  108 PBMC were placed into a T75 flask with 5 x 107 stimulator cells 
that had been irradiated using a cesium source (Gammacell 40; Nordion International, Ottawa, 
ON, Canada) at a dose of 950 rads. Cultures were maintained in “ARM” medium: 10% FCS 
(Clontech, Mountain View, CA), 45% AIMV, 45% RPMI-140, 1X NEAA, 0.5X NaPyruvate, 
1X Penicillin/Streptomycin, 1X 2-mercaptoethanol (all Gibco, Grand Island, NY).  Flasks were 
incubated upright at 37°C in 5% CO2 for 7 days. On day 7, the cultures
 were re-stimulated with 
freshly prepared irradiated stimulator cells that were plated at half the density of the surviving 
responder cells. All cultures were stimulated for a total of 10 days. Pokeweed mitogen (Sigma, 
St. Louis, MO)-stimulated target cells were labeled with 51chromium (Perkin-Elmer, Boston, 
MA) for 6 hours at 37°C, 5% CO2.   Labeled targets were plated to give effector:target ratios of 
100:1, 50:1, 25:1,12.5:1, 6.25:1, and 3.1:1in 150 ml final volume in 96-well round-bottom plates. 
Spontaneous release control wells contained only target cells and medium. Total release control 
wells contained 10% Triton X-100 (Sigma) and target cells. The average spontaneous release did 
not exceed 15% in any assay. All test dilutions and controls were done in triplicate. The assay 
plates were incubated at 37°C in 5% CO2 for 4 h and then centrifuged at 1000xg for 5 minutes. 
Cell supernatants were harvested using Molecular Devices Supernatant Collection System 
(Sunnyvale, CA).  51Cr activity was measured with a Wallac 1470 gamma counter (Perkin Elmer) 
as cpm over 2 minutes. 
Data Analysis
Percent cytotoxicity was normalized to the spontaneous and total release controls using the 
following formula: % cytotoxicity = [mean sample release - mean spontaneous release]/[mean 
total release - mean spontaneous release]. Deviations from Gaussian distribution were tested 
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for using the Kolmogorov-Smirnov normality test.  Non-parametric data were normalized 
using the simple transformation Y=log(Y) (Figure 3.5).   Normalized % cytolysis values at 
effector:target=100:1 were tested with a repeated-measures (paired) Student’s t-test to determine 
statistical significance (p<0.05). All statistics were performed using Graph Pad Prism software, 
v4.0 (San Diego, CA).  
Results
In order to test the antigen specificity of T-cell responses in mares carrying MHC compatible and 
MHC incompatible pregnancies, specific matings were established between animals based upon 
their MHC haplotypes (Table 3.1, Figure 3.1).  Paired PBMC samples were isolated from the 
mares while pregnant and non-pregnant. CTL were primed in vitro for 10 days, and then tested 
for cytolytic capacity using a standard quantitative chromium-release cell lysis assay. 
CTL Activity Against Third Party MHC Antigens is Reduced During Pregnancy
 We first investigated whether the previously observed pregnancy-associated reduction in 
CTL activity is limited to reactivity against paternal MHC antigens.  Six mares of various 
MHC haplotypes were artificially inseminated with semen from a stallion of a different MHC 
haplotype in order to establish MHC incompatible pregnancies. PBMC were isolated from the 
same mares while non-pregnant and during pregnancy.  CTL were generated in vitro against 
stimulator cells from: 1) the breeding stallion, and 2) a horse with a MHC haplotype different 
from both the mare and stallion (third party). These primed CTL were then tested for the ability 
to lyse cells from the respective stimulator animals as well as control animals. 
The baseline activity of CTL isolated from non-pregnant mares was robust and specific for the 
MHC of the stimulator animals (Figure 3.2).  As previously observed, CTL from mares carrying 
incompatible pregnancies demonstrated a significantly diminished capacity to lyse cells from 
the breeding stallion with the mean cytolysis decreasing from 30% (NP, non-pregnant) to 5% 
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Figure 3.1  Summary diagram of experimental design. Mares were artificially inseminated to 
generate either (a) MHC-incompatible) or (b) MHC-compatible) pregnancies.  PBMC were 
isolated from the mares during pregnancy, and while non-pregnant (dashed arrows). CTL 
were differentiated in vitro for 10 days and tested for the ability to lyse target cells from the 
breeding stallion and third party animals. Representative equine leukocyte antigen (ELA) 
MHC haplotypes are used (i.e. ELA-A2= “A2”); full animal details are listed in Table 3.1.  
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Figure 3.2  CTL activity in non-pregnant mares is robust and specific for the MHC of the 
stimulator animal.  Curves demonstrating cytolysis of target cells at decreasing effector: target 
cell ratios are shown for Mare #3558, homozygous at the MHC for the ELA-A2 haplotype, 
stimulated against an A3 (a) and A5 (b) animal during the 10 day in vitro CTL differentiation 
phase of the assay.  Target cells listed as “self” and “specificity controls” are negative controls to 
demonstrate specific lysis of only stimulator cells.  
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(P, pregnant) (Figure 3.3).  When CTL from these mares were tested for the ability to lyse cells 
from an unrelated third party individual, a similar decrease from 39% while non-pregnant to 9% 
cytolysis while pregnant was observed (Figure 3.4).  
CTL Activity is Reduced During MHC Compatible Pregnancy
In order to investigate whether a mismatch between maternal and paternal MHC antigens may 
be required to generate maternal tolerance, we next tested maternal CTL responses during MHC 
compatible pregnancy.
Four mares homozygous at the MHC region for the ELA-A2 or -A3 haplotype were mated to a 
homozygous stallion of the same haplotype in order to establish compatible pregnancies.  CTL 
were generated in vitro against stimulator cells from two different third party animals with MHC 
haplotypes distinct from both the stallion and mare.  Differentiated CTL were tested for the 
ability to lyse cells from the third party animals as well as negative controls. CTL from mares 
pregnant with MHC compatible pregnancies demonstrated a reduced capacity to lyse target cells 
from male (48% NP, 18% P; Figure 3.5a, b) and female (51% NP, 17% P; Figure 3.5c, d) third 
party animals. 
Discussion
These data expand upon the previous observation that anti-paternal CTL responses are 
dramatically reduced in pregnant mares (Baker, Bamford et al. 1999).  Here, we demonstrate 
that this reduction occurs independently of paternal MHC antigens on two levels.  First, the 
mare’s inability to generate effective CTL is not limited to responses directed against the MHC 
of the breeding stallion.  Second, a disparity between maternal and paternal MHC antigens is not 
necessary to induce this effect.
Our observations regarding the antigen-independent nature of these changes in CTL activity are 
consistent with data from both human and mouse studies.  In studies using selective breeding 
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p=0.0004
Figure 3.3  The CTL response is reduced against the breeding stallion during MHC incompatible 
pregnancy. Six mares were tested for the ability to generate effective CTL responses against 
cells from an MHC-disparate stallion while non-pregnant vs. while pregnant with incompatible 
pregnancies sired by that stallion. “Effectors” refers to CTL derived from the mares; “targets” 
refers to 51Cr-labeled lysis-target PBMC from the breeding stallion with either an ELA-A3 
or A2 MHC haplotype as indicated in Table 3.1. (a) Curve showing cytolysis at decreasing 
effector:target cell ratios for CTL collected from mare #3558 while non-pregnant and during 
pregnancy.  (b) Graph showing cytolysis at effector:target=100:1 for six mares.
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p=0.0043
Figure 3.4  The CTL response is reduced against third party cells during MHC incompatible 
pregnancy. The six mares described in Figure 3.3 were tested for the ability to generate effective 
CTL responses against cells from an animal (third party) with a MHC haplotype different from 
both the mare and breeding stallion. “Effectors” refers to CTL derived from the mares; “targets” 
refers to 51Cr-labeled PBMC from the third party animal with an ELA-A5 haplotype. (a) Curve 
showing cytolysis at decreasing effector:target cell ratios for CTL collected from mare #3558 
while non-pregnant and during pregnancy.  (b) Graph showing cytolysis at effector:target=100:1 
for six mares.
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Figure 3.5 The decreased CTL response observed during pregnancy does not require MHC 
incompatibility between sire and dam. Four mares were tested for the ability to generate effective 
CTL responses against cells from two different third party animals while non-pregnant  vs. while 
pregnant with MHC compatible pregnancies. Full cytolysis curves at decreasing effector:target 
cell ratios are shown for mare # 3099. Graphs showing cytolysis at effector:target=100:1 for all 
four mares. Top: cytolytic activity against cells from a male third party with either an ELA-A2 or 
A3 MHC haplotype, as appropriate for a mismatch, (a, b). Bottom: activity against cells from a 
female third party animal with an ELA-A5 haplotype (c, d). 
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of mice to generate allogeneic (MHC incompatible) pregnancies, results similar to ours were 
observed— CTL activity against third party MHC target cells was reduced during allogeneic 
pregnancy (Clark, McDermott et al. 1980; Thomas and Erickson 1986).  During human 
pregnancy, deficits in virus-specific CTL populations have been observed (Nakamura, Miyazaki 
et al. 1993), demonstrating that CTL responses against some non-paternal antigens may be 
modulated in pregnant women. Observations in other species also parallel our findings that there 
is a reduction of maternal CTL reactivity during MHC compatible pregnancies.  In multiple 
mouse studies investigating syngeneic (MHC compatible) pregnancies, reductions in maternal 
CTL reactivity against third party MHC were demonstrated (Hamilton and Hellstrom 1977; 
Chaouat, Monnot et al. 1982; Slapsys and Clark 1982; Thomas and Erickson 1986). 
If indeed the maternal CTL response is suppressed in an antigen-independent manner, one 
major concern is that the pregnant mother could have an increased susceptibility to infectious 
disease. Epidemiological evidence for an equine pregnancy-induced susceptibility to pathogens 
is not clear.  Mares are vulnerable to a number of pregnancy-associated abortogenic infections 
(Ellis, Bryson et al. 1983; Givens and Marley 2008; Lunn, Davis-Poynter et al. 2009), but this 
may be due pathogen tissue tropism rather than a general systemic immune tolerance. Equine 
Herpes Virus Type-1 (EHV-1) is one common equine abortogenic virus that is controlled by 
CTL responses.  It has been observed that seropositive pregnant mares have lower baseline 
numbers of EHV-1 specific effector CD8+ cells compared to normal healthy adults (Paillot, Daly 
et al. 2007). However, they were capable of increasing that population in response to infection. 
A similar situation has been observed in the response of pregnant women to cytomegalovirus 
(Lissauer, Choudhary et al. 2011). To date, no direct comparison has been made between CTL 
responses of pregnant and non-pregnant horses and there is not currently sufficient evidence to 
conclude whether pregnant mares might have a diminished response to pathogens. 
It is not yet clear what mechanism is causing the reduction in T cell responses seen here.  One 
explanation is that there could be a pregnancy-associated reduction in CD8+ CTL precursors, 
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as has been observed in transgenic mouse studies (Tafuri, Alferink et al. 1995). In the horse, 
no difference in the number of circulating CD8+ lymphocytes has been detected between non-
pregnant mares and mares in early and late pregnancy (Agricola, Carvalho et al. 2008; de Mestre, 
Noronha et al. 2010), or between normal pregnant mares and those that experienced early 
embryonic death (Krakowski, Krawczyk et al. 2010). 
An alternative explanation is that the number of CTL may not change, but their cytolytic 
activity may be suppressed.  One pregnancy-associated factor that can affect immune cells in an 
antigen-independent manner is the physiological state of pregnancy, i.e. the hormonal milieu. 
Levels of estrogens and progesterone, which reach extremely high levels in pregnancy, have 
been implicated in the increased susceptibility to pathogens in human and mice (Beagley and 
Gockel 2003). In progesterone treated pseudopregnant mice, a modulation in CTL activity has 
been observed, suggesting that the hormonal environment of pregnancy was sufficient to induce 
CTL modulation (Slapsys and Clark 1982).  In women, CTL cytolysis is nearly absent during 
the menstrual cycle secretory phase, which is characterized by high levels of estradiol and 
progesterone, (White, Crassi et al. 1997).  Therefore, there is evidence in two different species 
that hormonal changes alone, in the absence of paternal antigens, can modulate CTL activity.  In 
the horse, there is some evidence for a progesterone-associated increase in neutrophil activity 
(Watson, Stokes et al. 1987), but no relationship has been demonstrated between reproductive 
hormones and acquired immunity.
Another potential mechanism of CTL modulation related to hormonal suppression is the 
production of soluble immunomodulatory factors by the placenta and uterus.  In humans and 
mice, several placenta-derived secreted factors, such as IDO, Fas ligand, soluble HLA-G, and 
trophoblast microvesicles (Morales, Pace et al. 2003; Pap, Pallinger et al. 2008), have shown 
evidence for T-cell modulation at local and systemic levels. Maternal endometrial factors such as 
galectin-1and PD-1, also demonstrate such activity.  In the horse, no specific factors have been 
isolated, but several groups have demonstrated that soluble factors produced by trophoblast and 
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endometrium can inhibit the proliferation and activity of peripheral maternal lymphocytes in 
vitro (Watson 1990; Lea and Bolton 1991; Watson and Zanecosky 1991; Roth, White et al. 1992; 
Flaminio, Yen et al. 2004; Flaminio and Antczak 2005). It is not yet known if these molecules are 
capable of acting systemically in the pregnant mare.
CTL function may also be modulated by the suppressive activity of other immune cells. 
Regulatory T cells (Tregs) have been observed to expand during allogeneic and syngeneic 
mouse pregnancy in an antigen-independent manner, possibly due to the hormones of pregnancy 
(Aluvihare, Kallikourdis et al. 2004).  During horse pregnancy, CD4+FOXP3+ Tregs increases 
dramatically in the uterus, but no difference in FOXP3 gene expression has been detected 
between PBMC from mares carrying early pregnancies and non-pregnant mares in the luteal 
phase of estrous (de Mestre, Noronha et al. 2010).  However, because Treg expansion in 
pregnancy may be an estrogen-dependent event (Polanczyk, Carson et al. 2004; Prieto and 
Rosenstein 2006), the difference may not have been detectable at these time points which are 
both progesterone-dominant in the horse. Therefore, while Tregs appear to have a role at the 
fetal-maternal interface of the horse, it is not known if they contribute to the effect seen here with 
peripheral CTL populations.
A number of immunomodulatory cytokines produced by T cells and innate immune cells can 
also reduce CTL activity. IL-4 has been shown to reduce anti-viral CTL responses (Aung, Tang 
et al. 1999) and protect against CTL-mediated allograft rejection (Gao, Chen et al. 1996).  It 
can also be induced in an antigen-independent manner by estradiol (Hepworth, Hardman et al. 
2010) and progesterone (Druckmann and Druckmann 2005).  We have previously reported that 
mares experience an increase in the number of circulating IL-4+ lymphocytes during MHC 
incompatible pregnancy (de Mestre, Noronha et al. 2010).  However, this did not occur during 
MHC compatible pregnancy (data not shown), and is therefore unlikely to be the cause of the 
CTL deficiency seen here.  
The mechanism of CTL modulation during equine pregnancy is not yet clear.  The effect appears 
94
to exist in manner independent of maternal-fetal MHC compatibility. However, the reduction in 
cytolysis in this study was most pronounced among mares carrying an MHC-incompatible fetus.  
It is possible therefore that the phenomenon has a multifactorial origin with some amount antigen 
dependence.  The cumulative effect of multiple, less antigenic minor histocompatibility antigens 
in MHC compatible pregnancies could be sufficient to induce CTL modulation. This is consistent 
with what has been observed in women carrying MHC matched, H-antigen mismatched fetuses; 
a combination of a reduction in circulating CTL, and a suppression of remaining CTL by Tregs 
(van Halteren, Jankowska-Gan et al. 2009).  
The collective data from multiple species remains inconclusive regarding the role of paternal 
antigen in maternal tolerance. Here, we show here that the horse may contribute novel 
information to further investigations of this highly complex phenomenon.
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CHAPTER 4
MOLECULAR EVIDENCE FOR NATURAL KILLER CELLS  
IN EQUINE ENDOMETRIAL CUPS1
1Noronha, L.E., Huggler, K.H., de Mestre, A.M., Miler, D.M., Antczak, D.F., Molecular Evi-
dence for Natural Killer Cells in Equine Endometrial Cups. Placenta (submitted) 
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Abstract
Objectives
To identify equine orthologs of major NK cell marker genes and utilize them to determine 
whether NK cells are present among the dense infiltration of lymphocytes that surround the 
endometrial cup structures of the horse placenta during early pregnancy.
Study Design 
PCR primers were developed to detect the equine orthologs of NKP46, CD16, CD56, and CD94; 
gene expression was detected in RNA isolated from lymphocytes using standard 2-step reverse 
transcriptase (RT) PCR and products were cloned and sequenced. Absolute real-time RT-PCR 
was used to quantitate gene expression in total (n=5), CD3+ (n=4), and CD3- (n=4) peripheral 
lymphocytes, and invasive trophoblast (n=5).  Lymphocytes surrounding the endometrial cups 
(ECL) of five mares in early pregnancy were isolated and NK marker gene expression levels 
were assayed by quantitative RT-PCR.
Main Outcome Measures 
Absolute mRNA transcript numbers were determined by performing quantitative RT-PCR and 
comparing values to plasmid standards of known quantities.
Results
NKP46 gene expression in peripheral CD3- lymphocytes was higher than in CD3+ lymphocytes, 
CD16 levels were higher in the CD3+ population, and no significant differences were detected 
for CD56 and CD94 between the two groups. Expression of all four NK cell markers was 
significantly higher in lymphocytes isolated from the endometrial cups of pregnant mares 
compared to PBMC isolated from the same animal on the same day (NKP46, 14-fold higher; 
CD94, 8-fold higher; CD16, 20-fold higher; CD56, 44-fold higher). 
Conclusions
These data provide the first evidence for the expression of major NK cell markers by horse cells 
and the existence of a previously undetected population of NK cells in the equine endometrium 
during pregnancy.
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Introduction 
 Placentation in the mare is diffuse, epitheliochorial, and primarily non-invasive. However, 
the horse placenta contains a population of invasive placental cells called the chorionic girdle 
trophoblast.  These cells of fetal origin express both maternal and paternal polymorphic MHC 
class I antigen at very high levels (Bacon et al., 2002; Donaldson et al., 1994). During a period in 
early pregnancy, they invade the uterus of the pregnant mare, differentiate, and organize to form 
discrete tissue structures in the superficial endometrium known as endometrial cups (Allen et al., 
1973). Maternal mononuclear leukocytes are recruited into the endometrial stroma around the 
cups, forming a dramatic cellular infiltrate at the cup periphery. Our lab has previously identified 
these leukocytes as primarily CD4+ and CD8+ lymphocytes, most of which are also CD3+ 
(Grunig et al., 1995). Despite the seemingly hostile environment in which the trophoblast cells 
of the cups exists, they persist in situ until their eventual death approximately two months later.  
During this time, the paternal MHC class I antigen expressed on the surface of these trophoblasts 
is recognized by the maternal immune system and induces a robust humoral immune response 
in nearly all pregnant mares (Antczak, 1984). It is not clear how the highly antigenic trophoblast 
cells are able to evade the maternal immune response for such an extended period. 
In humans and mice, NK cells are the primary leukocyte population in the decidua during 
early pregnancy. Despite the implications of their name, they are weakly lytic and promote 
the establishment and maintenance of pregnancy.  In most species, NK cells of the uterus and 
decidua are distinct from peripheral populations in terms of phenotype and function (Croy et al., 
2006). Their role in pregnancy is not completely understood, but they have been implicated in 
vascular remodeling and facilitation of trophoblast invasion (Harris, 2011; Tabiasco et al., 2006).  
Changes in NK cell numbers and phenotype have been associated with multiple reproductive 
disorders in women (Lash and Bulmer, 2011); and NK cell-depleted mice demonstrate aberrant 
spiral artery development (Croy et al., 2003). Based upon the important role that NK cells play 
in species with invasive placentae, we wanted to determine whether they are present among the 
leukocyte infiltration that surround the invasive trophoblast of the equine endometrial cups.
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There is some evidence for an NK cell presence at the maternal-fetal interface of the horse.  
Electron microscopy studies of the equine endometrium during early pregnancy reveal large 
granular lymphocytes consistent with uterine NK cells (uNK) (Enders and Liu, 1991). But 
progress in the investigation of equine NK cells has been inhibited by a lack of reagents. Our 
lab has previously described a population of peripheral lymphocytes that exhibit NK cell-like 
characteristics by using a cross-reactive monoclonal antibody to a catfish vimentin-like protein 
shown to identify human NK cells (Viveiros and Antczak, 1999). Also, expression of LY49 
family genes has been detected by screening a horse spleen cDNA library (Bacon et al., 2002).  
However, to date, none of the primary markers used to phenotype NK cell cells, or methods to 
detect them, have been described in the horse.  In order to explore whether NK cells might play a 
role at the equine fetal-maternal interface, we identified equine orthologs of four NK cell marker 
genes and using molecular methods, investigated their expression in the endometrium during 
early pregnancy.
Materials and Methods
Animals
Horses used in this study were maintained at the Cornell Equine Genetics Center; all procedures 
were performed in accordance with guidelines established by the Institutional Animal Care and 
Use Committee of Cornell University. Adult horses of mixed genetic backgrounds, sexes, and 
ages were used (Table 4.1). Pregnancies were established as previously described (Adams and 
Antczak, 2001).  Major Histocompatibility Complex haplotypes were assigned to horses using 
serological and genomic methods (Lazary et al., 1988; Tseng et al., 2010). 
Cells and Tissues
Peripheral blood mononuclear cells (PBMC) and peripheral blood lymphocytes (PBL) were 
isolated using density gradient centrifugation with (PBL) or without  (PBMC) pre-incubation 
with carbonyl iron to remove phagocytes. Endometrial cup lymphocytes (ECL) were similarly 
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Table 4.1 Animals used for leukocyte isolation
Peripheral blood studies
Cornell # Breed DOB Sex MHC Haplotype1
3099 Thoroughbred 1992 Mare A2/A2
3521 Thoroughbred 2000 Gelding A2/A2
3903 Thoroughbred 2001 Mare A9/A9
3639 Pony 2000 Mare A7/?
3105 Thoroughbred 1992 Gelding A3/A3
Endometrial cup lymphocyte studies
Cornell # Breed DOB
Day of  
gestation
Mare MHC  
Haplotype1
Mating Stallion 
MHC Haplotype
3382 Thoroughbred 1995 46 A10/? A3/A3
3549 Thoroughbred 1994 43 A19/? A3/A3
3842 Thoroughbred 2000 45 A5/A19 A2/A2
3845 Pony 2004 44 A5/W16 A3/A3
3901 Thoroughbred 2001 45 A2/A19 A2/A2
1”?” one allele could not be determined using available typing sera.    
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isolated following surgical dissection and collagenase digestion as previously described (de 
Mestre et al., 2010).  Chorionic Girdle trophoblast were microdissected from conceptuses 
collected at days 33-34 of pregnancy as previously described (de Mestre et al., 2009). CD3 cell 
sorting was performed using an AutoMACS cell sorter (Miltenyi Biotec, Auburn, CA) following 
incubation of PBL with a mouse monoclonal antibody specific for equine CD3 (clone F6G, 
UC Davis, Davis, CA) and rat anti-mouse IgG1 MicroBeads (Miltenyi Biotec). CD3-depleted 
and enriched populations were verified by flow cytometry.  Depleted populations were a mean 
8% CD3+; enriched populations were 91% CD3+. RNA isolation and cDNA synthesis were 
performed as previously described (de Mestre et al., 2010). 
Cloning
Equine NKP46, CD16, CD56, and CD94 were amplified from horse PBMC cDNA using Pfu 
DNA polymerase (Stratagene, La Jolla, CA), gel purified/extracted, cloned into pCR4Blunt-
TOPO vector (Invitrogen, Carlsbad, CA), and sequenced on an Applied Biosystems Automated 
3730 DNA Analyzer at the Cornell Life Sciences Center.  Sequences were analyzed using the 
DNAStar software suite.
qPCR
SYBR Green (Applied Biosystems, Carlsbad, CA) real time PCR reactions for amplification of 
genes listed in Table 4.2, or the housekeeper gene equine ubiquitin-conjugating enzyme E2D 2 
(UBE2D2), were performed using an ABI 7500 Fast sequence detector (Applied Biosystems). 
Primers were designed with Primer3 software (MIT, Cambridge, MA) to cross intron/exon 
boundaries to prevent amplification of genomic DNA (Table 4.1).  A dissociation curve was 
performed after each experiment to confirm a single product was amplified. A standard curve 
was generated for all genes using known copy numbers of a plasmid that contained the DNA 
specific to the gene. Each sample was first normalized to 1.5 x 104 copies of UBE2D2. Data 
were analyzed using Graph Pad Prism Software.  Data sets were checked for normality using the 
Kolmogorov-Smirnov test (for n>4) or normal Q-Q plots (for n<4). Differences between groups 
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Equine Gene
Chromosome
location
Genbank 
Accession #
Quantitative PCR 
Primers (5’-3’)
NCR1
(NKP46)
10:24121252-
24125282 JN808451
F: CACCTGGAATGATGAACAAAG
R: CCTGGGATGAACTGAGAGG
CD3G 7:26203732-26210259 JN808452
F: GGCCTCATCCTGGCTATCAC
R: CCCAGATTCCGTGTAGTTTCTC
FCGR3
(CD16)
5:36222322-
36228997 JN795139
F: AGACAGCCCTCTCACCACTC
R: GTGCACATGCTTGTTCTTCC 
NCAM1
(CD56)
7: 21413392-
21712444 JN808450
F: CCGGCATTTACAAGTGTGTG
R: GGGTTGGTGCATTCTTGAAC
KLRD1
(CD94)
6:37355730-
37361350 JN795140
F: AGAATGGCTCTGCTGTCTCC 
R: CCCTTGGCAGTCTTCATCC
GCM1 20:50724492-50740140 XM_001503164.1
F: CAACTTCTGGAGGCACGAC 
R:  CGCCTTCTTCATTGCTCTTC
Table 4.2 Gene sequences and quantitative PCR primers used
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were determined using unpaired (Figs. 3, 4) or paired (Fig. 5) two-tailed Student’s t tests, or the 
Mann-Whitney test for non-parametric data (Figure 4.4C). 
Results 
Comparative genomics of equine NK cell receptor gene orthologs
We chose the NK cell markers NKp46, CD94, CD56, and CD16 to investigate equine NK cells 
based upon their expression patterns in peripheral and uterine NK cells of other species. PCR 
primers for these genes were designed by analyzing the equine whole genome sequence (WGS) 
for regions of homology with annotated genes of other species. Full-length (NKP46, CD94, and 
CD16) and partial (CD56) transcripts were amplified from cDNA generated from PBMC RNA 
derived from the WGS-donor animal maintained in our research herd.  Coding sequences (CDS) 
were translated and aligned with the human, bovine, murine, and porcine protein sequences, as 
available (Figure 4.1).
 Equine NKP46 was identified on chromosome 10 (ECA10) in a region syntenic with the 
leukocyte receptor gene complex (LRC) of human chromosome 19 (HSA19), where the 
NKP46 gene is located (Colucci et al., 2011). Multiple splice variants were identified, most 
correlating closely to validated human transcript variants (Figure 4.2). The translated sequence 
of the dominant NKp46 isoform shares 54-67% identity with the protein sequences of other 
selected species (Figure 4.1A, Table 4.3).  Conservation of critical protein motifs such as two 
immunoglobulin (Ig)-like domains, a transmembrane domain containing an arginine required 
for activation, and cysteines that form stabilizing intramolecular disulfide bonds, suggest a 
functional capacity of the gene product.
Equine CD16 was identified on ECA5, clustered with other predicted Fc receptor genes and 
syntenic to a homologous region on HSA1. The translated sequence shares 37-60% identity with 
other species (Figure 4.1B, Table 4.3); the two Ig-like domains, stabilizing cysteine residues, and 
transmembrane domain with a required aspartic acid, are conserved in the equine ortholog.
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Figure 1. Multi-species alignments of NK cell marker protein sequences. Amino acid 
sequences of equine NKp46 (A), CD16 (B), CD94 (C), and CD56 (D) orthologs were 
determined by translation of cDNA sequences determined from a combination of bioinformatic 
analysis of the equine WGS and amplification from horse PBMC mRNA by RT-PCR.  Equus 
caballus (EC) sequences were aligned with sequences of Homo sapiens (HS), Bos taurus (BT), 
Sus scrofa (SS) and Mus musculus (MM) using Clustal W.  Full-length clones were obtained 
for NKP46, CD16, and CD94 genes; a 247 bp partial clone was obtained from CD56, as 
indicated by brackets. Dots represent identities, dashes represent gaps.  Dashed boxes represent 
transmembrane domains and grey bars represent conserved immunoglobulin-like domains. 
Asterisks highlight highly conserved transmembrane domain charged residues (arginine and 
aspartic acid) required for association with adaptor molecules responsible for intracellular 
signaling.   Closed boxes represent cysteine residues known to stabilize intramolecular 
secondary structures. Genbank IDs for sequences used: NP_004820 (HS), NP_899209 (BT), 
NP_001116615.1 (SS), NP_034876 (MM), NKp46; AAH17865.1 (HS), AAI12757.1 (BT), 
NP_999556 (SS), NP_034318.2 (MM), CD16; NP_001107868 (HS), NP_001002890 (BT), 
EDK99936 (MM), CD94; NP_851996.2 (HS), NP_776824.1 (BT), NP_001074914.1 (MM), 
CD56
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Figure 4.2  Relation of equine and human NKP46 splice isoforms.  (A) Schematic diagram of 
NKP46 genomic structure.  (B) Agarose gel of PCR products generated from PBMC cDNA using 
primers designed to amplify the full-length CDS. Bands were extracted, cloned, and sequenced, 
yielding 3 transcripts with open reading frames (C).  Equine transcript variant 1 is similar to 
full length human NKP46 isoform a (NM_004829.5). Variant 2 uses an alternate in-frame splice 
site at the exon 4-5 boundary, similar to human isoform b (NM_001145457.1).  Variant 3 has a 
deletion of exon 4, corresponding to the loss of one Ig-like domain, similar to the human exon 
3 deletion isoform d (NM_001242356.1).  The band observed at 900bp is an intron-retention 
mutant of variant 3 with a premature stop codon (ψ, pseudogene).
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Equine CD94 was located in a region of ECA6 syntenic with the natural killer gene complex 
(NKC) of HSA12 (Colucci et al., 2011); and a splice variant conserved between human, horse, 
and cow was identified (data not shown). The translated dominant CD94 sequence shares 51-
67% identity with other species  (Figure 4.1C, Table 4.3).  The C-type lectin domain, lack of a 
cytoplasmic signaling motif, and structure-stabilizing cysteine residues of the human protein are 
conserved in the equine homolog.
Equine CD56 was found on ECA7 and demonstrated very high homology with other species 
at the amino acid level (96-98%). It shared the highest homology of all selected species to the 
human protein (Table 4.3).  Due to its low abundance in PBMC, the full 6kb mRNA was difficult 
to clone in its entirety. A region spanning predicted exons 2-4 was cloned, sequenced, and used 
for the studies below.
 
Table 4.3  Percent amino acid identity of equine NK cell markers 
with those of other selected species
NKp46 CD16 CD94 CD56
Homo sapiens 65 60 67 98
Bos taurus 65 58 60 97
Sus scrofa 67 57 N/A N/A
Mus musculus 54 37 51 96
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Expression of equine NK cell receptor genes in peripheral lymphocytes
In order to determine expression levels of NK marker genes in the circulating immune cells of 
the horse, quantitative PCR was performed on cDNA generated from equine PBL.  Lymphocyte 
expression levels were compared to those from a non-immune tissue: chorionic girdle (CG) 
trophoblast microdissected from conceptuses recovered at days 33-34 of pregnancy.  These 
invasive cells are the immediate precursors of the endometrial cup trophoblast.  In addition 
to NK marker genes, expression levels for the T-cell marker CD3 gamma (CD3G) and the 
trophoblast marker glial cells missing homologue 1 (GCM1) (de Mestre et al., 2009) were used 
as controls for the two cell types.
Transcripts for the NK markers CD16, CD94, and NKP46 were present in PBL, with CD16 
and CD94 demonstrating robust expression and NKP46 exhibiting modest expression (Figure 
4.3A, B, D). Trophoblast expressed at most trace amounts of these three genes. CD56 exhibited 
barely detectable expression levels in PBL, consistent with the low expression levels of 
antigen observed on the predominantly CD56dim peripheral NK cells of other species (Fig 3C).  
Somewhat surprisingly, CD56 expression was detected in the CG trophoblast. This expression 
pattern is also observed in human and macaque invasive trophoblast (Golos et al., 2010; Proll 
et al., 1996).  Predictably, CD3G demonstrated high expression in lymphocytes, but none in 
trophoblast (Fig 3E). GCM1 was highly expressed in trophoblast but absent in PBL (Fig 3E). 
We next determined the expression of these NK cell markers in CD3+ and CD3- lymphocyte 
populations, in order to compare the patterns to those seen in other species. cDNA was generated 
from peripheral lymphocytes magnetically sorted according to expression of cell-surface CD3 
antigen. NKP46 was expressed at 4-fold higher levels in the CD3-depleted (CD3-) population 
(Figure 4.4A).  This is consistent with the canonical CD3- NKp46+ NK cell phenotype exhibited 
by most species. CD94 expression did not differ between the two-lymphocyte groups (Figure 
4.4D).
This is not surprising as, in addition to CD3- NK cells, conventional CD3+ lymphocytes and 
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Figure 4.3  Detection of NK cell marker expression in equine peripheral lymphocytes. 
Expression of equine NKP46 (A), CD16 (B), CD56 (C), and CD94 (D) was determined using 
quantitative RT-PCR performed on RNA isolated from PBL and chorionic girdle trophoblast 
(CG). CD3G (D) and GCM1 (E) expression levels were also measured as controls; n=5.
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Figure 4.4  Expression of NK cell marker expression in CD3-depleted vs. CD3-enriched 
lymphocyte populations. PBL were magnetically sorted into CD3 depleted (CD3-) and 
enriched (CD3+) populations; isolated RNA was analyzed for expression of NKP46 (A), CD16 
(B), CD56 (C), CD94 (D), and CD3G (E) using quantitative RT-PCR; n=4.
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NK cells can express CD94.  However CD16, which is usually associated with peripheral CD3- 
NK cells, was 5-fold more highly expressed in the CD3-enriched (CD3+) population (Figure 
4.4B). This higher CD16 expression among the CD3+ cells may therefore represent NKT cells, 
a CD16+ T lymphocyte subset (Lanier et al., 1985), or a species-related difference in NK cell 
phenotype. Changes in CD56 levels were difficult to detect due to its low expression levels in the 
periphery (Figure 4.3C).  After increasing the input cDNA by 6-fold, transcript levels were still 
low, but we observed a trend toward increased expression in CD3- lymphocytes (Figure 4.4C).   
NK cell marker expression is higher in endometrial cup lymphocytes compared to PBMC
Expression of NK cell marker genes was next investigated in the equine uterus during early 
pregnancy.  Lymphocytes were isolated from the endometrial cups of five mares pregnant 
between days 43 and 46 of gestation.  Expression levels of NK markers in these endometrial cup 
lymphocyte (ECL) samples were compared to PBMC isolated from the same mares just prior to 
euthanasia. 
Expression levels of all NK markers were dramatically increased in ECL samples compared 
to the paired PBMC (Fig. 5).  NKP46, which was modestly expressed in the periphery, was 
expressed at 7-43 fold (mean=14) higher levels in the endometrial cups (Fig. 5A). CD16, 
which was highly expressed in PBL, shows a dramatic 20-fold higher expression in ECL (Fig. 
5B).  Based upon the slight decrease in CD3G expression in the endometrial cups (Fig. 5E), the 
increase in CD16 is not likely due to cells like the CD3+CD16+ population seen in the periphery 
(Figure 4.4B).   CD94, also highly expressed in the periphery, is 8-fold higher in the ECL (Fig. 
5D); again this is unlikely attributable to CD3+ cells.  Finally, CD56, a marker that is nearly 
undetectable in the periphery, exhibits a 44-fold increase in the endometrial cup lymphocyte 
samples (Fig. 5C).  Because CD56 expression was also observed in chorionic girdle trophoblast, 
we measured GCM1 in the ECL samples in order to detect contaminating trophoblast cDNA.  
GCM1 expression was detected (Fig. 5F), but at levels 1/5 of those in the trophoblast samples 
(Figure 4.3F) and the difference between ECL and PBMC expression was not statistically 
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Figure 4.5  Comparison of NK cell marker expression in peripheral and endometrial cup 
lymphocytes. Paired PBMC and ECL were isolated from five mares pregnant at days 43-46 of 
gestation. Expression of NKP46 (A), CD16 (B), CD56 (C), CD94 (D), CD3G (E), and GCM1(F) 
were measured using quantitative RT-PCR. 
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significant.  Therefore, contaminating trophoblast cannot account for the dramatic increase in 
CD56 expression seen in the ECL samples.  
Discussion
Using a highly specific and sensitive quantitative molecular assay, we have demonstrated that 
the four primary markers used to determine NK cell phenotype in other species are expressed 
by horse lymphocytes. These genes exhibit conservation of critical structural and functional 
elements despite the approximately 100 million years of divergence between horses and humans 
(Figure 4.1).  This suggests that they have undergone evolutionary pressure to maintain these 
functional motifs, and are therefore likely to have biological activity.  The conservation of 
alternative splicing patterns of human and horse NK marker transcripts also seen here (Figure 
4.2) is not a broadly observed phenomenon across genomes (Yeo et al., 2005).  This suggests 
an evolutionary pressure at the mRNA processing level, further supporting preservation of gene 
functionality. 
The activating receptor NKp46 is considered to be a specific marker for NK cells in multiple 
species, and is present on all NK subsets in primates and rodents at stable expression levels 
(Narni-Mancinelli et al., 2011). Therefore, the dramatic increase of NKP46 in ECL suggests the 
presence of lymphocytes with an NK phenotype in the mare endometrium. CD16, while not 
associated with the NK cells found in the decidua during human pregnancy, is expressed in the 
pregnant uteri of the mouse (Yadi et al., 2008), rhesus monkey (Dambaeva et al., 2011), and pig 
(Engelhardt et al., 2002). 
The expression patterns of equine CD94 and CD56 genes seen here are particularly interesting 
because to date, expression of these molecules at the maternal-fetal interface has only been 
observed in primates. The CD94 proteins, a co-receptor for non-classical MHC class I molecules, 
is more highly expressed in the human decidua compared to the periphery (King et al., 2000), as 
seen here with the equine gene. CD56, perhaps the most important marker of primate decidual 
NK cells, is minimally expressed in the periphery but highly expressed in the decidua (Kalkunte 
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et al., 2008), similar to what we observed in the ECL. Neither marker is expressed by mouse 
uterine NK cells.
The CD56 bright NK cells of the primate decidua are characterized by a poor cytolytic capacity and 
the secretion of high levels of IFNg (Kalkunte et al., 2008). Interestingly, we have previously 
observed an increase in the number of IFNg+ lymphocytes among the same ECL samples 
studied here (de Mestre et al., 2010).  In order to determine if there is a relationship between 
CD56 and IFNg in these ECL, we examined the correlation between CD56 expression levels 
and the percent of IFNg+ lymphocytes in the ECL (Figure 4.6).  Of the four data points tested, 
Figure 4.6  Relationship between CD56 gene expression and IFNγ+ lymphocytes in 
endometrial cup lymphocytes.  ECL samples from four horses were previously assayed for 
intracellular IFNγ expression by flow cytometry (de Mestre et al., 2010). CD56 expression 
was measured in frozen samples of the same cells using qPCR as described in Fig. 5.  The 
number of IFNγ+ ECL was compared to CD56 gene expression for each sample.  The outlier 
point was obtained from an animal carrying a twin pregnancy (#3382), which may contribute 
to the dramatic difference in IFNγ+ cells at her maternal-fetal interface.  No association was 
observed with the other cytokines measured (IL-4, IL-10).  
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three demonstrated a relationship suggesting a strong correlation (r=0.99); the fourth outlying 
data point was from ECL collected from a twin pregnancy.  The sample size was insufficient to 
determine if a statistically significant relationship exists, but the pattern clearly suggests further 
investigation is warranted to determine if these two molecules are expressed by the same cells.
The stage of pregnancy studied here, days 43-46, is roughly one week following trophoblast 
invasion. The presence of NK cells in the equine uterus during this period could help explain 
the poorly understood phenomenon of paternal class I MHC expression by the chorionic girdle 
trophoblast.  Interaction between uterine NK cell activating receptors and allogeneic paternal 
MHC I has recently been shown to be important for trophoblast invasion, vascular development, 
and fetal growth in both humans and mice (Hiby et al., 2010; Madeja et al., 2011).  The 
horse uterus does not show the same spiral artery alteration seen in species with hemochorial 
placentae, so this uNK-cell function may operate irrespective of placentation in order to facilitate 
trophoblast invasion and endometrial remodeling. It will be interesting to further explore what 
role this population of cells plays in equine pregnancy, and what new insights it will lend to our 
knowledge of evolutionarily-conserved maternal-fetal interactions.  
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CHAPTER 5
GENERATION AND CHARACTERIZATION OF MONOCLONAL 
ANTIBODIES TO EQUINE CD161
1Noronha, L.E., Harman, R.M., Wagner, B., and Antczak, D.F. Generation and characterization 
of monoclonal antibodies to equine CD16. To be submitted to Veterinary Immunology and 
Immunopathology.
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Abstract 
The low-affinity Fc receptor CD16 plays a central role in the inflammatory and innate immune 
responses of many species, but has not yet been investigated in the horse. Using the predicted 
extracellular region of equine CD16 expressed as a recombinant fusion protein with equine IL-4 
(rIL-4/CD16), we generated a panel of mouse monoclonal antibodies (mAbs) that recognize 
equine CD16. Nine mAbs were chosen for characterization based upon recognition of CD16 in 
ELISA, but not IL-4.  All nine mAbs recognized full-length, cell-surface CD16 expressed as a 
GFP fusion protein by CHO cells, but not the closely related Fc receptor CD32 expressed in the 
same system.  In flow cytometric analysis with equine peripheral leukocytes, the mAbs labeled 
cells in the granulocyte, monocyte, and lymphocyte populations in a pattern consistent with other 
species.  Monocytes that were strongly labeled with CD16 mAb 9G5 were also positive for the 
LPS receptor CD14.  Cytospins made with peripheral leukocytes were immunohistochemically 
labeled and showed mAb recognition of primarily mononuclear cells.  ELISA revealed that the 
nine mAbs can be grouped into three patterns of epitope recognition.  These new antibodies 
will serve as useful tools in the investigation of equine immune responses and inflammatory 
processes.
Introduction
The recognition of immune complexes is a key initiating event in the establishment of innate 
immune responses and inflammation.  A primary mediator of this process is the membrane 
glycoprotein CD16 (FcgRIII), a low-affinity receptor for the Fc region of aggregated IgG.  
Together with CD64 (FcgRI) and CD32 (FcgRII), it forms a family of three closely related 
Fcg receptors (Ravetch and Kinet, 1991). CD16 is an activating receptor; its effector function 
is initiated when the extracellular region, comprised of two C2-type immunoglobulin-like 
domains, binds to the Fc regions of IgG in immune complexes (Lanier et al., 1989; Simmons 
and Seed, 1988; Trinchieri and Valiante, 1993). Depending on the cell type, activation can lead 
to phagocytosis, antibody-dependant cytotoxicity (ADCC), release of inflammatory mediators, 
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or degranulation.  A soluble form of CD16 in human plasma has also been shown to bind 
complement receptors, resulting in the production of inflammatory cytokines (Galon et al., 
1996). Mice deficient in CD16 demonstrate impaired NK cell, monocyte, and mast cell effector 
functions, as well as reduced inflammation-induced pathology (Hazenbos et al., 1996). 
In the human, CD16 exists as two isoforms encoded by closely related genes: a transmembrane 
form (IIIa) and glycosylphosphatidylinositol (GPI)-linked form (IIIb). The extracellular regions 
of the two proteins are nearly identical and differ by only six amino acids (Ravetch and Perussia, 
1989).  The transmembrane form is expressed on NK cells, monocytes, macrophages, mast cells, 
and small T-cell subsets, while the GPI-linked form is expressed exclusively on neutrophils 
(Ravetch and Kinet, 1991).  In non-primate species that demonstrate CD16 expression, no 
glypiated forms have been identified, and all CD16+ cell populations are thought to express the 
transmembrane form (Collins et al., 1997; Halloran et al., 1994; Hughes, 1996; Nishimura et al., 
2000).  
Expression of an equine CD16 ortholog has not yet been demonstrated at the genetic or protein 
level. Although CD16 molecules of other livestock species have been successfully identified with 
commercially available cross-reactive antibodies (Boysen et al., 2008; Elhmouzi-Younes et al., 
2010), our group and others (Ibrahim and Steinbach, 2007) have not successfully identified such 
reagents for use with horse cells.  Researchers studying equine immunology and inflammation 
have therefore been limited by an inability to study this fundamental immunoreceptor.  Here, we 
describe the generation of a recombinant equine CD16 protein, and the subsequent development 
of a panel of CD16-specific monoclonal antibodies that can be used in multiple immunological 
applications to address this knowledge gap.
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Materials and Methods
Recombinant IL-4/CD16 (rIL-4/CD16)  
Equine CD16 was amplified from horse PBMC cDNA using Pfu DNA polymerase (Stratagene, 
La Jolla, CA), gel purified/extracted, cloned into pCR4Blunt-TOPO vector (Invitrogen, Carlsbad, 
CA), and sequenced on an Applied Biosystems Automated 3730 DNA Analyzer at the Cornell 
Life Sciences Center; sequence IDs and PCR primers listed in Table 5.1.  Sequences were 
analyzed using the DNAStar software suite. The amplified sequence was identical to a region 
of equine chromosome 5 that is syntenic to the FcgR region of human chromosome 1. No 
evidence of a second soluble form of CD16 was found in the genome.  The extracellular domain 
(bases 52-579 of the coding sequence) was predicted by performing Clustal W alignments with 
validated CD16 sequences of other species, and was directionally cloned into a pcDNA3.1 
vector (Invitrogen, Carlsbad, CA) 3’ to the coding sequence of equine IL-4 as previously 
described (Wagner, 2011). CHO K-1 cells were transfected with the linearized vector using the 
Geneporter2 system (Genlantis, San Diego, CA).  Stable transfectants were selectively cultured 
in G418 (Invitrogen), cloned by limiting dilution, and screened for IL-4 production by flow 
cytometry and ELISA as previously described (Wagner, 2011). rIL-4/CD16 was purified from 
serum-free supernatant by fast protein liquid chromatography using an anti-IL-4 affinity column 
as previously described (Wagner, 2011). A fraction of the purified fusion protein was resolved by 
SDS-PAGE on a 10% non-reducing polyacrylamide gel to determine molecular weight.  
Immunization and splenic fusion 
Mice were maintained at the Baker Institute for Animal Health rodent facility at Cornell 
University. Animal care was performed in accordance with the guidelines set forth by the 
Institutional Animal Care and Use Committee of Cornell University.  Immunization was 
performed as previously described (Wagner et al., 2003). Animal response was measured by 
monitoring serum titers to equine IL-4 using ELISA.  Spleen cells were fused to SP2/0 myeloma 
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Table 5.1 Sequences of genes and primers used.
Gene Accession # Primers (5’-3’)
CD16 JN795139 IL-4 fusion construct
F-GGCGGATCCTGGCACACGAGCTGAAGATC
R-GGCAAGCTTTCAACCTTTAACAATGACGTTCATAGCC
GFP fusion construct
F-GGCGCTAGCATGTGGCAGATGCTATCACCAACGG
R-GGCGGTACCTCAGAGCCCCGGCTCCATGTG
IL-4 GU139701 GFP fusion construct
F-GGCGCTAGCATGGGTCTCACCTACCAACTGATTCCAG
R-GGCGGTACCTCACACTTGGAGTATTTCTCTTTCATGATCGTCTTTAGC
CD32 JN795138 GFP fusion construct
F-GGCGCTAGC ATGACTATGGAGATCCTGATGTTTCCAAATGTACATC
R-GGCGGTACCTCTTTGTTTTCAGGGCTCTGGCTCCA
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cells as previously described (Appleton et al., 1989).  Nascent hybridomas were plated into 96 
well tissue culture plates and supernatants from all wells were screened for reactivity to rIL-4/
CD16 and rIL-4/IgG using ELISA, and for cell surface labeling of equine PBMC using flow 
cytometry.  Antibodies which labeled PBMC and detected rIL-4/CD16 but not rIL-4/IgG were 
selected for further study. Cultures were cloned by performing three rounds of limiting dilution, 
measuring sensitivity and specificity of secreted immunoglobulin by ELISA and flow cytometry 
as above after each round.  Mouse immunoglobulin isotypes of secreted antibodies were 
determined by ELISA (Sigma, St. Louis, MO).  Antibodies were purified by fast protein liquid 
chromatography using a protein G affinity column (GE Healthcare, Piscataway, NJ).  Proteins 
were quantified using a Bradford assay (Bio-rad, Hercules, CA).  Selected antibodies were 
biotinylated using Sulfo-NHS-Biotin (Thermo Fisher Scientific, Waltham, MA).  
Antibody screening and ELISA
Cell culture supernatants were screened for mAbs to rIL-4/CD16 by ELISA as described 
previously (Wagner, 2011) and against rIL-4/IgG1 (Wagner et al., 2005) to confirm their 
specificity to CD16.  For epitope ELISA, plates were coated with 1ug purified mAbs, washed, 
then followed with rIL-4/CD16 fusion protein.  Following washing, 1ug of biotinylated 
antibodies were then added, followed by streptavidin-HRP.  Reactions were developed and 
analyzed as previously described (Wagner et al., 2006).  For mAb 2A2, an additional ELISA 
was performed where plate-bound fusion protein was incubated with unlabeled antibody prior to 
adding the biotinylated antibody.
GFP fusion protein expression and flow cytometric analysis 
Full-length sequence (minus termination codon) for the equine CD16, CD32, and IL-4 genes 
were PCR amplified using Pfu DNA polymerase from equine PBMC cDNA and directionally 
cloned into the multiple cloning region of pEGFPN1 vector 5’ to the EGFP gene (PCR primers 
listed in Table 5.1).  CHO-K1 cells were transfected with the vectors using the Geneporter2 
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system and assayed for protein expression 48 hours post- transfection.  Successful expression 
of GFP was confirmed by fluorescence microscopy and indicated correct reading frame cloning 
of the fusion protein, as GFP sequence was downstream of the protein of interest.  Cells were 
detached with trypsin and used either fresh or fixed with 2%PFA for 20 minutes.  Cells were 
labeled in FACS buffer [PBS, 0.5%BSA, 0.02%NaN3 with (fixed) or without (fresh) 0.5% 
saponin)] with mAb supernatants, isotype controls, or anti IL-4 mAb 13G7 (Wagner et al., 
2006) followed by DyLight649-conjugated goat-anti-mouse IgG (H+L) F(ab’)2 (Jackson 
Immunoresearch, West Grove, PA).  Cells were analyzed on a FACSCalibur flow cytometer (BD 
Biosciences, San Jose, CA), and with FlowJo Software (Tree Star, Inc., Ashland, OR).  
Leukocyte flow cytometry and immunohistochemistry
Heparinized blood samples were isolated from horses at the Equine Genetics Center, Baker 
Institute for Animal Health, Cornell University (animal details in Table 5.2). Animal care was 
performed in accordance with the guidelines set forth by the Institutional Animal Care and Use 
Committee of Cornell University.  Erythrocytes were removed from blood samples using isotonic 
lysis (0.2% NaCl followed by 1.6% NaCl).  Leukocytes were washed and assayed for viability 
using trypan blue exclusion and phase contrast microscopy.  One million fresh cells were labeled 
with mAb 9G5 and/or a monoclonal antibody recognizing equine CD14 (Kabithe et al., 2010), 
or a mAb recognizing anti-canine parvovirus (CPV) as an isotype control, and analyzed by flow 
cytometry. Dead cells were excluded following staining for viability with propidium iodide.  Five 
hundred thousand leukocytes were adhered to a glass slide with a Cytospin centrifuge, fixed in 
acetone, and labeled with mAbs as previously described (de Mestre et al., 2010).
Results 
Expression of rIL-4/CD16 and selection of mAbs to equine CD16
To generate monoclonal antibodies to equine CD16 we employed a system using a recombinant 
secreted fusion protein made with equine IL-4 and the protein of interest (Wagner, 2011).  To 
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Table 5.2  Animals used for leukocyte isolation
Cornell # Breed DOB Sex MHC Haplotype1
3099 Thoroughbred 1992 Mare A2/A2
3521 Thoroughbred 2000 Gelding A2/A2
3958 Thoroughbred 2002 Mare A2/A10
3880 Thoroughbred 2006 Mare A3/A3
2885 Thoroughbred 1988 Mare A3/A3
2955 Thoroughbred 1990 Gelding A3/A3
3954 MO Fox Trotter 1997 Gelding A1/A8
3916 Thoroughbred 2002 Mare A5/A7
1Equine Leukocyte Antigen haplotypes assigned by serologic and genomic testing.
create the fusion protein, the predicted extracellular domain of CD16 was PCR-amplified from 
equine PBMC cDNA and inserted into a mammalian expression vector downstream of equine 
IL-4 (Figure 5.1A). CHO-K1 cells were stably-transfected with this construct and the secreted 
fusion protein was purified from the culture medium by fast protein liquid chromatography 
using an equine IL-4 affinity column.  The size of the recovered protein was consistent with the 
36.7 kDa predicted molecular weight of rIL-4/CD16 (Figure 5.1B). The extracellular domain 
of equine CD16 contains two predicted N-linked glycosylation sites (N-X-S/T-X), therefore the 
three bands observed on SDS-PAGE likely represent differentially glycosylated species of the 
fusion protein (Figure 5.1B, arrowheads).  The fusion protein was used to immunize mice, the 
spleens of which were recovered to generate hybridomas. Media samples from the hybridomas 
were screened for the ability to recognize the rIL-4/CD16 fusion protein in ELISA (Figure 5.1C). 
Specificity of this recognition was determined by testing the media samples against a rIL-4/IgG1 
fusion protein (Figure 5.1C). Antibodies that recognized the CD16 fusion protein, but not rIL-4/
IgG1, were considered CD16 specific.  MAbs generated by nine hybridoma clones met these 
initial screening criteria and were selected for further characterization.
136
  Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IL-4 CMV   
BamHI HindIII 
  1      2 
A B 
31 
21.5 
14.4 
6.5 
66 
116 
kDa 
pA CD16 
C 
Figure 5.1 Construction and expression of rCD16/IL-4, and utilization to identify anti-
CD16 hybridomas.  (A) The predicted extracellular domain of equine CD16 was  directionally 
inserted 3’ to equine IL-4 in a pcDNA3.1 expression vector (CMV, Human cytomegalovirus 
immediate-early promoter; pA, Bovine Growth Hormone polyadenylation signal). (B) Soluble 
rIL-4/CD16 was expressed in CHO cells, affinity purified, and resolved by SDS-PAGE on a 10% 
gel under non-reducing conditions (lane 2). Arrowheads denote multiple glycosylation forms. (C) 
Culture media from hybridomas were tested by ELISA for the ability to recognize rIL-4/CD16 
and rIL-4/IgG1; negative mAb control, anti-CPV. 
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 MAbs recognize full-length equine CD16 
To test the ability of the nine mAbs to recognize full-length CD16 expressed on the cell surface, 
the full coding sequence (minus the stop codon) was cloned into the pEGFPN-1 mammalian 
expression vector upstream of the EGFP gene (Figure 5.2A).  This allowed membrane 
expression of CD16 with minimal alterations to surface protein conformation, as eGFP would 
be expressed on the cytosolic side of the cell membrane. CHO-K1 cells were transfected with 
the construct and GFP expression was verified by fluorescence microscopy.  The cells were 
labeled with the nine mAbs and analyzed by flow cytometry, where they demonstrated robust 
recognition of the full-length CD16 protein (Figure 5.2B).  Because CD16 is one of three closely 
related Fc receptors known to have significant sequence similarity in other species, we also 
tested the specificity of the selected mAbs to CD32, the FcgR with the most predicted similarity 
to CD16.  Equine CD32 was similarly cloned into pEGFPN-1 and expressed in CHO cells; none 
of the nine antibodies recognized the CD32 construct in flow cytometric analysis (Figure 5.2B).  
MAb labeling was performed on fresh cells, so that only native, cell surface protein could be 
recognized (data not shown) as well as fixed, permeabilized cells, so that control cells producing 
soluble IL-4-GFP could be included to confirm the lack of mAb reactivity to IL-4 seen in ELISA 
(Figure 5.2B). All mAbs demonstrated the ability to recognize membrane-expressed CD16 in a 
specific manner.  
MAbs recognize native CD16 on equine leukocytes
We next tested the ability of the antibody panel to recognize native CD16 on intact horse 
cells. Total equine leukocytes were used so that the granulocyte, monocyte, and lymphocyte 
populations could be investigated. First, the labeling patterns of the nine mAbs were compared 
on samples from one animal. The mean fluorescence intensity (MFI), an indicator of relative 
antigen density, varied between the three cell populations in a pattern that was similar for all 
mAbs (Figure 5.3A, exceptions noted in Table 5.4). Granulocytes were dimly labeled, most 
lymphocytes and monocytes were labeled with moderate intensity, and a small population 
138
Figure 5.2 Generation of full-length CD16-, CD32-, and IL4-GFP expression constructs 
and flow cytometric analysis showing recognition by anti-equine-CD16 mAbs.  (A) Full 
length CD16, CD32, and IL-4 coding sequences (minus stop codons) were directionally inserted 
into the pEGFP-N1 mammalian expression vector 5’ to EGFP (CMV, Human cytomegalovirus 
immediate-early promoter; pA, SV40 polyadenylation signal).  (B) CHO cells transfected with 
fusion constructs were labeled with anti-equine-CD16 mAbs and a fluorescently-labeled anti-
mouse immunoglobulin secondary antibody (goat-anti-mouse-IgG (H+L)-647) and analyzed by 
flow cytometry. MAb 9G5 is shown as representative mAb. Anti-equine-IL-4 mAb (13G7) and 
sera taken from mouse spleen donor prior to immunization (pre-immunization) and at spleen 
collection (post-immunization) were used as controls. 
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of cells in the monocyte/large lymphocyte size range labeled very intensely, indicating the 
highest levels of expression. The percent of total leukocytes labeled varied between 1.5 and 7.6 
(median=3.0%) and the observed patterns were similar to Figure 5.3A for all mAb.
In order to further investigate the leukocyte populations labeled by these mAbs, cells were 
isolated from seven additional horses, labeled with representative mAb 9G5, and analyzed by 
flow cytometry. The lymphocyte, granulocyte, and monocyte/large lymphocyte populations were 
gated based upon morphology (Figure 5.3B) and analyzed for percent labeled within each group. 
Individual animal variability of roughly 3- to 4-fold was observed for each cell population. The 
number of labeled granulocytes varied from 1.2% to 8.3% (median=3.1%); monocytes and large 
lymphocytes varied from 4.6% to 13.9% (median=8.4%); and lymphoctyes varied from 1.1%-
3% (median=2.1%). 
In order to visualize the labeled cells, leukocytes were adhered to slides and labeled with the 
mAbs by immunohistochemistry (Figure 5.3D).  No positively stained granulocytes were 
observed, possibly due to a low receptor density as evidenced by the low MFI observed in the 
flow cytometry experiments.  Among the labeled cells, the most intensely stained (9G5hi) had 
large lymphocyte and monocyte morphologies, while smaller lymphocytes and some monocytes 
were moderately or dimly stained (9G5lo).  These observations are consistent with the MFI 
values of these populations observed in Figure 5.3A.  
The 9G5hi monocyte/large lymphocyte population was further investigated using 2-color 
flow cytometry.  In humans, cows, and sheep, a substantial fraction of CD16+ monocytes are 
positive for the LPS receptor CD14 (Elhmouzi-Younes et al., 2010; Ziegler-Heitbrock, 2007).  
To determine whether this is also the case in the horse, leukocytes from 6 horses were labeled 
with mAb 9G5 and a monoclonal antibody to CD14. Cells in the monocyte/large lymphocyte 
population were gated and analyzed as above.  In all horses, the 9G5hi population was 
consistently CD14+ (Figure 5.3E). 
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Figure 5.3 Recognition of horse peripheral blood leukocytes by anti-CD16 mAb 9G5. 
(A) Isolated leukocytes were labeled with IgG1 control mAb (anti-CPV, left) or clone 9G5 
(right) and analyzed by flow cytometry. (B) Dot plot showing morphology of positive staining 
cells (black) in relation to total cells (grey) and gating strategy for leukocyte populations (G, 
granulocytes; M/LL, monocytes/large lymphocytes; L, lymphocytes).  (C) Graph depicting 
percentages of 9G5-labeled cell populations for eight horses. (D) Immunohistochemical labeling 
of peripheral leukocytes with mAb 9G5 (1000X) showing a representative brightly-stained 
lymphocyte (top) and dimly-stained monocytic cell (bottom). (E) Leukocytes were labeled 
with mAb 9G5 in conjunction with a mAb recognizing equine CD14. Dot plots show M/LL 
populations as indicated in B.
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MAbs recognize three different epitopes
Finally, the nine mAbs were assayed by ELISA in order to determine if they recognized different 
antigen epitopes.  rIL-4/CD16 was captured using each of the mAbs.  Biotinylated mAbs were 
then applied to determine if the remaining free sites on the fusion protein could be bound, 
indicating recognition of distinct epitopes (Table 5.3). Based on this assay, the mAbs were 
assigned to one of three groups of epitope recognition.  One mAb, 2A2, appeared to recognize 
a repeating epitope based upon its ability to bind rIL-4/CD16 already captured by 2A2.  To test 
this, we incubated the captured fusion protein with increasing concentrations of unlabeled 2A2 to 
saturate remaining epitopes prior to probing with biotinylated 2A2.  Binding of the biotinylated 
antibody was reduced in a dose-dependent manner, indicating that the mAb bound multiple sites 
on the protein (data not shown).
    Table 5.3 ELISA and Epitope Recognition Group Assignments
2. Biotinylated Antibody
1A2 2A2 3B8 3E8 7G8 8B7 8D1 9H4 9G5
Group
Assignment
1.
 C
ap
tu
re
 A
nt
ib
od
y
1A2 A
2A2 * C
3B8 A
3E8 B
7G8 A
8B7 B
8D1 B
9H4 B
9G5 A
Black: Reduced binding by biotinylated antibody; White: No reduction in binding; *based on additional 
assays, mAb 2A2 binds a repeating epitope on CD16
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Discussion
We determined that the nine mAb characterized here specifically recognize CD16 in multiple 
assays. In addition to the specificity demonstrated by ELISA and recognition of transfected cells, 
the consistent pattern observed in flow cytometric analysis of leukocytes indicates recognition of 
the same cell surface molecule among the numerous immunoreceptors on the leukocyte surface. 
Some variation in the percentage of labeled leukocytes was observed between mAb. This may 
be due to factors such as differences in affinity for antigen, variability in antibody concentration 
within the hybridoma culture media samples, or subtle differences in epitope recognition due 
to differential glysolyation of leukocyte populations.  Some variation was also observed when 
leukocytes isolated from different horses were labeled. This difference among individuals is not 
unexpected.  We have previously observed that cell surface expression of immunoreceptors can 
vary markedly among individual horses of mixed genetic backgrounds housed in an outdoor 
environment (de Mestre et al., 2010). Furthermore, expression of CD16 is known to be up-
regulated during inflammation in other species. As the sampled horses are exposed to standard 
environmental insults, it is reasonable that individual animals may be in different states of 
normal, sub-clinical inflammation, therefore contributing to variability in CD16 expression.  
Comparison of leukocytes among livestock species shows some variations in CD16 expression 
patterns.  In the pig, CD16 is expressed on 13% lymphocytes, 70% monocytes, and >95% 
neutrophils (Dato et al., 1992).  CD16 expression on sheep PBMC is reported at a median 9.1% 
(7.5-12.6) and 10.2% (8.1-11) for cows, in a pattern similar to Figure 5.3A (Elhmouzi-Younes et 
al., 2010).  To compare our data in context, the percent of labeled equine PBMC was calculated 
by gating only the mAb 9G5-labelled monocyte and lymphocyte populations, yielding a median 
3.7% (1.1-8.1). One explanation for this difference among livestock species may be an age-
related difference in CD16 expression.   The animals used for the cow and sheep studies were 
juveniles, while the horses used here were adults over 5 years of age.  The difference may also 
be species-related, which is not surprising as CD16 expression levels vary significantly even 
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among closely related non-human primates (Rogers et al., 2006). Notably, however, the pattern 
of equine CD14+CD16+ monocytes that we observed here was strikingly similar to that seen in 
humans (Fingerle et al., 1993).  This is particularly interesting considering that mice do not have 
a monocyte population with this phenotype (Sunderkotter et al., 2004).  Therefore, the horse may 
serve as a useful model species for the study of these cells.
 Table 5.4 Summary of aCD16 mAbs
Epitope
Group mAb Isotype ELISA
Application
FACS1 IHC4
1A2 IgG1 + ++ ++
A 3B8 IgG1 + ++ +
7G8 IgG1 + + +5
9G5 IgG1 + ++ ++5
3E8 IgG2b  + +2 +++5
B 8B7 IgG1 + + +
8D1 IgG1 + +3 +
9H4 IgG1 + + +
C 2A2 IgG1 + ++ ++
1Labels both fresh and PFA-fixed cells;  2Labels additional lymphocyte population (common 
IgG2b artifact with fresh horse cells);  3Labels a small fraction of granulocytes more brightly; 
4Frozen acetone-fixed cells (and tissues, data not shown);  5Also labels PFA-fixed cells 
(other mAbs not tested)
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Conclusion
The antibodies described here, summarized in Table 5.4, demonstrate recognition of recombinant 
CD16 in ELISA and full-length CD16 in flow cytometry.  This recognition appears specific for 
CD16 and does not occur with other structurally-similar immunoreceptors.  These antibodies 
label equine leukocyte populations in a pattern that is consistent with CD16 expression observed 
in other species. We therefore conclude that this panel of monoclonal antibodies recognizes the 
equine CD16 antigen in ELISA, flow cytometry, and immunohistochemistry, and will expand our 
ability to study horse health and disease. 
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CHAPTER 6
GENERATION AND CHARACTERIZATION OF MONOCLONAL 
ANTIBODIES TO EQUINE NKP461 
1Noronha, L.E., Harman, R.M., Wagner, B., and Antczak, D.F. Generation and characterization 
of monoclonal antibodies to equine NKp46. To be submitted to Veterinary Immunology and 
Immunopathology.
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Abstract 
The immunoreceptor NKp46 is considered to be the most consistent marker of NK cells 
across mammalian species. Here, we use a recombinant NKp46 protein to generate a panel 
of monoclonal antibodies that recognize equine NKp46.  The extracellular region of equine 
NKp46 was expressed with equine IL-4 as a recombinant fusion protein (rIL-4/NKp46) and 
used as an immunogen to generate mouse monoclonal antibodies (mAbs).  MAbs were first 
screened by ELISA for an ability to recognize NKp46, but not IL-4, or the structurally related 
immunoreceptor CD16. Nine mAbs were selected and were shown to recognize full-length 
NKp46 expressed on the surface of transfected CHO cells as a GFP fusion protein.  The mAbs 
recognized a population of lymphocytes by flow cytometric analysis that was morphologically 
similar to NKp46+ cells in humans and cattle.  In a study using nine horses, representative mAb 
4F2 labeled 0.8-2.1% PBL with a mean fluorescence intensity consistent with gene expression 
data.  MAb 4F2+ PBL were enriched by magnetic cell sorting and were found to express higher 
levels of NKP46 mRNA than 4F2- cells by quantitative RT-PCR. CD3-depleted PBL from 
five horses contained a higher percentage of 4F2+ cells than unsorted PBL.  Using ELISA, we 
determined that the nine mAbs recognize three different epitopes.  These mAbs will be useful 
tools in better understanding the largely uncharacterized equine NK cell population.
Introduction
Natural killer (NK) cells serve a vital role in the innate immune response due to their ability to 
destroy foreign cells, such as virus-infected cells and tumor cells, during a primary encounter.  
Their cytotoxic activity is determined by a complex interaction of activating and inhibitory 
cell-surface receptors (Joncker et al., 2009). While many of these receptors can be expressed on 
multiple cell types, the activating receptor NKp46 (NCR1, CD335) appears to be specific to NK 
and NK-like cells (Sivori et al., 1997). Thus, NKp46 is currently considered the most reliable 
identifying marker for NK cells across species (Walzer et al., 2007).  
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NKp46 is a type-I glycoprotein belonging to the immunoglobulin (Ig) superfamily. NKp46, 
with NKp30 (NCR3), and NKp44 (NCR2) comprise the natural cytotoxicity receptors (NCRs):  
activating receptors capable of inducing NK cell mediated cytotoxicity. Although the NCRs 
have similar cellular functions, NKP46 is structurally distinct from the other two molecules and 
is located in a different region of the genome (Biassoni et al., 2002). It also appears to be more 
stably expressed, and is generally present on all resting and activated NK cells (Sivori et al., 
1997). 
The structure of NKp46 consists of two extracellular C2-type Ig-like domains, a transmembrane 
region, and a short cytoplasmic tail (Ponassi et al., 2003).  The receptor alone cannot transmit 
an activating signal; it acts by complexing with intracellular signaling molecules, such as CD3z 
and FCeRIg, which contain immunoreceptor tyrosine-based activation motifs that initiate signal-
transduction cascades resulting in NK cell activation (Biassoni et al., 2001).  Known ligands 
that engage NKp46 include viral hemagglutinins and cellular heparan sulfate proteoglycans 
(Bloushtain et al., 2004; Mandelboim et al., 2001). Based upon the NKp46-mediated cytolysis of 
tumor cells, additional unidentified cellular ligands are presumed to exist (Halfteck et al., 2009). 
Indeed, mice that lack NCR1, the murine NKp46 ortholog, are more susceptible to influenza and 
the growth of some types tumors (Gazit et al., 2006; Halfteck et al., 2009).  
NKp46 appears to be well conserved among species and its expression has been identified in 
primates, mice, rats, cattle, sheep, and pigs (Biassoni et al., 1999; Connelley et al., 2011; De 
Maria et al., 2001; Jozaki et al., 2010; Sivori et al., 1997; Storset et al., 2003). Monoclonal 
antibodies (mAbs) have been developed to recognize NKp46 in most of these species, and thus 
far, its expression is limited to NK or NK-like cytotoxic lymphocyte populations.
Our group has recently described the identification of the equine ortholog of the NKP46 gene 
(Noronha, 2012a).  It is expressed by lymphocytes, and its sequence contains conserved domains 
required for protein function. The predicted equine protein shares 65% identity with the human 
and bovine proteins. This degree of similarity is apparently insufficient to permit cross-reactivity 
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with anti-human and -bovine NKp46 mAbs, as our attempts to label horse lymphocytes with 
several have shown a lack of recognition (data not shown). Therefore, using a system we recently 
employed to develop mAbs to equine CD16 (Noronha, 2012b), we generated a panel of novel 
mAbs that recognize equine NKp46.
Materials and Methods
Recombinant IL-4/NKP46 (rIL-4/NKP46)  
Sequence IDs and PCR primers are listed in Table 6.1. The full-length coding sequence (CDS) of 
equine NKP46 was previously cloned and sequenced (Noronha, 2012a). The extracellular domain 
(bases 62-668 of the CDS) was predicted by performing Clustal W alignments with validated 
NKP46 sequences of other species, and was directionally cloned into a pcDNA3.1 vector 
(Invitrogen, Carlsbad, CA) downstream from the CDS of equine IL-4 as previously described 
(Noronha, 2012b; Wagner, 2011). CHO K-1 cells were transfected with linearized IL-4/NKP46 
plasmid using the Geneporter2 system (Genlantis, San Diego, CA).  Stable transfectants were 
selectively cultured in G418 (Invitrogen), cloned by limiting dilution, and screened for IL-4 
production by flow cytometry and ELISA as previously described (Wagner, 2011). rIL-4/NKP46 
was purified from serum-free supernatant by fast protein liquid chromatography using an anti-
IL-4 affinity column as previously described (Wagner, 2011). 1ug of the purified fusion protein 
was resolved by SDS-PAGE on a 10% non-reducing polyacrylamide gel to determine molecular 
weight.  
Immunization and splenic fusion 
Mice were maintained at the Baker Institute for Animal Health rodent facility at Cornell 
University. Animal care was performed in accordance with the guidelines set forth by the 
Institutional Animal Care and Use Committee (IACUC) of Cornell University.  Immunization 
was performed as previously described (Wagner et al., 2003). Animal response was measured 
Table 6.1  Sequences of genes and primers used
Gene Accession # Primers (5’-3’)
NKP46 JN808451 IL-4 fusion construct
F-GGCGGATCCCCAGAAGCGTACTCCCTCTAAAC
R-GGCAAGCTTTCATGAATCAGGAGAAGAGATGTGC
GFP fusion construct
F-GGCGCTAGCATGCCTTCTATACTCACTGTCCTGCTC
R-GGCGGTACCTCTTTGTCCAGGGATCTTTGTGTTCTGAAC
qPCR
F-CACCTGGAATGATGAACAAAG
R-CCTGGGATGAACTGAGAGG
IL-4 GU139701 GFP fusion construct
F-GGCGCTAGCATGGGTCTCACCTACCAACTGATTCCAG
R-GGCGGTACCTCACACTTGGAGTATTTCTCTTTCATGATCGTCTTTAGC
CD16 JN795139 GFP fusion construct
F-GGCGCTAGCATGTGGCAGATGCTATCACCAACGG
R-GGCGGTACCTCAGAGCCCCGGCTCCATGTG
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by monitoring serum titers to equine IL-4 using ELISA.  Spleen cells were fused to SP2/0 
myeloma cells as previously described (Appleton et al., 1989).  Nascent hybridomas were 
plated into 96 well tissue culture plates and supernatants from all wells were screened for 
reactivity to rIL-4/NKP46 and rIL-4/IgG using ELISA, and for cell surface labeling of equine 
PBMC using flow cytometry.  Antibodies that labeled PBMC and detected rIL-4/NKP46 but 
not rIL-4/IgG were selected for further study. All hybridoma cultures except mAb 8F9 were 
cloned by performing three rounds of limiting dilution, measuring sensitivity and specificity 
of secreted immunoglobulin by ELISA and flow cytometry as above after each round.  Mouse 
immunoglobulin isotypes of secreted antibodies were determined by ELISA (Sigma, St. Louis, 
MO).  Antibodies were purified by fast protein liquid chromatography using a protein G affinity 
column (GE Healthcare, Piscataway, NJ).  Proteins were quantified using a Bradford assay (Bio-
rad, Hercules, CA).  Selected antibodies were biotinylated using Sulfo-NHS-Biotin (Thermo 
Fisher Scientific, Waltham, MA).  
Antibody screening and ELISA
Cell culture supernatants were screened for mAbs to rIL-4/NKP46 by ELISA as described 
previously (Wagner, 2011) and against rIL-4/IgG1 (Wagner et al., 2005) and rIL-4/CD16 
(Noronha, 2012b) to confirm their specificity to NKP46.  For epitope ELISA, plates were coated 
with 1ug purified mAbs, washed, then followed with rIL-4/NKP46 fusion protein in transfected 
CHO cell supernatant.  Following washing, 1ug of biotinylated antibodies was then added, 
followed by streptavidin-HRP.  Reactions were developed and analyzed as previously described 
(Wagner et al., 2006).  For 8F9, purified and biotinylated antibodies were not available; capture 
antibody was in the form of hybridoma supernatant.  
GFP fusion protein expression and flow cytometric analysis 
Full-length sequence (minus termination codon) for the equine NKP46, CD16, and IL-4 genes 
were PCR-amplified and cloned into the pEGFPN1 vector as previously described (Noronha, 
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2012b).  CHO-K1 cells were transfected with the vectors using the Geneporter2 system and 
assayed for protein expression 48 hours post- transfection.  Successful expression of GFP was 
confirmed by fluorescence microscopy and indicated correct reading frame cloning of the fusion 
protein, as GFP sequence was downstream of the protein of interest.  Cells were detached with 
trypsin and used either fresh or fixed with 2%PFA for 20 minutes.  Cells were labeled and 
analyzed by FACS as previously described (Noronha, 2012b).
Lymphocyte isolation, flow cytometry, and immunohistochemistry
Heparinized blood samples were collected from horses maintained at the Equine Genetics Center, 
Baker Institute for Animal Health, Cornell University (animal details in Table 6.2). Animal care 
was performed in accordance with the guidelines set forth by the Cornell University IACUC.  
Lymphocytes were isolated by incubation with carbonyl-iron followed by density gradient 
centrifugation as previously described (de Mestre et al., 2010).  PBMC were similarly isolated 
but without use of carbonyl-iron. Cells were assayed for viability using trypan blue exclusion 
and phase contrast microscopy.  For flow cytometry experiments, one million fresh cells were 
labeled with mAb 4F2 or a monoclonal antibody recognizing anti-canine parvovirus (CPV) as an 
isotype control. Dead cells were excluded following staining for viability with propidium iodide. 
Five hundred thousand leukocytes were adhered to a glass slide with a Cytospin centrifuge, fixed 
in acetone, and labeled with mAbs as previously described (de Mestre et al., 2010).
Magnetic cell sorting and qPCR
CD3 cell sorting was performed using an AutoMACS cell sorter (Miltenyi Biotec, Auburn, 
CA) following incubation of 108 PBL with a mouse monoclonal antibody specific for equine 
CD3 (clone F6G, UC Davis, Davis, CA) and rat anti-mouse IgG1 MicroBeads (Miltenyi 
Biotec). CD3-depleted populations were a mean 8% CD3+ as verified by FACS. 4F2 sorting 
was similarly performed using 5x108 PBL and mAb 4F2.  Total RNA isolation and cDNA 
synthesis were performed as previously described (de Mestre et al., 2010). SYBR Green 
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Table 6.2 Animals used for lymphocyte isolation
Cornell # DOB Sex1 Breed2 MHC Haplotype3
3875 2006 F TB x pony A2/?
3908 2007 F TB A2/A2
3099 1992 F TB A2/A2
3521 2000 MC TB A2/A2
3709 2003 M Pony A6/?
2885 1988 F TB A3/A3
3157 1993 F TB A3/A3
4056 2009 MC TB A3/A3
1F, female; M, male; MC, male castrate. 2TB, thoroughbred. 3Equine Leukocyte Antigen haplotypes assigned by 
serologic and genomic testing.
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(Applied Biosystems, Carlsbad, CA) real time PCR reactions for amplification of NKP46 or 
the housekeeper gene equine ubiquitin-conjugating enzyme E2D 2 (UBE2D2), were performed 
using an ABI 7500 Fast sequence detector (Applied Biosystems) as previously described (de 
Mestre et al., 2010).  Primers were designed with Primer3 software (MIT, Cambridge, MA) to 
cross intron/exon boundaries to prevent amplification of genomic DNA. A dissociation curve 
was performed after each experiment to confirm a single product was amplified. A standard curve 
was generated for all genes using known copy numbers of a plasmid that contained the DNA 
specific to the gene. Each sample was first normalized to 1.5 x 104 copies of UBE2D2. Data 
were analyzed using Graph Pad Prism Software.  Data sets were checked for normality using the 
Kolmogorov-Smirnov test. Differences between groups were determined using a paired two-
tailed Student’s t tests. Values were considered significantly different at P values <0.05.
Results 
Expression of rIL-4/NKp46 and selection of mAbs to equine NKp46
To generate monoclonal antibodies to equine NKp46, we employed a system that we recently 
used to generate mAbs to equine CD16 (Noronha, 2012b). This method utilizes a recombinant 
protein made by tagging equine IL-4 to a target antigen (Wagner, 2011).  To create this fusion 
protein, the extracellular domain of NKp46 was predicted by comparing the CDS of NKP46 to 
annotated sequences from other species and identifying homologous regions. The extracellular 
region was PCR-amplified from equine lymphocyte cDNA and inserted into a mammalian 
expression vector downstream of equine IL-4 (Figure 6.1A); CHO-K1 cells transfected with this 
construct secreted the soluble protein.  Secreted protein was purified from the culture medium 
by fast protein liquid chromatography using an affinity column designed to capture equine 
IL-4 (Wagner, 2011).  SDS-PAGE of the purified protein showed a molecular weight consistent 
with 39.9 kDa, the predicted molecular weight of rIL-4/NKp46 (Figure 6.1B). The three bands 
observed on SDS-PAGE likely represent differentially glycosylated species of the fusion protein, 
as it contains three predicted N-linked glycosylation sites with an N-X-S/T-X motif (Figure 6.1B, 
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Figure 6.1 Construction and expression of rNKp46/IL-4, and utilization to identify anti-NKp46 
hybridomas.  (A) The predicted extracellular domain of equine NKP46 was  directionally 
inserted 3’ to equine IL-4 in a pcDNA3.1 expression vector (CMV, Human cytomegalovirus 
immediate-early promoter; pA, Bovine Growth Hormone polyadenylation signal). (B) Soluble 
rIL-4/NKP46 was expressed in CHO cells, affinity purified, and resolved by SDS-PAGE on 
a 10% gel under non-reducing conditions (lane 2). Arrowheads denote multiple glycosylation 
forms. (C) Culture media from hybridomas were tested by ELISA for the ability to recognize 
rIL-4/NKP46, rIL-4/IgG1, and rIL-4/CD16.
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arrowheads).  The purified protein was used in combination with an adjuvant to immunize Balb/c 
mice from which splenocytes were recovered and used to generate hybridomas. Media samples 
from hybridoma cell clones were screened for the ability to recognize rIL-4/NKp46 in ELISA 
(Figure 6.1C).   Specificity of this recognition was determined by also testing the samples against 
rIL-4/IgG1 and rIL-4/CD16 fusion proteins (Figure 6.1C). CD16 was used as a specificity 
control because like NKp46, it has two extracellular C2-type Ig-like domains, and is therefore 
more structurally similar than the other NCR family members.  Antibodies that recognized only 
the NKp46 fusion protein were considered to be specific for NKp46. Nine hybridoma clones 
produced mAbs that were selected for further characterization based upon fulfillment of these 
initial screening criteria.
 MAbs recognize full-length equine NKp46 
We next wanted to determine if the selected mAbs could recognize NKp46 in its native 
conformation of the surface of a cell.  To test this, full-length CDS (minus the stop codon) of 
NKP46 was inserted into the pEGFPN-1 expression vector upstream of the EGFP gene (Figure 
6.2A).  This fusion protein was designed to express NKp46 on the cell surface, with eGFP 
confined to the cytosolic compartment, thereby mimicking the conformation of NKp46 on NK 
cells. CHO-K1 cells were transfected with the expression vector, and successful expression was 
verified by fluorescence microscopy. eGFP fluorecence also verified in-frame cloning of NKP46. 
Transfected cells were then labeled with the nine mAbs and analyzed by FACS.  In order to 
demonstrate specificity of recognition, additional cells were transfected with IL-4- and CD16-
eGFP constructs.  Labeling was performed with both fresh cells and fixed, permeablized cells, 
as permeabilization was required to detect intracellular IL-4-GFP. All nine mAbs demonstrated 
recognition of the NKp46-expressing cells, but not IL-4 (Figure 6.2B). Eight of the nine clones 
failed to label CD16-transfected cells.  One clone, 3B7, showed faint recognition of CD16 in a 
pattern similar to what was seen with the polyclonal post-immune sera (Figure 6.2B).   
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Figure 6.2  Generation of full-length NKP46-, CD16-, and IL4-GFP expression constructs and 
flow cytometric analysis showing recognition by anti-equine-NKP46 mAbs.  (A) Full length 
NKP46, CD16, and IL-4 coding sequences (minus stop codons) were directionally inserted 
into the pEGFP-N1 mammalian expression vector 5’ to EGFP (CMV, Human cytomegalovirus 
immediate-early promoter; pA, SV40 polyadenylation signal).  (B) CHO cells transfected with 
fusion constructs were labeled with anti-equine-NKP46 mAbs and a fluorescently-labeled anti-
mouse immunoglobulin secondary antibody (goat-anti-mouse-IgG (H+L)-647) and analyzed by 
flow cytometry. MAb 4F2 is shown as representative mAb. Anti-equine-IL-4 mAb (13G7) and 
sera taken from mouse spleen donor prior to immunization (pre-immunization) and at spleen 
collection (post-immunization) were used as controls. 
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MAbs recognize NKp46 on equine lymphocytes 
We next tested the ability of the antibody panel to recognize NKp46 on intact horse cells. The 
mAbs were first tested on isolated PBMC.  Labeling was only observed in the lymphocyte 
population (Figure 6.3); therefore PBL were used for all subsequent analyses.  All nine mAbs 
labeled lymphocytes with a similar pattern (Figure 6.4A). The percent of labeled PBL varied 
between 1.0 and 1.5 (median=1.25%) among the mAbs on cells from the same horse. PBL were 
then isolated from eight additional horses, and representative mAb 4F2 was used for labeling.  
The percent of labeled lymphocytes varied from 0.8%-2.1% (mean=1.3%) among animals 
(Figure 6.4B).    
In order to determine if the cells labeled with mAb 4F2 expressed NKp46, we labeled PBL with 
mAb 4F2 and separated the cells into positive and negative fractions by magnetic cell sorting.  
The 4F2-enriched fraction increased from an initial 1.1% to 49.1% 4F2+ cells.  cDNA was 
prepared from these cells as well as the 4F2-depleted (4F2-) fraction, and expression of NKP46 
transcripts was measured by real-time quantitative PCR.  NKP46 expression in the enriched 
population was 23-fold higher than in the depleted population.   
We next wanted to determine if the 4F2+ population demonstrated the typical CD3- phenotype 
seen in NKp46+ cells of most species.  To do this, we examined whether the depletion of CD3+ 
affected the number of 4F2+ cells.  PBL from five horses were labeled with a CD3 mAb and 
CD3+ cells were depleted by magnetic cell sorting. Unsorted cells and CD3-depleted (CD3-) 
cells were labeled with mAb 4F2 and the paired samples were compared.  The number of 4F2+ 
cells increased by 2.3-fold following CD3-depletion.  The fold-change for the five individual 
animals ranged from 1.1-3.4.  
In order to visualize the morphology of the cell population recognized by these mAbs, PBMC 
were adhered to slides and labeled with the mAbs by immunohistochemistry (Figure 6.4G).  A 
small population of dimly stained lymphocytes was observed (arrow).  The frequency of positive 
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Figure 6.3 Recognition of horse peripheral leukocytes by anti-NKP46 mAb 4F2 is limited to 
lymphocytes.  Isolated PBMC were labeled with IgG1 control mAb (anti-CPV, left) or mAb 4F2 
(right) and analyzed by flow cytometry.
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Figure 6.4  Recognition of horse peripheral blood lymphocytes by anti-NKP46 mAb 4F2. (A) 
Isolated lymphocytes were labeled with IgG1 control mAb (anti-CPV, left) or mAb 4F2 (right) 
and analyzed by flow cytometry. (B) Graph depicting percentages of 4F2-labeled lymphocytes 
for nine horses.  (C) Histogram showing mean fluorescence intensity (MFI) of 4F2-labeled 
lymphocytes prior to (shaded curve) and following (open curve) enrichment of 4F2+ cells using 
magnetic cell sorting. Bars reflect the percentage of labeled lymphocytes (lower, pre-enrichment; 
upper, post-enrichment). (D) Real-time quantitative PCR analysis of NKP46 transcripts in 4F2-
depleted (4F2-) and enriched (4F2+) lymphocyte populations. (E) Histogram showing MFI of 
CD3-labeled lymphocytes prior to (shaded curve) and following (open curve) depletion of CD3+ 
cells using magnetic cell sorting. Bars reflect the percentage of labeled lymphocytes (upper, pre-
depletion; lower, post-depletion). (F) Graph comparing percentages of 4F2-labeled lymphocytes 
of five horses prior to (total) and following (CD3-) CD3 depletion. (G) Immunohistochemical 
labeling of PBMC with mAb 4F2 (1000X) showing a representative dimly-stained lymphocyte 
(arrow).
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cells was approximately 10-fold lower than that observed by flow cytometry.  
MAbs recognize three different epitopes
Lastly, the epitope-recognition of the nine mAbs were analyzed by ELISA. Each of the mAbs 
was first used to capture rIL-4/NKp46.  Remaining free sites on the recombinant protein were 
then labeled with a biotinylated version of each mAb in a checkerboard fashion (Table 6.3).  
Failure to bind by the second antibody indicated a blocked site, and therefore recognition of the 
same epitope as the “capture” mAb.  Using this assay, we determined that the nine mAbs could 
             Table 6.3 ELISA and Epitope Recognition Group Assignments
2. Biotinylated Antibody
3B7 4D10 4F2 7C2 8A3 8E8 8G3 9C1
Group
Assignment
1.
 C
ap
tu
re
 A
nt
ib
od
y
3B7 A
4D10 A
4F2 A
7C2 A
8A3 B
8E8 A
8F9* C
8G3 A
9C1 A
Black: Reduced binding by biotinylated antibody; White: No reduction in binding; *8F9 was only 
used as a capture antibody
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be divided into three groups of epitope recognition.    
Discussion
Using a combination of ELISA, flow cytometry, and molecular methods, we have demonstrated 
that the mAbs described here demonstrate specific reactivity with equine NKp46.  These mAbs 
show recognition of recombinant NKp46, as well as native protein on the surface of equine 
lymphocytes. 
The size and granularity of equine leukocytes labeled by these mAbs, as determined by FACS 
forward and side scatter, was similar to what is seen with NKp46+ cells of humans and cattle 
(Almeida-Oliveira et al., 2011; Kulberg et al., 2004).  However, the intensity of labeling, i.e. 
the mean fluorescence intensity (MFI) measured by FACS (Figure 6.4A), appears to be lower 
than in other species. It is unlikely that this relatively dim labeling is due to poor antibody 
affinity for NKp46 because all of the mAbs have a similar pattern, which cannot be overcome 
by increasing the antibody concentration.  Also, CHO cells transfected with NKp46-eGFP 
demonstrated a high MFI following labeling. Therefore, it is more likely that the low signal is 
due to a low antigen density on the cell surface.  This is consistent with quantitative RT-PCR 
studies we have previously reported showing that lymphocytes express a modest level of NKp46 
mRNA (Noronha, 2012a).  This low level of antigen expression may explain why the number 
of cells detected by immunohistochemistry (IHC) was less than what was seen with FACS, as 
colorimetric IHC is a less sensitive assay. While these mAbs appear to be capable of labeling 
cells in IHC assays, under the conditions here we are only able to visualize the cells expressing 
the most antigen. More sensitive immunofluorescence microscopy assays may be required to 
visualize the entire population.
The 1.3% of lymphocytes recognized here in adult horses is less than what is seen in adult 
humans (7%), but is similar to what is reported for adult cows (1.8-2.6%) (Almeida-Oliveira et 
al., 2011; Kulberg et al., 2004).  It is also lower than what is observed in juvenile sheep (3-16%). 
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However, this may reflect an age-related effect as a progressive decline in the percentage of 
NKp46+ cells from birth to adulthood has been observed in some species (Almeida-Oliveira et 
al., 2011; Kulberg et al., 2004).
Our data clearly support that the mAbs described here recognize the equine NKp46 ortholog 
on horse cells.  However, it is not yet clear if these cells are functional NK cells. As discussed 
above, NKp46 is generally considered the most reliable identifying marker of NK cells across 
species.  Here, we see that the percentage of mAb 4F2+ PBL increases following depletion of 
CD3+ cells, which is consistent with the canonical CD3-NKp46+ phenotype used to describe 
NK cells in most species.  However the 2.3-fold increase was not proportional to the 8.4-fold 
reduction in CD3+ cells, and one animal increased only marginally (1.1-fold).  These data 
suggest that some NKp46+ cells could also be CD3+.  Such cells may be NKp46+ NKT cells 
similar to those recently described in the human and mouse (Yu et al., 2011), or they may 
represent a species-related difference in the horse. CD3+ natural killer-like cells have previously 
been observed in lymphoid tissues recovered from severe combined immunodeficiency (SCID) 
foals that were devoid of conventional lymphocytes (Lunn et al., 1995).  
Our group has previously identified equine lymphocytes with an NK cell phenotype using 
a cross-reactive monoclonal antibody to a catfish vimentin-like protein (“FAM,” function-
associated molecule) (Viveiros and Antczak, 1999).  Those cells constitute a larger percentage of 
the lymphocyte population (4.5 to 23.3%) than what is seen here, and are all CD3-.  Interestingly, 
in those studies, when CD3+ cells were depleted then labeled with anti-FAM mAb, the increase 
in presumptive NK cells was roughly 2.6 fold, very similar to the 2.3 fold increase seen here 
(Figure 6.4F).  It is not yet clear what the relationship is between FAM+ cytotoxic cells and the 
NKp46+ cells we have identified. Multiple overlapping phenotypic subsets are seen among the 
NK cells of other species (Lanier, 2005), and it is reasonable to think that equine NK cells would 
be equally complex.
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 Table 6.4 Summary of aNKp46 mAbs
Epitope
Group mAb Isotype ELISA
Application
FACS1 IHC2
3B7 IgG1 +3 +3 +/-
4D10 IgG1 + + +/-
4F2 IgG1 + + +/-
A 7C2 IgG1 + + +/-
8E8 IgG1 + + +/-
8G3 IgG1 + + +/-
9C1 IgG1 + + +/-
B 8A3 IgG1 + + +4
C 8F9 IgG1 + + +/-
1Labels both fresh and PFA-fixed cells; 2Frozen acetone-fixed cells, “+/-“: only brightest 10% of cells detected 
due to low antigen and limits of assay sensitivity;  3Slight crossreactivity with CD16 observed in ELISA and 
FACS with transfected cells; 4Strongly labels granulocytes in acetone-fixed sections.
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Conclusions
The mAbs described here demonstrate the ability to recognize native and recombinant NKp46 
in multiple assays (Table 6.4). These new reagents, in conjunction with our recently described 
antibodies recognizing equine CD16, will allow immunologists to better describe and understand 
the largely uncharacterized population of equine NK cells.  They will also facilitate new study in 
areas with clinical relevance such as viral immune responses and tumor immunology.
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CHAPTER 7
EXPRESSION OF NK CELL MARKERS ON THE PERIPHERAL
 AND ENDOMETRIAL CUP LYMPHOCYTES OF THE HORSE
176
Summary
Natural killer (NK) cells are innate immune cells with constitutive cytotoxic activity.  They 
are often defined by their cell surface marker profile, including the markers CD16 and NKp46.  
Here, using newly developed monoclonal antibodies specific for the equine homologs of these 
markers, we investigate their expression in peripheral and endometrial cup lymphocytes.  Pe-
ripheral lymphocytes were observed to contain a CD16+NKp46+CD4-CD8+LFA-I+MHCII+ 
population of cells that were CD3+ to varying degrees, depending on the horse.  Endometrial 
cup lymphocytes contained predominantly CD16+ cells, which overlapped with a previously 
observed CD3+ population.  NKp46+ cells were also present among the ECL to a lesser extent.  
Together, these findings suggest that NK cells in the horse may have a CD3+ NK cell pheno-
type that differs from other species, or that the dominant cell type recognized by these markers 
is NKT cells. Furthermore, it appears that the CD3+ cells observed in the dramatic infiltration 
around equine endometrial cups are also CD16+.
Introduction
Natural Killer cells (NK cells) are vital components of the innate immune system. Among their 
multiple functions are the abilities to eliminate tumor cells and to confer host protection against 
pathogens during the gap between exposure and the maturation of acquired immune responses. 
Activating receptors are critical components in the effector functions of NK cells, so much so 
that NK cells are often defined by their receptor repertoire.  This aim of this study is to utilize 
recently developed reagents to investigate the expression of two of these receptors, CD16 and 
NKp46, on equine lymphocytes in order to better understand the largely uncharacterized equine 
NK cell population.
CD16 (FCGRIII) is a low-affinity Fc receptor present on NK cells, monocytes, and in some spe-
cies, granulocytes (Boysen et al., 2008; Dato et al., 1992; Elhmouzi-Younes et al., 2010; Fingerle 
et al., 1993; Rogers et al., 2006).  It triggers NK cell mediated lysis primarily by binding cell 
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surface bound IgG and initiating antibody dependent cellular cytotoxicity (ADCC) (Trinchieri 
and Valiante, 1993). Our group has recently developed a panel of mouse monoclonal antibodies 
(mAbs) that specifically recognize equine CD16 (Noronha et al., 2012a). We have also developed 
a panel of mAbs to the equine homolog of the natural cytotoxicity receptor NKp46 (CD335, 
NCR1) (Noronha et al., 2012b).  This molecule directly activates NK cell lysis through the bind-
ing of viral and tumor ligands, and is generally considered to be the most consistent and specific 
marker of NK cells across species (Walzer et al., 2007).  It has been identified on functional NK 
cells of mice, rats, humans, non-human primates, sheep, and cattle (Biassoni et al., 1999; Connel-
ley et al., 2011; De Maria et al., 2001; Sivori et al., 1997; Storset et al., 2003).  In the horse, these 
two NK cell markers were each found to be expressed on a small population (1-2%) of peripheral 
equine lymphocytes (Noronha et al., 2012a, b).  It is not yet known how these two markers relate 
to each other or to equine NK cells.
NK cells of the horse have been largely unstudied due to a lack of available reagents. Our group 
has previously described a population of peripheral lymphocytes that exhibit NK cell-like char-
acteristics by using a cross-reactive monoclonal antibody to a catfish vimentin-like protein 
shown to identify human NK cells (Viveiros and Antczak, 1999). These cells were observed to 
be CD3-CD4-CD8-LFA-I+MHCI+.  In that study, it was also shown that CD3-depleted periph-
eral lymphocytes have a higher innate cytotoxic capacity than total lymphocytes.  Together these 
finding suggest that NK cells of the horse may reside in the CD3- lymphocyte population.
More recently, we have shown evidence for a regional accumulation of NK cells in the equine 
uterus during early pregnancy.   Using quantitative RT-PCR, we detected increased gene expres-
sion of equine NKP46, CD16, CD56, and CD94 in the endometrial cups— uterine structures 
formed in the superficial endometrium by invasive trophoblasts (Allen et al., 1973). Maternal 
mononuclear leukocytes, which our group has previously identified as being primarily CD3+, 
CD4+, and CD8+ (Grunig et al., 1995), infiltrate the stroma surrounding the cups and surround 
the trophoblast cells (reviewed in Noronha and Antczak, 2010). Here, we seek to determine if our 
newly developed mAbs will detect NK cell marker expression by these endometrial cup lympho-
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cytes (ECL).
Materials and Methods
Animals 
Horses used in this study were maintained at the Cornell Equine Genetics Center; all procedures 
were performed in accordance with guidelines established by the Institutional Animal Care and 
Use Committee of Cornell University. Adult horses of mixed genetic backgrounds, sexes, and 
ages were used (Table 7.1). Pregnancies were established as previously described (Adams and 
Antczak, 2001).  Major Histocompatibility Complex haplotypes were assigned to horses using 
serological and genomic methods (Lazary et al., 1988; Tseng et al., 2010). 
Cells and Tissues
Lymphocytes were isolated from heparinized blood samples by incubation with carbonyl-iron 
followed by density gradient centrifugation as previously described (de Mestre et al., 2010). 
Cells were assayed for viability using trypan blue exclusion and phase contrast microscopy.  Sec-
tions of endometrial cups (day 46 of pregnancy) and lymph nodes (non-pregnant horse) were 
obtained at necropsy and transferred immediately to O.C.T. embedding compound (VWR Scien-
tific Products, Willard, OH), snap frozen in an isopentane bath in liquid nitrogen, and then stored 
at -80oC.  
Flow Cytometry and Immunohistochemistry
Peripheral lymphocytes were labeled immediately after isolation or following 18 hours of 
stimulation with 25 ng/ml phorbol 12-myristate 13-acetate (PMA) and 1 µM ionomycin (IO) in 
the presence of 10 µg/ml brefeldin A as previously described (Wagner et al., 2008). Cells were 
labeled with monoclonal antibodies to equine cell surface markers CD3 (Blanchard-Channell et 
al., 1994), LFA-I CZ3.2, (Zhang et al., 1998), CD16 (Noronha et al., 2012a), NKp46 (Noronha 
et al., 2012b), CD4 (HB61A, VMRD, Pullman, WA), CD8 (CVS8, Lunn et al, 1998),  MHCII 
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(CZ11, Lunn et al, 1998), CD56 (clone 123C3, Zymed labs), and anti-c-myc (Invitrogen).  Cy-
tokine staining was performed on stimulated cells using anti-bovine interferon gamma (IFNg ) 
(MorphoSys, AbD Serotec, Oxford, UK) and anti-equine interleukin 4 (IL4;Wagner et al., 2006) 
as previously described (Wagner et al., 2005, 2006). Immunofluorescence flow cytometry was 
performed using a BD FACSCalibur (BD, Franklin Lakes, NJ) and data analysis was performed 
using Flowjo software (Tree Star, Ashland, OR).  Immunohistochemical labeling of frozen sec-
tions was performed as previously described (de Mestre et al., 2008).
Results
CD16 and NKp46 can be co-expressed on equine lymphocytes
Flow cytometric analysis was used to determine the relationship between CD16+ and NKp46+ 
lymphocyte populations.  Lymphocytes were isolated from nine horses and labeled with mAbs 
recognizing equine NKp46 and CD16.  Dot plots representing three of the nine horses are shown 
in Figure 7.1.  In most cases, approximately half of the CD16+ cells were NKp46+, while most 
NKp46 cells were CD16+.  A notable exception is that in the two youngest animals, the ratio of 
NKp46+ to CD16+ single positive cells was higher.  
Horses can express CD16 and NKp46 on CD3+ lymphocytes
We next investigated the relationship between the NK cell markers CD16 and NKp46, and 
the conventional T cell marker CD3.  NK cells in other species are typically described as be-
ing CD16+NKp46+CD3-.  Lymphocytes were isolated from ten horses and labeled with mAbs 
recognizing equine CD3, NKp46 and CD16.  Dot plots representing three of the nine horses are 
shown in Figure 7.2.  In all but one horse (center), half or more of the CD16+ cells were also 
CD3+  (Figure 7.2A).  The horses showed more variability in expression patterns regarding CD3 
on NKp46+ cells (Figure 7.2B).  Some showed the classic NKp46+ cell pattern with few CD3+ 
cells, others had CD3+ cells to varying degrees up to 92% NKp46+CD3+ (right).  The pattern for 
each horse was found to be consistent when experiments were repeated on different days separat-
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Table 7.1 Animals used for lymphocyte and tissue isolation
Cornell # DOB Sex1 Breed2 MHC Haplotype3
3875 2006 F TB x pony A2/?
3908 2007 F TB A2/A2
3099 1992 F TB A2/A2
3521 2000 MC TB A2/A2
3709 2003 M Pony A6/?
2885 1988 F TB A3/A3
3157 1993 F TB A3/A3
4056 2009 MC TB A3/A3
3903 2001 F TB A9/A9
4056 2009 MC TB A3/A3
3105 1992 MC TB A3/A3
3419 1998 F SB x TB A5/A2
1F, female; M, male; MC, male castrate. 2TB, thoroughbred, SB, standardbred. 3Equine Leukocyte Antigen haplo-
types assigned by serologic and genomic testing.
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ed by 4-6 weeks.  This suggests that the phenotype is not the result of a temporary up-regulation 
of inducible receptors.  
CD16+NKp46+ lymphocytes are CD8+
Lymphocytes from five horses were then labeled with CD16 and/or NKp46, and several mark-
ers for horse T cells (Figure 7.3, 7.4).  Unfortunately, the mAb our group previously used to 
identify NK-like cells is now manufactured by a different vendor and causes a dose-dependent 
cell-death when used to label cells (data not shown).  Few or no CD16+ and NKp46+ cells were 
CD4+.  Most of the of the NKp46+ and CD16+ populations were each found to be CD8+.  In-
terestingly, three-color analysis showed that these were almost exclusively the double positive 
NKp46+CD16+ population.  The exception was a CD16hi population that was found to be CD8+, 
CD3-,  and NKp46-.  We next looked at MHCII, which is found on most horse lymphocytes and 
antigen presenting cells.  All NKp46+ cells and most CD16+ cells were MHCII+ with a mean 
fluorescence intensity in the center of the positive population.  The exception was the CD16hi 
group, which was also MHCIIhi.  Finally, all cells highly expressed the pan-lymphocyte marker 
LFA-I, which is a requirement for cytolytic activity in NK cells and CTL of other species (Barber 
et al., 2004).  
CD16+ and NKp46+ lymphocytes express minimal cytokines following pharmacological stimu-
lation
In order to determine if CD16+ or NKp46+ cells produce basal levels of cytokines that might 
suggest that they have effector functions, we performed ex vivo pharmacological stimulation 
overnight in the presence of a secretion blocker, then labeled extracellular markers and intracel-
lular cytokines and performed three-color flow cytometric analysis (Figure 7.5).  We first looked 
at the canonical NK cell cytokine, IFNg .  There was modest production of IFNg  by CD16+ 
cells, but essentially none by NKp46+ cells.  Because we had observed a CD3+ subset of NK 
cells that could potentially represent NKT cells, we next looked at IL-4 production, as some 
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Figure 7.1 Dual labeling of CD16 and NKp46 on peripheral lymphocytes.  Flow cytometric 
analysis of peripheral lymphocytes isolated from three representative normal horses. Cells were 
labeled with monoclonal antibodies to equine CD16 and NKp46.  
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Figure 7.2  Cell surface expression of CD3 and NK cell markers on peripheral lymphocytes.  
Flow cytometric analysis of peripheral lymphocytes isolated from three representative normal 
horses. Cells were labeled with monoclonal antibodies to equine CD3 and CD16 (A) or NKp46 
(B).  
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Figure 7.3  Immunophenotyping of peripheral CD16+ and NKp46+ lymphocytes. Flow cyto-
metric analysis of peripheral lymphocytes, representative dot plots of cells isolated from one 
horse are shown. Cells were labeled with monoclonal antibodies to equine CD16 (middle row) 
or NKp46 (bottom row) and antibodies to other cell surface leukocyte markers, as indicated.  
Top row: forward-scattter and side scatter plot showing morphology of cells studied (left), cells 
stained with 2-color isotype controls (center), and CD16+NKp46+ co-localization for this horse.
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Figure 7.4  Three color labeling with NK cell and T cell markers.  Flow cytometric analysis of 
peripheral lymphocytes, representative dot plots of cells isolated from one horse are shown. Cells 
were labeled with monoclonal antibodies to equine CD16, NKp46, and antibodies to other T cell  
markers, as indicated.  
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Figure 7.5 Cytokine production in PMA/IO stimulated peripheral CD16+ and NKp46+ lympho-
cytes.  Flow cytometric analysis of IFNg and IL-4 expression by lymphocytes  stimulated ex vivo 
for 4 hours with PMA and 18h in the presence of Brefeldin A. Representative dot plots of cells 
isolated from one horse following intracellular labeling with IFNg (left column) or IL-4 (right 
column).
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populations of NKT cells produce IL-4 in other species (Denyer et al., 2006; Subleski and Ortal-
do, 2009).  Neither the CD16+ or NKp46+ populations produced significant amounts of IL-4.
Distribution of CD16+ and NKp46+ cells in the lymph node
In order to visualize the in situ distribution of cells expressing CD16 and NKp46, we performed 
immunohistochemical labeling on submandibular lymph nodes taken from a healthy horse 
(Figure 7.6).  Submandibular lymph nodes drain the oral cavity and generally contain activated 
leukocytes of different types, including NK cells (Martin-Fontecha et al., 2004).  
NKp46+ cells were observed to be in the cortical and paracortical regions in a pattern similar 
to the distribution of NKp46+ cells observed in bovine and ovine lymph nodes (Boysen et al., 
2008; Connelley et al., 2011).  CD16+ cells demonstrated a very distinctive pattern, lining the 
subcapsular and trabecular sinuses.  We have previously shown that CD16 is expressed on equine 
monocytes (Noronha et al., 2012a), and this tissue expression pattern is consistent with expres-
sion on myeloid lineage APCs, such as macrophages and dendritic cells.
Distribution of NK marker molecules in endometrial cups
As we have recently shown molecular evidence for NK marker gene expression in lymphocytes 
surrounding the endometrial cups during early pregnancy (Noronha et al., 2012c), we next in-
vestigated protein expression of these markers on endometrial cups taken during this time frame.  
Serial sections of endometrial cups were labeled by IHC with antibodies recognizing NK cell 
markers and the primary markers of T-cells, B-cells, and monocytes.
The pattern of infiltrating LFA-I+, CD3+, CD4+, and CD8+ cells (Figure 7.7) is similar to what 
we have observed in past studies (Grunig et al., 1995).  Here, we observe that CD16+ cells also 
exhibit a similar pattern.  Among the lymphocyte accumulation directly adjacent to the endome-
trial cup trophoblasts, the number of CD16+ cells exceeds CD4+ and CD8+, and is comparable 
to CD3+ cells.  Additionally, CD16+ cells continue distally into the endometrial stroma in fairly 
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Figure 7.6  Distribution of CD16+ and NKp46+ cells in lymph nodes. Frozen sections of  sub-
mandibular lymph nodes take from healthy adult horses were immunohistochemically labeled 
with monoclonal antibodies against equine CD16 and NKp46, as indicated.  Negative control 
(top panel), is anti-c-myc.
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Figure 7.7  Distribution of cells expressing NK cell markers among the cellular response of early 
endometrial cups. Frozen serial sections of an endometrial cup taken from a horse on day 46 of 
pregnancy were immunohistochemically labeled with monoclonal antibodies against equine cell 
surface markers, as indicated. Negative control, anti-c-myc.  Tissues are oriented with tropho-
blasts in lower left corner and endometrium to right.  (A) low power (40X) view; (B) higher 
power (200X) view of central transition zone between endometrial cup and endometrium.  
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B
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large numbers, where the T-cell markers do not.  
Because many of the markers used here (LFA-I, CD4+, CD8+) can also be expressed on equine 
cells of the monocyte lineage, we compared the CD16 pattern to that seen with a marker for this 
population, CD14.  Unlike CD16, CD14 was expressed in only a small number of cells among 
the lymphocytes surrounding the endometrial cup trophoblasts. 
Our previous molecular data demonstrated that CD56 and NKp46, which were both expressed 
in low levels in peripheral lymphocytes, demonstrated a dramatic upregulation of expression in 
endometrial cup lymphocytes.  We next investigated the expression of these molecules on endo-
metrial cup tissue sections.  
CD56 transcripts are nearly undetectable in peripheral equine lymphocytes, but are expressed at 
levels 40-fold higher in the ECL.  The equine CD56 protein shares 98% amino acid identity with 
the human protein, so we used a commonly used anti-human CD56 antibody to attempt to detect 
the equine protein (Figure 7.7).  A small number of bright cells were detected among the ECL 
and none were found in the adjacent endometrium.  At first glance, NKp46 appeared to demon-
strate the same pattern of a few isolated bright cells.  However, many dim cells were also present 
(Figure 7.8).  This staining intensity is consistent with what is seen in peripheral cells, i.e. low 
antigen density, suggesting that NKp46 may be at the limits of detection of this colorimetric as-
say.  Alternatively, this mAb may not work effectively in immunohistochemical assays.
Discussion
These data describe the expression profile of the common NK cell markers CD16 and NKp46 in 
equine lymphocytes. We have investigated their expression on peripheral lymphocyte popula-
tions, and regional populations in situ.  Together these data suggest a unique profile for equine 
NK cells.
The two NK cell markers studied here, CD16 and NKp46, have some shared expression pat-
terns.  They co-localize on the majority of lymphocytes on which they are expressed, they are 
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Figure 7.8 Close-up view of distribution of  NKp46+ cells in early endometrial cups.  Frozen se-
rial sections of an endometrial cup taken from a horse on day 46 of pregnancy were immunohis-
tochemically labeled with a monoclonal antibodiy against NKp46. Negative control, anti-c-myc.  
Center row, closer views of dimly labeled cells.  Bottom row, high power views of dimly stained 
(left) and brightly stained (right) NKp46+ cells in the lymphocyte-dense region of the endome-
trial cup. 
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all MHCII+LFA-I+CD4-, and most of the CD16+NKp46+ double positive lymphocytes are also 
CD8+, a phenotype consistent with the NK cells of species including humans, macaques, rats, 
pigs, and sheep (Carter et al., 1999; Elhmouzi-Younes et al., 2010; Gerner et al., 2009; Perussia 
et al., 1983; Torres-Nagel et al., 1992).  However, they differ in respect to CD3 expression.  The 
CD16+ cells of virtually all horses tested here were predominantly CD3+.  The CD3 pattern in 
Nkp46+ cells varies significantly between individual animals.  While CD16 can be expressed 
on multiple cell types, NKp46 has been considered to be the most consistent NK cell marker 
across species. It is typically found on CD3- cells in primates, mice, cows, and rats (Biassoni et 
al., 2002; Connelley et al., 2011; Sivori et al., 1997; Storset et al., 2004; Westgaard et al., 2004).  
Here, we see it to a variable extent, sometimes exclusively, on CD3+ cells.  One explanation is 
that these could be NKT cells, which have both NK cell and T cell markers. CD3+NKp46+ NKT 
cells have been described in humans and mice (Yu et al., 2011) and CD3+CD16+ NKT cells 
have been found in pigs (Denyer et al., 2006).   Another explanation is that this phenotype could 
be an equine-specific difference.  T-cells and NK cells are derived from a common lymphoid 
progenitor that expresses cytoplasmic CD3ε (the same subunit that the equine mAb recognizes), 
but go on to lose this marker during maturation (T- cells later regain it) (Plum et al., 1999; San-
chez et al., 1994).  Consequently, CD3+ NK cells are the predominant type found in the fetal 
liver (Phillips et al., 1992). However, cytoplasmic CD3ε has also been observed in adult NK cell 
clones (Lanier et al., 1992).  So perhaps that while the amino acid sequences of the major NK 
phenotypic molecules have remained conserved between species (Noronha et al., 2012c), the cell 
ontogeny has not, and the horse NK cell is more primitive in terms of lineage maturation.  Other 
groups have seen evidence of possible equine CD3+ NK cells; CD3+ cells with NK-like activity 
have previously been observed in foals with severe combined immunodeficiency, a condition that 
renders them devoid of conventional lymphocytes (Lunn et al., 1995).  There, like here, the CD3 
profile varied among individuals. Those putative NK cells were also CD4-CD8+LFA-I+MHCII+. 
The small CD3+CD16+ phenotype seen in PBL appears to be the rpredominant type among 
the endometrial cup lymphocytes.  CD16+ cells are numerous among the ECL and are clearly 
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overlapping with the CD3+ population, presenting a cellular profile different than what we had 
thought.   It is somewhat more difficult to make conclusions about the degree to which the small-
er CD4+ and CD8+ populations overlap with CD16+.  The CD14+ does not appear to exhibit a 
similar pattern, suggesting that CD16 expression is not due to myeloid cells.  CD56 appears to 
be present in very small numbers; but it is not yet clear if this is an actual representation of and 
inability to react with sufficient affinity to horse proteins.  Likewise, it is difficult to make con-
clusions about NKp46 expression with the current assay due to its low antigen density and the 
limitations of colorimetric IHC.  NKp46 labels peripheral cells with very low mean fluorescence 
intensity as measured by FACS.  This reflects a low antigen density which is likely the reason 
that cells appear so dim in IHC assays.  The next step in investigating these unanswered ques-
tions, and determining co-localization of markers on the ECL is to use a more sensitive assay 
where more than one marker can be visualized, i.e. fluorescence microscopy.
Regardless of the cell surface phenotype of these cells, the primary question that remains is 
whether they are NK cells.  Ultimately that is not determined by their marker profile, but by 
their capacity for innate effector function.  IFNg  production is considered a good surrogate for 
cytolytic capacity.  The chemical stimulation conditions used here has been shown to work with 
human peripheral NK cells (Shi et al., 2007), but did not yield significant cytokine production 
here.  Perhaps a more NK cell specific stimulation protocol, such as IL-12 driven stimulation, 
would be more informative.  The gold standard ultimately would be to directly measure cytolytic 
capacity of these cells, as this function is what defines them.  Our group has previously identified 
cells with innate cytolytic capacity as being CD3-.  This does not necessarily conflict with our 
results here. As we have determined CD3 expression on NKp46+ cells if highly variable among 
individuals, it may be that the horses in that study had CD3- NK cells.  Or it may be that, like in 
other species, the horse has multiple, sometimes overlapping, NK and NK-like populations. 
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Conclusions
Here we have made advances toward better understanding the NK and/or NK-like cell popula-
tion in the horse.  A population of NKp46+CD16+CD8+ CD4-LFA-I+MHCII+CD3+/- cells has 
consistently been identified in the peripheral lymphocytes of multiple horses.  These cells share 
a phenotype with the cells that accumulate in the maternal endometrium during early pregnancy.  
Their role there is not yet known, but their sheer number makes them an intriguing target for 
further studies.
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CHAPTER 8
DISCUSSION AND CONCLUSIONS 
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The aim of this dissertation was to better understand maternal-fetal tolerance during equine 
pregnancy, with the larger goal of making observations that could help elucidate the phenomenon 
across species. The ability of a pregnant mother to accept the presence of a genetically foreign 
fetus is quite remarkable. In parallel situations outside the context of pregnancy, such as organ 
transplantation, individuals must take immunosuppressive drugs in order to prevent rejection 
of histocompatible tissues, and even then success is mixed.  Indeed, the concept of the “fetal 
allograft” as a model for understanding pregnancy immunology was developed nearly 60 years 
ago, and is still relevant today (Medawar, 1953).  
The work described here studied changes in the immune system of the mare that occur at both 
the systemic and regional (uterine) levels.  In particular, it focused on the cytotoxic lymphocyte 
population, as they are the effector cells primarily responsible for tissue rejection.  This first part 
investigated lymphocytes of the acquired immune system such as CD8+ cells and the CD4+ cells 
that affect their behavior.  The second part concentrated on innate cytotoxic cells, the natural 
killer (NK) cells.
Chapter 1 reviewed the pertinent aspects of equine pregnancy immunology that provided the 
impetus for the studies in the following chapters.  Of particular importance were the following 
observations previously made by previous members of our group: 1) the invasive chorionic 
girdle (CG) trophoblast cells of the horse express high levels of allogeneic paternal class I 
MHC antigens, similar to what is found in immune cells (Bacon et al., 2002; Donaldson et al., 
1994); 2) these CG trophoblasts invade the maternal endometrium and recruit large numbers 
of maternal leukocytes which maintain direct contact with them for several weeks without 
causing their destruction (Allen, 1975); 3) nearly 100% of pregnant mares develop high titers 
of cytotoxic antibodies directed against the class I MHC antigens of the mating stallion, thereby 
demonstrating that trophoblast alloantigens are recognized by the maternal immune system 
(Antczak, 1984; Antczak et al., 1982); and 4) pregnant mares exhibit a reduced ability to mount 
an effective systemic cell-mediated immune response against paternal alloantigen, as measured 
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by peripheral CTL activity against target cells from the mating stallion (Baker et al., 1999).  
These observations raise many unanswered questions.  If a mare clearly recognizes paternal class 
I MHC, then why does she not mount a deleterious immune response?  Why are the endometrial 
cup trophoblasts not destroyed by the wall of lymphocytes that surround them? If a mother’s 
immune system tolerates paternal antigens, does it tolerate exogenous antigens also?  The work 
in this dissertation was an attempt to address some of these pressing questions.
In Chapter 2, the aims were to determine if the peripheral lymphocytes of the mare are 
phenotypically different during pregnancy, and whether immune reactivity may differ between 
the peripheral and regional compartments. We compared peripheral blood lymphocytes (PBL) 
of pregnant and non-pregnant mares, as well as tissue lymphocytes from the endometrium and 
endometrial cups (ECL) with PBL obtained on the same day of gestation from pregnant mares.  
We did not detect dramatic differences in peripheral lymphocytes during pregnancy. The ratio 
of CD4:CD8 was reduced in pregnancy compared to the non-pregnant state resulting from a 
trend towards decreasing CD4+ lymphocytes and increasing CD8+ lymphocytes in the mares 
during pregnancy. There was a modest increase in the percentage of IL-4+ cells and a decrease 
in the IFNg:IL-4 ratio in the overall lymphocyte population in the mares during pregnancy. This 
finding is consistent with the high levels of paternal alloantibodies observed during pregnancy, 
as the presence of IL-4 favors a humoral immune response.  There was also trend towards an 
increase in FOXP3 gene expression in the pregnant group, but the difference was not statistically 
significant. 
At the regional level of the endometrial cups, we measured increased numbers of FOXP3+ CD4+ 
T cells around the endometrial cups compared to peripheral blood.  In the lymphocytes recovered 
from the endometrial cups, there was also a marked increase in IFNg + cells in the total and 
CD8+ populations, and a decrease in lymphocytes expressing IL-4.  This observation appears to 
be in conflict with the traditional dogma of a TH2 bias during successful pregnancy (Wegmann 
et al., 1993). However, the cytokine profiles of lymphocyte subsets has been determined to 
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be more complex than previously thought (Mosmann et al., 2009).  And these results were 
similar to results from a study of human decidual CD8+ lymphocytes that reported high levels 
of expression of IFNg  and undetectable levels of IL-4 (Scaife et al., 2006). Furthermore, IFNg 
has been implicated at the maternal-fetal interface as having a critical role in human, murine, 
and porcine pregnancy (Murphy et al., 2009).  The results of this chapter also highlighted that 
significant differences may exist between local and peripheral immune cells during pregnancy. 
The aim of the studies in Chapter 3 was to further explore the previously observed deficits 
in peripheral CTL activity of the pregnant mare, and investigate the role paternal class I 
MHC antigens.   Although pregnant mares demonstrate clear immunological recognition of 
an allogeneic fetus, they demonstrate a reduced ability to generate effective CTL responses 
against stallion MHC antigens (Baker et al., 1999).  In order to determine the role of paternal 
alloantigens in this effect, we generated MHC compatible and incompatible horse pregnancies 
and tested paired PBMC samples isolated from mares while pregnant and non-pregnant 
for cytolytic capacity. CTL from mares carrying incompatible pregnancies demonstrated 
a significantly diminished capacity to lyse cells from the breeding stallion as well as cells 
from an unrelated third party individual.  By determining the existence of a reduced ability 
of pregnant mares to lyse cells from a third party animal, we were then able to test this effect 
in MHC matched pregnancies. CTL from mares pregnant with MHC compatible pregnancies 
also demonstrated a reduced capacity to lyse target cells from third party animals.  These data 
demonstrate that the observed reduction of CTL activity occurs independently of paternal MHC 
antigens on two levels.  First, the mare’s inability to generate effective CTL is not limited to 
responses directed against the MHC of the breeding stallion.  Second, an MHC incompatibility 
between mare and stallion is not necessary to induce this effect.  
It is not yet clear what mechanism is causing the antigen-independent reduction in T cell 
responses, but results from Chapter 2 lends some insights.   There, no difference was detected 
in the number of circulating CD8+ lymphocytes between non-pregnant mares and mares in 
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early pregnancy.  Other groups studying late equine pregnancy have gotten similar results 
(Agricola et al., 2008).  This suggests that the mechanism might not be a pregnancy-associated 
reduction in CD8+ CTL precursors as has been observed in transgenic mouse studies (Tafuri 
et al., 1995).  CTL could also be modulated by the suppressive activity Tregs, which expand in 
the periphery in other species during allogeneic and syngeneic mouse pregnancy in an antigen-
independent manner (Aluvihare et al., 2004).  In Chapter 2, we observed only a statistical trend 
towards an increase in the gene expression of FOXP3 between PBMC from mares carrying 
early pregnancies and non-pregnant mares in the luteal phase of estrous.  However, These 
samples were taken in early pregnancy, before estrogen rises significantly.  As Treg expansion in 
pregnancy may be estrogen-dependent (Polanczyk et al., 2004; Prieto and Rosenstein, 2006), the 
difference may have been sufficient to be suppressive, but not enough to be measurable at this 
stage of equine pregnancy.  
Chapter 4 begins the second set of studies— the investigations of equine NK cells.  In this 
chapter, we performed molecular studies looking for evidence of expression of common NK 
cell phenotypic markers in PBL.  We then used this new information to determine whether a 
previously undetected population of NK cells might exist in the lymphocytes surrounding the 
endometrial cups.  We determined the sequences for the equine orthologs of the NK cell markers 
NKP46, CD16, CD56, and CD94, and that they were expressed in PBL. In the four animals 
measured, NKP46 gene expression in peripheral CD3- lymphocytes was higher than in CD3+ 
lymphocytes. CD16 levels were higher in the CD3+ population, an unexpected observation 
that was later corroborated at the protein level by flow cytometry experiments in Chapter 7. 
Expression of all four NK cell markers was significantly higher in lymphocytes isolated from the 
endometrial cups of pregnant mares compared to PBMC isolated from the same animal on the 
same day, suggesting that NK cells may be present in the equine endometrium during pregnancy. 
Uterine and decidual NK cell populations are generally characterized as having poor cytolytic 
capacity, but have the ability to secrete cytokines, often large amounts of IFNg  (Platt and Hunt, 
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1998; Saito et al., 1993).  This is consistent with the finding in Chapter 2 that lymphocytes 
around the endometrial cups produce elevated amounts of IFNg . The stage of pregnancy studied 
here, days 43-46, is roughly one week following trophoblast invasion; therefore it is possible 
that IFNg  may have a role in tissue remodeling as has been described in other species (Tayade 
et al., 2007; Zhang et al., 2011). NK cells could also mediate this remodeling via interaction 
with polymorphic paternal class I MHC as seen in human and mice (Hiby et al., 2010; Madeja et 
al., 2011).  This could help explain the poorly understood phenomenon of paternal class I MHC 
expression by the chorionic girdle trophoblast at the time of invasion.
In order to progress in our studies of NK cells at the maternal-fetal interface, it was necessary 
obtain monoclonal antibodies that recognized equine NK cell markers.  We obtained several 
antibodies that recognize these proteins in other species, but none demonstrated suitable 
cross-reactivity with horse cells.  This is not surprising considering that, as we determined in 
Chapter 4, the homology across species of the NK markers was typically in the 60% range.  The 
exception here was CD56, which was 98% identical to the human protein. The anti-catfish-FAM 
(vimentin-like cytotoxic cell marker) mAb previously used to identify NK-like cells by our group 
(Viveiros and Antczak, 1999), was now manufactured by a new company and determined to be 
unsuitable for experiments. Therefore, we set out to develop novel monoclonal antibodies that 
recognized equine NK cell markers.  The generation and characterization of these antibodies are 
described in Chapters 5 and 6. 
Chapter 5 describes the creation of a panel of mAbs that recognize equine homolog of the 
low-affinity Fc receptor CD16.  These mAbs were created using a recombinant CD16 (rCD16) 
protein as an immunogen.  Using techniques such as ELISA and flow cytometry on rCD16-
transfected cells, the mAbs were determined to be specific for CD16.  FACS analysis of equine 
peripheral leukocytes showed a recognition of cells in the lymphocyte (2.1%), large lymphocyte/
monocyte (8.4%), and granulocyte (3.1%) populations. The overall number of cells that were 
labeled was modest (3%), but the pattern of labeling was similar to that seen in sheep and cattle 
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(Elhmouzi-Younes et al., 2010).  A portion of cells in the monocyte gate were also CD14+, a 
recognized sub-population of CD16+ cells, and looked remarkably similar to the human pattern 
for these cells (Fingerle et al., 1993).  
Chapter 6 describes the generation of a panel of mAbs that recognize the equine homolog 
of the natural cytotoxicity receptor NKp46.  Similar methods were used to characterize the 
specificity of these mAbs as in Chapter 5.  These mAbs labeled 1.3% of lymphocytes and no 
monocytes or granulocytes.  This is roughly 1/10th the population identified using the anti-
FAM mAb.  Although the percent of positively-labeled lymphocytes was similar to that seen in 
cows (1-8-2.6; Kulberg et al., 2004), a species where this marker has been well characterized, 
the labeling appeared to be dim and continuous, as opposed to positive/negative as in other 
species.  Therefore, we performed additional characterization assays on these antibodies.  One 
mAb (4F2) was used as a label for magnetic cell sorting.  The enriched and depleted populations 
were then analyzed for gene expression of NKP46.  The enriched population had a 23-fold 
higher NKP46 expression, indicating that the mAb was in fact recognizing cells that express 
NKp46 proteins. We then depleted CD3+ cells and found an increase in NKp46+ cells in 
the CD3- fraction.  Interestingly, the depleted fraction was 2.3-fold higher than the total cell 
population, nearly identical to the 2.6-fold  increase seen when the anti-FAM antibody was used 
(Viveiros and Antczak, 1999).  Although these data suggest that on the whole, NKp46+ cells are 
associated with CD3- cells, it was observed that in one animal the number of NKp46+ cells did 
not change after CD3 depletion, suggesting that some of the CD3+ cells must be NKp46+.  The 
multicolor FACS experiments in Chapter 7 go on to demonstrate this observation in more detail.  
Finally, it was observed that when we performed immunohistochemical labeling on cytospins 
of peripheral blood, the number of cells that were detected were lower than that seen by FACS. 
Rare bright cells could be observed, but the number of positive cells did not amount to the 1% 
seen by FACS.  Based upon the low mean fluorescence intensity (MFI) seen in FACS analyses, 
it appears that the antigen density of NKp46 is very low on the surface of lymphocytes.  This 
is consistent with the quantitiative PCR experiments of Chapter 4, which showed peripheral           
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lymphocytes as having an estimated 1-10 copies per cell.  This raises the question of whether 
the increase in NKP46 transcripts seen among the endometrial cup lymphocytes in Chapter 4 
is due to an increase of a few bright cells with a lot of expression, or many dim cells with dim 
expression.
We attempted to answer this question in Chapter 7 where we used the newly generated NKp46 
and CD16 mAbs to investigate peripheral and endometrial cup lymphocyte expression of the 
NK cell markers (summarized in Figure 8.1 and Table 8.1).  We observed that most horses have 
a distinct population of double positive CD16+NKp46+ cells.  CD16+ cells were typically at 
least half, sometimes all, CD3+.  These results were consistent with the unexpected qPCR data 
in Chapter 4 showing that CD3+ cells had higher levels of CD16 expression.  This is a profile 
not typically seen on NK cells.  CD16+CD3+ cells have been observed as a T-cell subset in 
humans (Lanier et al., 1985), and an NKT population in pigs (Denyer et al., 2006). CD3 was also 
associated with a variable number of NKp46+ cells, depending on the animal.  Some animals 
had primarily CD3- cells, others had mostly CD3+.  The CD3+NKp46+ cells appear to also be 
CD16+.  Again, this is not the typical phenotype of NK cells described in any species.  Until 
recently, there were few reports of NKp46+ NKT cells (Yu et al., 2011) it was considered to be 
highly specific for NK cells.  However, it has long been observed that CD3ε, a marker usually 
present on only fetal NK cells, may be found in the cytoplasm of adult NK cells, (Lanier et al., 
1992).  So one possible explanation is that horse cells could be retaining fetal cell surface CD3, 
or exporting adult cytoplasmic CD3 to the cell surface.  Alternatively, this could be a species-
related phenotypic variation, similar to the MHCII expression seen on equine T-lymphocytes.  
Another explanation is that some animals have NKT cells that co-express these markers, while 
others do not.  However, NKT cells are not simply NK cells with CD3, they have a distinct, 
thymic-derived cell type with a unique type of class I MHC that recognizes CD1d-bound 
glycolipid molecules.  It does not seem like this population should vary from all to none between 
horses.  The CD3+NKp46+CD16+  cells seen here could be tested for gene or protein expression 
of TCR  molecules in order to further investigate this possibility.
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b. NKp46+CD16+
d. CD3+NKp46+CD16+
c. CD3+CD16+
e. CD16hiCD8+MHCIIhi
a. NKp46+
NKp46
CD16
CD3
Figure 8.1.  Diagram Summarizing  current knowledge of CD16+ and NKp46+ lymphocyte 
phenotypes.  Overlap between lymphocyte populations is represented by circle overlays.  This 
is a general representation; the number of CD3+ cells with NK markers varies considerably 
between horses.
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a NKp46+ (single positive)
Uncommon-only seen in youngest animals, 
seem to have higher MFI
b NKp46+CD16+ Common
c CD3+CD16+ Varies between animals, consistent day-to-day
d CD3+NKp46+CD16+ Varies as product of c
e (CD3-) CD16hiCD8+MHCIIhi Varies between days?
Table 8.1 Summary of current knowledge of CD16+ and NKp46+ lymphocyte  
phenotypes
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The lymph node distribution of these markers was consistent with what would be predicted.  
NKp46 exhibited a pattern seen in cows and sheep (Boysen et al., 2008; Connelley et al., 2011), 
and CD16 was distributed to areas of the lymph node where CD16+ antigen presenting cells 
typically reside.  In the endometrial cups, there was a large population of CD16+ cells that 
seemed to overlap with the CD3+ population.  This is not surprising based on what was observed 
in the periphery.   It would be interesting to use paired peripheral and endometrial cup samples 
from the same horse, to see if this CD3+CD16+ population changes between compartments.  
Also, this would allow us to investigate the CD8+ and CD4+ status of the CD16+ ECL.  It is 
possible that the IFNg-producing CD8+ cells seen in Chapter 2 could be these cells.  NKp46 
labeling again yielded many dim cells, as was seen with peripheral blood slides.  It is difficult 
to determine the true number of these cells, but it appears to be higher than the ~1% in PBL.  In 
order to answer these questions about the number of NKp46 cells and their phenotype(s), one 
could use fluorescence microscopy of tissues sections, or cell isolation as in Chapter 2.
Our new mAbs have been very useful in generating new information about horse lymphocytes, 
but they have opened up more questions than they have answered.  In order to determine what 
the NKp46+CD16+ cells are, the next step should be to determine if they exhibit behaviors 
consistent with NK cells.  This should include three types of experiments: 1) measure the ability 
to spontaneously lyse cells that lack class I MHC; 2) measure IFNg  production in response to 
IL-12 stimulation; and 3) determine if they proliferate in response to IL-15. The other set of 
experiments that should be performed are the aforementioned assays for TCR expression.  This 
should differentiate them from NKT cells. Information obtained from this group of experiments 
should allow us to determine if these are in fact, NK cells.
In closing, the experiments here succeeded in advancing our prior knowledge, such as 
determining the lack of antigen specificity in maternal CTL modulation, and determining that 
many cells at the maternal-fetal interface are CD16+.  They have also opened up many new 
avenues of study such as characterizing what appears to be a unique NK cell phenotype.  It will 
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be exciting to see where all of these areas lead and ultimately intersect.
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